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RAD52 deficiency is synthetically lethal in BRCA1 and BRCA2 deficient 
tumors. RAD52 is therefore a potential therapeutic target for breast cancer 
patients with BRCA mutations, but not much is known about its role in 
humans. RAD52 and the BRCA proteins are involved in the homologous 
recombination (HR) pathway of DNA double-strand break (DSB) repair. In HR, 
DSBs are processed to generate single-stranded DNA (ssDNA) overhangs, 
which are then bound by the RPA complex. RAD51 is then recruited and 
performs homology search and strand invasion. S. cerevisiae RAD52 and 
hBRCA2 mediate the exchange of RPA for RAD51 and stimulate RAD51 
strand invasion. Recent publications show that hRAD52 provides an 
alternative mediator pathway in cells that lack the BRCA pathway. RPA 
hyperphosphorylation and dephosphoprylation after DNA damage are 
important for HR, but its effect on RAD52 function is not well understood. 
Here, we show that phosphorylation of RPA is important for the alternative 
RAD52 pathway. Using BRCA2-depleted human cells, in which the only 
available mediator pathway is RAD52-dependent, expressing non-
phosphorylatable (RPA2-A) and mock phosphorylated (RPA2-D) RPA2, we 
show that HR is reduced in the RPA2-phosphomutant cells compared to 
RPA2-WT cells, measured by the DR-GFP recombination assay and RAD51 
focus formation. Furthermore, RPA-phosphomutant cells have reduced 
association of RAD52 and RAD51 by colocalization. Interestingly, there is no 
effect of RPA phosphorylation on RAD52 recruitment to repair foci in RPA-
mutant cells after treatment with camptothecin. However, the RPA-
phosphomutants do not colocalize with RAD52 as well as the RPA-WT protein 
and more RAD52 immunoprecipitates with RPA-WT than RPA-A after 
camptothecin treatment. Finally, using biochemical assays we show that RPA 
phosphorylation does not affect RAD51 strand exchange, RAD52-mediation of 
RAD51 strand exchange, and RAD52-dependent ssDNA annealing, 
suggesting there are factors in cells not present in these assays that allow 
RPA phosphorylation to promote RAD52 function, or that cycling of 
phosphorylation and dephosphorylation is needed. Thus, although RAD52 is 
able to be recruited regardless of RPA phosphorylation status, RPA 
phosphorylation improves RAD52’s association with RPA, and subsequently 
promotes RAD52-HR. RPA phosphorylation is therefore important for both 
BRCA2-directed and RAD52-directed HR. 
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CHAPTER ONE 
INTRODUCTION 
DNA DOUBLE STRAND BREAK REPAIR 
Double strand breaks (DSBs) are the most deleterious type of DNA 
damage, arising during DNA replication or after exposure to ionizing radiation 
and other DNA damaging agents. DSBs can cause cell death or chromosomal 
rearrangements when they are not repaired or repaired incorrectly1-3. DSBs 
are resolved by two main pathways, homologous recombination (HR) or 
nonhomologous end joining (NHEJ). HR uses a homologous template to fill in 
breaks and is considered error free; it is active during the S and G2 phases of 
the cell cycle when sister chromatids are available as a template. NHEJ can 
be mutagenic and functions throughout the cell cycle, ligating DNA ends 
without homology. Studies in mammalian cells have shown that NHEJ-
deficient cells have reduced repair in all cell cycle stages while HR-deficient 
cells have only a minor defect in G1 and a more clear repair defect in S, G2 
and M phases 2,4. Evidence of competition between HR and NHEJ to repair 
DSBs is further supported by observations that HR is increased in NHEJ 
mutant lines5, and that HR mutants are rescued by deficiencies in certain 
NHEJ factors6,7. HR and NHEJ double mutant mice have more severe 
phenotypes than single mutants, supporting their roles repairing differing DNA 
DSBs8,9.  
NHEJ involves alignment of DNA ends with minor processing to clear 
damage, and then DNA gap filling and end relegation. At clean breaks with 
compatible overhangs, religatable 5’ phosphates and 3’ overhangs, NHEJ is 
usually accurate. “Dirty” breaks with chemically damaged ends repaired by 
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NHEJ, and ligation between different chromosomes, can lead to mutations and 
translocations.  
Homologous recombination begins with resection to generate 3’ single-
stranded DNA (ssDNA) overhangs. These overhangs are eventually coated by 
the RAD51 recombinase, which performs homology search and strand 
invasion of a complementary duplex. It is less error prone due to the fact that it 
repairs using the sister chromatid. HR also plays a role in regulating and 
repairing damage due to replication stress.  
Other less well-characterized pathways of DSB repair include 
alternative-NHEJ (alt-NHEJ) and single strand annealing (SSA). Alt-NHEJ 
functions as a backup to canonical NHEJ and uses micro-homology to anneal 
ends; it is also referred to as microhomology mediated end joining (MMEJ), as 
it can ligate ends with small regions of homology. Single strand annealing 
(SSA) is a sub-pathway of HR that also begins with resection but then 
reanneals broken DNA ends at tandem repeats3,10. How a cell determines 
which pathway to utilize in order to repair DSBs is not well understood.  
This thesis focuses on the RPA and RAD52 proteins, two important 
players in the HR pathway. Following in this chapter is a more detailed 
discussion of the HR pathway and when it is used. An in depth review of the 
RPA complex, which is an ssDNA-binding protein complex that binds the 
resected DNA ends in HR, is included. RPA is hyperphosphorylated in 
response to DNA damage, and the regulation and importance of this 
phosphorylation is described in detail. Finally, we discuss recombination 
mediators, including the BRCA2 and RAD52 proteins. Recombination 
mediators facilitate RPA replacement from ssDNA by RAD51 filaments and 
promote RAD51 homology search and strand invasion. BRCA2 mediates the 
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primary HR pathway in human cells, with RAD52 functioning in a backup 
pathway. The factors needed for the RAD52 pathway are not currently known. 
This thesis focuses on the potential role of RPA hyperphosphorylation in the 
RAD52 pathway.   
Replication stress 
DNA replication is highly coordinated in eukaryotes. The replisome is 
composed of polymerases, helicases, nucleases, and ligases. Replication 
requires replisomes to unwind chromatin, move bidirectionally, terminate 
synthesis, and repackage DNA. It is divided into three steps: initiation, 
elongation, and termination11. Errors in replication and replication stress can 
lead to genomic instability11. 
Replication stress can be caused by a number of factors, including the 
replisome encountering DNA lesions, conflicts with transcription or DNA-RNA 
hybrids, DNA secondary structure, proteins bound to the DNA template, 
topological strain, overexpression or constitutive activation of oncogenes, and 
chromosomal regions that are difficult to replicate like fragile sites, repetitive 
sequences, telomeres, and non-B form DNA12. Cells have a number of ways 
of dealing with replication stalling, including bypass of lesions or HR, though in 
eukaryotes the existence of multiple origins of replication allows some stalled 
forks to be offset by activating other replisomes12,13.  
Replisomes that are paused for too long lose activity and may result in 
fork collapse and a DSB, thought to be mediated by nuclease cleavage by the 
MUS81/EME1 complex14,15. In addition, when a replisome encounters a break 
in the phosphodiester backbone, the fork structure is lost, causing a DSB end. 
These breaks can be due to a failure to ligate Okazaki fragments, to repair 
breaks, or to topoisomerases failing to reseal breaks12,16.  
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ATR is essential for DNA replication and is activated during S phase to 
regulate origin firing, to stabilize forks, and to promote repair and restart of 
damaged forks, ensuring complete DNA synthesis prior to mitosis17. It is 
recruited by ATRIP bound to RPA-ssDNA. RPA also stimulates binding and 
activation of RAD17-RFC clamp loader, which loads the PCNA related 9-1-1 
complex and stimulates ATR kinase activity through TOPBP11,17-21. In cells 
with extensive replication stress, the replication checkpoint is needed to 
prevent new origin firing and RPA exhaustion22.  
A cell can deal with replication blocks in a number of ways. Stalled forks 
can be cleared by translesion synthesis through polymerase switching, 
bypassing the lesion, or template switching, which can involve fork regression 
or strand invasion of the sister chromatid by HR. Fork regression involves 
reannealing the parental strands and is believed to be mediated by BLM, WRN, 
FANCM, HLTF, or SMARCAL1, generating a “chicken foot” which could allow 
restart of DNA synthesis1,23-26. The choice of which pathway is used is best 
characterized in yeast, where it is mediated through posttranslational 
modifications of PCNA1,11,27-38. There is evidence that this is also the case in 
humans11. 
The HR machinery has several roles at replication forks. It seals ssDNA 
gaps after replication, known as post-replication repair (PRR). It can protect 
nascent forks from extensive resection. Finally, recombination proteins can 
rebuild the replisome after collapse, as DSBs are generated when replication 
forks collapse and can then be repaired by HR. RAD51, BRCA2, MRE11, 
XRCC3, FANCA and FANCD2 have all been implicated in fork restart or 
stabilization—if defective, DSBs accumulate when cells are challenged with 
replication inhibitors or even during normal replication39-41.  
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Fork protection by HR proteins helps prevent degradation of the 
nascent strand by nucleases, such as MRE11. RAD51 filaments and BRCA2 
dependent stabilization of RAD51 filaments inhibits this nucleolytic 
degradation of nascent DNA42-45. Forks are also stabilized by other 
mechanisms, including preventing dissociation of replication proteins, 
regulation of HR proteins through phosphorylation, promotion of sister 
chromatid cohesion, upregulation of helicases that remodel forks to promote 
restart, downregulation of nucleases that may damage the stalled fork, 
regulation of chromatin modifications and histone supply, and targeting 
nuclear pore components that tether transcribed genes to release topological 
strain on replicating DNA11. 
DNA Damage Response signaling 
There is a network of interacting pathways that mediate the cellular 
response to DNA damage, known as the DNA damage response (DDR). After 
breaks, four main sensors that can detect DSBs: PARP, Ku70/Ku80, MRN, 
and RPA1. Three central kinases mediate the DDR: DNA-PKcs, ATM, and 
ATR, members of the phosphatidylinositol-3-kinase-related kinase (PIKK) 
family46. DNA-PKcs primarily targets proteins involved in NHEJ and is 
recruited through Ku70/Ku8047. ATM and ATR also activate more 
phosphorylation through the CHK1 and CHK2 kinases1,17. ATM is primarily 
activated by DSBs through the MRN complex48, while ATR responds to a 
broader spectrum of damage including DSBs through RPA-ssDNA17. PARP is 
thought to promote NHEJ, to mediate the accumulation of MRN, and to 
facilitate ATM activation49,50. These kinases have overlapping roles in the DDR, 
and coordinate the response, acting to regulate DNA repair enzymes through 
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post-translational modifications (PTMs), modifying chromatin around the 
damage and in the nucleus or cell to allow for repair.  
The DDR can activate cell cycle checkpoints, including the G1/S, intra-S, 
G2/M checkpoints1,11,18. Detection of DNA damage during these points in the 
cell cycle will prevent cell cycle progression while the damage is repaired, 
through the PIKKs. Checkpoints regulate DNA replication at the initiation, fork 
progression, and fork stability steps, and also involve the decision between 
cell cycle arrest, apoptosis, or senescence, through post-translational 
modification signaling and transcriptional regulation1,11. 
The PIKKs have several mechanisms of dealing with DNA damage. 
ATR activation occurs through recruitment to RPA. RPA bound to ssDNA at 
damage sites and replication stress centers recruits ATRIP, which recruits 
ATR20. RPA also recruits RAD17, which loads the Rad9-Hus1-Rad1 complex 
(9-1-1 complex); the 9-1-1 complex then loads TopBP1, which activates 
ATR17,19-21. Activated ATR activates Chk1, which can inhibit new replication 
origin firing to allow for repair22. ATR also directly targets replication and 
recombination proteins, which are necessary for fork restart, to regulate 
checkpoints17. Another mechanism proposed is that prevention of origin firing 
prevents “exhaustion” of nuclear RPA levels—increasing amounts of ssDNA 
would occur if dormant origins fired during replication stress, and ssDNA 
unbound by RPA due to RPA exhaustion would be converted to DSBs22,51. 
ATM may also function in the response to replication stress by activating the 
HR pathway, though some models suggest that ATM is only important in 
replication stress once DSBs are formed. Another important protein in the 
DDR, p53, is regulated by ATM and CHK2 in response to DSBs1. P53 induces 
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cell cycle arrest, apoptosis, or senescence in response to DNA damage 
through transcriptional regulation52.  
A major hallmark of damage is phosphorylation of histone H2AX at 
S139, which spreads megabases in mammals flanking the DSB; this 
phosphorylated form is referred to as γH2AX53-55. Phosphorylation of H2AX is 
likely through ATM, and recruits MDC1. Phosphorylated MDC1 then recruits 
the E3 ligase RNF856,57, which is mediated through the RNF8 FHA domain56-58. 
RNF8 with UBC13 then ubiquitinates histones H2A and H2AX. RNF168, which 
is also an E3 ligase, is then recruited and with UBC13 amplifies the ubiquitin 
signal via lysine 63 linked chains of ubiquitin on H2A and H2AX59,60. These 
polyubiquitinated histones recruit RAP80 through its ubiquitin interacting motif, 
and RAP80 then recruits BRCA1 through Abraxas58,61-68. 53BP1 is also 
recruited through MDC1 and RNF168, and binds dimethylated histone H4 
(H4K20me2)69. Besides ubiquitination signaling, sumoylation by PIAS1 and 
PIAS4 is also important for assembly of BRCA1, 53BP1, and RNF168, at 
damage sites70,71. After this signaling pathway leads to recruitment of BRCA1 
and 53BP1, these factors compete and coordinate to determine which DNA 
repair pathway is used to repair the break; this will be discussed in more detail 
later. If resection is activated, it is thought to induce an ATM to ATR switch, as 
the ssDNA leads to ATR activation while ATM activity is attenuated72. ATR 
then activates Chk1, which phosphorylates RAD51 and promotes repair of 
break through HR after DSBs at stalled forks73.  
Besides the repair of DSBs, cells have other pathways to repair simpler 
damage to DNA. Mismatch Repair (MMR) and base excision repair (BER) can 
repair mismatches and small chemical damage, involving excision of the 
damaged base. Nucleotide excision repair (NER) removes more complex, 
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bulky lesions, like pyrimidine dimers, and removes a stretch of 
oligonucleotides around the damage around 30 nucleotides. Intrastrand-
crosslink repair (ICL) occurs by the Fanconi Anemia pathway, which requires 
many HR factors46.  
Homologous recombination (Figure 1) 
Studies in yeast have shown that in somatic cells there is a bias toward 
recombination using the sister chromatid rather than the homologous 
chromosome74, though there is evidence of HR between homologs in G175. 
Cohesion of sister chromatids ensures proximity of the recombination template 
and stabilizes interactions between them. HR repairs DSBs and replication 
associated breaks in the S and G2 phases of the cell cycle; ssDNA nicks and 
gaps can also be repaired by HR. Homologous recombination in meiosis 
involves similar mechanisms to mitotic HR and occurs after Spo11 initiates 
DSBs76. Though functional HR promotes genome stability, it can also cause 
genomic instability when it acts inappropriately or in an unregulated 
manner77,78. Proteins recruited to repair DSBs can be visualized by the 
formation of repair foci at lesions79.    
Mutations in genes involved in DNA repair have been implicated in 
human disease. For example, BRCA1 and BRCA2 are important factors in the 
homologous recombination pathway, and mutations in these proteins are 
associated with increased risk of cancer. Hereditary breast cancer from 
heterozygous germline BRCA mutations accounts for 5-7% of all cases of 
breast cancer, and patients with BRCA mutations have 50-80% risk of breast 
cancer and 30-50% risk for ovarian cancer, as well as a slightly increased risk 
for prostate and pancreatic cancers80. It is generally thought that BRCA 
tumors have loss of heterozygosity (LOH) or reduction in BRCA expression, 
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Figure 1: Homologous Recombination pathway. After a DNA DSB, DNA 
ends are resected to generate 3’ ssDNA overhangs that are then bound by 
RPA. In order for HR to proceed, mediators such as BRCA2 and RAD52 are 
needed to promote RAD51 filament formation and strand invasion. The 
RAD51 recombinase then performs homology search, essential to HR, forming 
a D-loop intermediate that can be processed by several pathways. 
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but LOH does not always happen in tumors81 and it is possible there is 
haploinsufficiency. Biallelic BRCA2, BRCA1, and PALB2 mutations are rare 
and cause Fanconi Anemia, which is associated with defects in interstrand 
crosslink (ICL) repair82-86. Other diseases caused by HR defects include 
Nijmegen breakage syndrome (due to NBS1 mutation), Fanconi Anemia (ICL 
repair protein mutations)87, Bloom’s syndrome (BLM mutation)88, ataxia 
telangiectasia (ATM mutation)89, ataxia telangiectasia-like disorder (Mre11 
mutations)90, Seckel syndrome (ATR and CtIP mutation)91,92, Werner 
syndrome (WRN mutation)23, and Rothmund-Thomson Syndrome (RECQL4 
mutation)18,23,90-92. Thus, HR is important to DNA repair function. 
An outline of the initial steps of the homologous recombination pathway 
of DNA repair can be found in figure 1.  
BRCA1 
BRCA1 is a key player in DNA repair through HR. SSA and HDR are 
reduced by mutation of BRCA1, suggesting it is important upstream in these 
homology-directed pathways93. BRCA1 forms several different complexes with 
other proteins, and is involved not only in DSB repair but transcription 
regulation and cell-cycle checkpoints. BRCA1 has RING domain and nuclear 
localization signal (NLS) at its N-terminus, a coiled-coil domain, and BRCT 
repeats at the C-terminus80. The RING interacts with BARD1, and is important 
in BRCA1’s function as an E3 ubiquitin ligase94. The coiled-coil domain 
mediates BRCA1’s interaction with PALB295-97. The C terminal BRCT repeats 
interact with phosphopeptides, mutually exclusively with Abraxas, BRIP1, and 
CtIP. BRCA1 forms complexes labeled A, B, and C, based on these BRCT 
interactions. The BRCA1-A complex forms through BRCA1 interaction with 
Abraxas. This complex ubiquitinates targets at DSBs through UBC13 and also 
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contains RAP80, which recognizes polyubiquitinated histones like γH2AX to 
target the complex to damage sites62,66,68. The BRCA1-B complex includes the 
BRIP1 helicase, which is required for checkpoint activation when replication 
forks are stalled or collapsed98,99. Finally, the BRCA1-C complex includes CtIP 
and MRN, and may play a role in resection100-102. The BRCA1-A complex has 
surprising anti-resection activity—depleting RAP80 results in hyper-
recombination phenotype, mediated through CtIP resection103. Because 
BRCA1 complexes are mutually exclusive, this may be a result of BRCA1 that 
would be in BRCA1-A instead forming BRCA1-B or -C complexes83. 
Another complex forms through the BRCA1 interaction with PALB2, 
which connects BRCA1 to BRCA295-97. BRCA1 disruption reduces PALB2, 
BRCA2, and RAD51 foci; PALB2 disruption reduces BRCA2 and RAD51 foci; 
BRCA2 disruption only prevents RAD51 foci. These observations suggest a 
pathway for HR, with BRCA1 is recruited upstream, and then recruits the 
BRCA2 mediator of RAD51 through PALB283. 
Resection 
Initiation of homologous recombination involves nucleolytic resection of 
the 5’ end at DSB sites to generate 3’ ssDNA overhangs10,104-107. Mammalian 
DSB resection and its regulation in vivo are not well understand, but it is 
believed to be an important mechanism in DSB repair pathway choice, as it 
inhibits NHEJ and promotes HR104,108,109. Other DSB repair pathways require 
resection as well: SSA begins similarly to HR, with fairly extensive resection, 
and MMEJ (or alt-NHEJ) also requires limited resection.  
Resection is initiated by the nucleases MRN and CtIP. The MRN 
complex, composed of MRE11, RAD50, and NBS1, recognizes and binds 
DSB ends. RAD50 and MRE11 stabilize the break and tether the DNA ends, 
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while NBS1 interacts with the ATM kinase, which phosphorylates and 
regulates many DNA repair proteins90,110,111. MRE11 has ssDNA 
endonuclease, and 3’-5’ exonuclease activities (though 5’-3’resection occurs in 
vivo); its endonuclease activity is believed to be important in resection111. MRN 
interacts with CtIP, which promotes resection106,107,112,113. CtIP has a 5’ flap 
endonuclease activity independent of MRN, and its phosphorylation at 
numerous sites in response to DNA damage by cyclin-dependent kinase 
(CDK), ATM, and ATR, is believed to regulate its function114. HR at complex 
breaks, like those with topoisomerase adducts or generated by IR, requires 
CtIP nuclease activity, while this nuclease activity is dispensable for CtIP’s role 
in HR repair of endonuclease breaks114. CtIP has also been shown to enhance 
the nuclease activity of MRE11 in vitro, and is important for ssDNA formation 
in vivo113. It has been suggested that MRN and CtIP may clip Ku from DNA 
ends similar to way they clip Spo11 off in meiosis115.   
A generally accepted model of resection is that MRN and CtIP initiate 
end resection by endonucleolytic cleavage of 5’ ends internal to break ends, 
releasing oligonucleotides116. Biochemical studies with human proteins and 
studies in yeast suggest that there are two routes for more extensive resection, 
stimulated by RPA and MRN, and requiring either the DNA2 nuclease in 
complex with BLM-TOPIIIα-RMI1 or the EXO1 nuclease117-120. Resection 
varies in length from a few hundred nucleotides to tens of kilobases, 
depending on the availability and location of homologous template116. 
BRCA1 colocalizes and interacts with MRN and CtIP after 
damage101,106,107,112,113,121,122. It promotes HR and SSA while it inhibits 
canonical NHEJ93,108,123, as does CtIP113,124 suggesting BRCA1 may also be 
involved in resection93. Nevertheless, there is controversy over the role of 
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BRCA1 in resection, as there is conflicting evidence over the role of BRCA1 
and its interaction with MRN-CtIP in resection, with some groups showing no 
role at all for BRCA1 in resection100,102,125-130. One model is that BRCA1 
recruits CDK-phosphorylated CtIP to DSB sites, as CtIP phosphorylation 
promotes the CtIP-BRCA2 interaction, but a CtIP mutant mouse that does not 
interact with BRCA1 has normal HR, disputing this131. Thus, the role of BRCA1 
in resection and interacting with MRN-CtIP needs to be better defined. 
Using a quantitative method to measure ssDNA intermediates in human 
cells at endonuclease-generated break sites, it was determined that DSBs are 
resected up to 3.5 kb in a cell cycle-dependent manner132. Depletion of CtIP, 
Mre11, Exo1, or SOSS1 blocked resection, while depletion of 53BP1, Ku or 
DNA-PKcs leads to increased resection132. Interestingly, they found no role for 
BRCA1 in this regulation132. Using this direct measurement in human cells and 
in vitro assays, DNA-PKcs inhibited resection by blocking the recruitment of 
resection enzymes such as EXO1, while ATM and MRN promoted resection133. 
MRN stimulated resection in presence of Ku and DNA-PKcs by recruiting Exo1 
and inhibited DNA ligase IV/XRCC4-mediated end rejoining133. Another study 
found that the CDK and PIKK sites of phosphorylation in CtIP were also 
essential for the recruitment of Exo1 and BLM to sites of laser-induced 
damage134.  
Limiting resection to the S and G2 phases of the cell cycle in turn limits 
HR to these phases. Reduced resection in G1 has been attributed to Ku 
binding DNA ends, NHEJ, and low CDK activity116. Cell cycle regulation is also 
achieved by CtIP degradation by the proteasome in G1, and through CDK 
phosphorylation of CtIP at S327 in S and G2, promoting its interaction with 
BRCA1 and MRN126,135. Limited resection in G1, likely by CtIP, promotes alt-
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NHEJ or MMEJ, as CtIP promotes alt-NHEJ102,106,124,136,137. CDK also 
phosphorylates Exo1, which contributes to this cell cycle specificity138. 
53BP1 is another important protein in the DNA damage response, and 
has been shown to limit resection. After DSB formation, 53BP1 rapidly 
localizes to discrete foci that co-localize with γH2AX and BRCA1; it has a key 
role in DNA repair response and checkpoint control. 53BP1 inhibition on its 
own increases levels of HR105,139,140, likely by relieving 53BP1 inhibition of end 
resection at DSBs6,7. 53BP1 binds and protects ends in G1, and competes with 
BRCA1 in S/ G2; BRCA1 spatially excludes 53BP1 from DSBs and 53BP1 
negatively regulates resection in G1141,142. BRCA1 loss leads to 53BP1 foci in 
G2, while 53BP1 loss leads to BRCA1 foci in G1127, suggesting the structures 
to recruit BRCA1 and 53BP1 are present in each cell cycle phase, but these 
protein mutually block one another. 53BP1 functions through effector proteins 
RIF1127,143-147 and PTIP148. In addition to preventing resection, 53BP1 plays a 
role in NHEJ139,149, partially by increasing stability and mobility of DSBs to find 
each other for productive ligation150,151.  
Interestingly, 53BP1 loss reverses much of the phenotype associated 
with BRCA1 loss, potentially through resection. 53BP1 loss rescues the 
embryonic lethality, tumor susceptibility, and premature aging in Brca1Δ11/Δ11 
mice, and rescues homology-directed repair in Brca1Δ11/Δ11 mouse cells 
without fully eliminating chromosome instability152. It reduces asymmetric 
radial chromosome structures in BrcaΔ11/Δ11 cells, increases RPA 
phosphorylation, reduces chromosome aberrations and reverses cisplatin 
sensitivity7, and reduces checkpoint activation elicited by unrepaired DNA 
damage due to Brca1 inactivation6. These data support a model where 53BP1 
prevents resection, and removing this inhibition rescues BRCA1-depleted cells. 
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53BP1 loss does not rescue PALB2 or BRCA2 mutants, so the synthetic 
viability between 53BP1 and BRCA1 is likely due to BRCA1’s role in 
resection153. Ku depletion does not also rescue BRCA1 loss154, so this effect 
specific to 53BP1 and not just due to NHEJ deficiency. Interestingly, depletion 
of 53BP1 or RIF1 depletion restores resection in BRCA1-deficient cells but not 
those lacking CtIP, supporting a function for CtIP in resection other than 
53BP1 removal61.  
After Resection—strand invasion or SSA 
After resection, the heterotrimeric ssDNA binding complex RPA binds 
the 3’ ssDNA overhangs1-3,72. For HR to proceed, RPA needs to be exchanged 
for filaments of the RAD51 recombinase, which performs the essential 
homology search and strand invasion steps of HR. The RAD51-ssDNA 
nucleprotein filament is called the presynaptic filament. When the 3’ ssDNA 
invades a DNA duplex, it base pairs to a complementary strand and displaces 
the other strand of the duplex, resulting in the formation of a displacement loop, 
or D-loop. S. cerevisiae RAD52 mediates the exchange of RPA for RAD51, 
promoting RAD51 filament formation on RPA-coated ssDNA and stimulating 
RAD51 strand invasion155,156. BRCA2 performs this mediator function in 
humans, leaving the role of human RAD52 unclear157,158. Moreover, RAD52 
mouse knockouts show little phenotype nor sensitivity to DSB-inducing agents, 
hRAD52 is inefficient at displacing RPA and stimulating strand exchange in 
vitro, and hRAD52 is not essential for RAD51 function or HR157,159,160.  
Nevertheless, recent evidence suggests that hRAD52 provides an 
alternative mediator pathway to BRCA2161,162.  In BRCA2-deficient human 
cancer cell lines depletion of RAD52 reduced cell survival and proliferation, 
thus there is a synthetic lethal relationship between the two proteins162.  
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RAD52 functions independently of BRCA2, since its localization to damage 
was not affected by the presence of the BRCA2 protein and RAD52 interacts 
with RAD51 independently of BRCA2162.  Additionally, RAD52 was necessary 
for RAD51-mediated HR in BRCA2-deficient cells162.  These results suggest 
that RAD52 provides a backup HR pathway in human cells: while BRCA2 is 
present, RAD52 has little effect on HR and viability, whereas in BRCA2-
deficient cells, RAD52 is important for viability and for HR162. A more in depth 
discussion of RAD51 and recombination mediators is presented later on. 
The SSA pathway also begins with resection, but is independent of 
RAD51 and is mutagenic. Rather than invasion of the resected strand of the 
sister chromatin, the break is repaired through annealing with downstream 
repeats. This pathway, in contrast to HR, has been shown to be dependent  
on RAD5293.  
Completing HR 
After RAD51-mediated strand invasion and D-loop formation, there are 
several ways repair can be completed. How a cell decides which pathway it 
uses to resolve this intermediate is not well understood, but likely depends 
upon the point in the cell cycle, the type of damage being repaired, and the 
DNA structure present. RAD51 D-loops can result in crossovers or 
noncrossovers (CO or NCO) depending on which pathway is chosen—a CO 
results in the loss or exchange of the chromosome arm surrounding the break, 
an NCO does not. COs can lead to loss of heterozygosity (LOH) in mitotic 
cells, which can lead to tumor formation depending on the genetic material lost. 
A CO between repeats can lead to copy number variation. The balance 
between COs and NCOs is different between mitotic and meiotic cells, as 
crossovers are needed in meiosis to allow exchange of genetic material and to 
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pair the homologous chromosomes163,164. D-loops can lead to break-induced 
replication (BIR), synthesis-dependent strand annealing (SDSA), or the 
formation of double Holliday Junctions (dHJ).  
BIR involves pairing between the resected 3’ ssDNA and the 
homologous duplex region of the sister chromatid, with no second end capture 
of the other end of the break due to loss or inaccessibility of the second end. 
The invading strand then replicates off of the duplex it invaded, allowing 
replisome assembly and initiation of leading and lagging strand synthesis. The 
3’ overhang can invade the sister chromatid, the homologous chromosome, or 
a homologous region of another chromosome to initiate DNA synthesis, but 
use of templates other than the sister chromatid leads to LOH. This pathway is 
disfavored in mitotic recombination over SDSA165.  
SDSA, in contrast to BIR, does involve annealing to the other end of the 
break. In this pathway, the extended D-loop is disrupted, and the invading 
strand dissociates to anneal to the other 3’ overhang on the other side of the 
DNA break. HR is then completed by filling in the gap and ligation166,167. This 
pathway can only result in noncrossovers. Antirecombinases promote this 
activity which reduces sister chromatid exchanges; helicases believed to 
promote SDSA include RECQ5168, RTEL1169. Mph1, and Fml1. 
 Second end capture of the displaced strand in the D-loop, by annealing 
to the second 3’ end of the break, leads to the formation of a dHJ. dHJs can 
result in CO or NCO depending on how they are processed. In mitotic cells, 
dHJs can be processed by dissolution by the BLM/TOP3α/RMI1/RMI2 
complex, which involves branch migration and topoisomerase activity leading 
to a NCO170. The DSB repair (or DSBR) pathway involves dHJ resolution to 
form CO or NCO, depending on where the strands are cut. This is performed 
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by different resolvases: MUS81/EME1, GEN1, or SLX1/SLX4171-174. In meiosis, 
there is a bias toward DSBR by CO, while COs are suppressed in mitotic 
HR175. Second end capture to generate dHJs are mediated by RAD52 in yeast 
and humans176-180, while the U. maydis Brh2 is capable of promoted second 
end capture when RAD52 annealing is inhibited181. 
Antirecombinases function to disrupt RAD51-ssDNA filaments or D-loop 
intermediates. In yeast, Srs2 and Sgs2 have been shown to function as 
antirecombinases. In humans, a number of proteins have been implicated, 
including FBH1, PARI, BLM, FANCJ, FANCM, RECQ5, RTEL1 and RECQ1, 
and mutations in some of these genes have been shown to increase 
crossovers and sister chromatid exchanges (SCEs)3,27,170,182. Their role may 
be to reduce excessive HR or to promote SDSA over dHJ formation and/or 
noncrossovers over crossovers through dHJ, but their exact function and 
mechanisms are not well understood. Similarly, the mismatch repair (MMR) 
machinery recognizes mismatches in HR intermediates and helps disrupt D-
loops of mismatched duplexes, potentially through Msh2 interacting with BLM 
or WRN183-186. The complexity of the regulation of the RAD51-filament has 
been suggested to be due to another activity of human RAD51 filaments 
beyond homology search and strand exchange: at stalled replication forks 
RAD51 filaments protect ssDNA from Mre11 degradation42, which may be 
regulated through BRCA227,44.  
In summary, homologous recombination is important in the repair of 
DNA double-strand breaks, including those resulting from errors in DNA 
replication. How cells choose which pathway of DSB repair to use is under 
complex regulation. Mutations in proteins involved in homologous 
recombination lead to an increased risk in certain cancer types, highlighting 
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the importance of this pathway. In the next section, we describe the RPA 
protein complex and its phosphorylation. This protein is involved in many DNA 
processes in cells, including DSB repair through HR. 
REPLICATION PROTEIN A (RPA): 
Replication Protein A (RPA) is a heterotrimeric protein complex 
composed of subunits RPA1, RPA2, and RPA3. RPA is the primary eukaryotic 
single-stranded DNA binding protein (SSB), which are found in both 
prokaryotes and eukaryotes. ssDNA is generated during many DNA metabolic 
processes and as a result of damage to DNA; SSBs bind this ssDNA, 
protecting it from endonuclease degradation and preventing the formation of 
DNA secondary structure to allow DNA processes to proceed. In addition to 
this role, RPA also is involved in a number of protein-protein interactions that 
allow it to regulate DNA metabolic processes including DNA replication, repair, 
and recombination. RPA is also involved in transcription, cell cycle and DNA 
damage checkpoints, and telomere maintenance187-191. 
SSBs, including RPA, are essential to cellular survival. While there is no 
strong homology between prokaryotic SSBs and RPA, there is a high level of 
homology between eukaryotic species in RPA, particularly in RPA1 and RPA2. 
RPA was originally isolated as a factor required for SV40 DNA replication192, 
and it is involved in the initiation and elongation steps of DNA replication. Loss 
of any of the three RPA subunits is lethal, and non-lethal mutations have been 
found to cause DNA repair defects and genome instability. RPA is found in the 
nucleus, and localizes to DNA in foci during replication and DNA repair. An 
abundant protein at a constant level through the cell cycle193-195, RPA binds 
ssDNA with high affinity, so as a result ssDNA in cells is rapidly bound by RPA.  
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RPA structure 
RPA’s subunits RPA1, RPA2, and RPA3, are 70, 32, and 14 kDa, 
respectively (Figure 2). Between these three subunits there are six DNA 
binding domains (DBD) labeled A through F, which are 
oligonucleotide/oligosaccharide-binding folds (OB folds), common to DNA 
binding proteins. The OB folds of RPA are composed of five beta sheets that 
form beta barrels that can wrap around ssDNA196,197. To form the trimeric 
complex, each subunit contributes an OB fold to the trimerization core, 
consisting of DBD-C, DBD-D, and DBD-E, from RPA1, RPA2, and RPA3, 
respectively. Outside of the trimerization core, the other domains of RPA 
extend on flexible unstructured linkers, which allow for dynamic binding to 
DNA and protein partners, and multiple conformations198.  
When subunits of RPA are expressed individually they are insoluble or 
aggregate with other proteins, but with all three expressed a large portion of 
each peptide forms a soluble complex. Interestingly, RPA2 and RPA3 were 
shown to form a soluble complex when coexpressed without RPA1, but this 
complex is not functional and is believed to be a precursor to the 
heterotrimeric complex199. 
RPA1 contains four OB fold domains: DBD-A, DBD-B, DBD-C, and 
DBD-F. The high affinity DNA binding of RPA is attributable to DBD-A and 
DBD-B. These domains have a short linker between them, allowing for 
cooperative binding. DBD-C also binds ssDNA in some conformations, and 
contains zinc finger motif that influences DNA binding200,201. DBD-F contains a 
basic cleft at the N-terminus of RPA1 and though it can bind with ssDNA, it is 
thought to primarily act in protein-protein interactions202. Some models 
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Figure 2: RPA domains and phosphorylation sites. Top, the domains of the 
three RPA subunits, RPA1, RPA2, and RPA3. DBD A-F are composed of OB 
folds. Protein interaction domains are located on RPA1 and RPA2, which both 
interact with RAD52. DBD-C, DBD-D, and DBD-F form the trimerization core. 
Bottom, the hyperphosphorylation domain of RPA2 at the N-terminus is 
phosphorylated by CDKs in a cell cycle dependent manner at S23 and S29, 
and by DNA-PK, ATM, and ATR, in a DNA damage inducible manner at S4, 
S8, S11, S12, S13, T21, and S33.  
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suggest that proteins and DNA are in direct competition for the binding site in 
DBD-F202. 
The other two subunits of RPA also play a role in DNA binding, inter-
subunit interactions, and protein-protein interactions with factors that allow 
RPA to regulate DNA processes. RPA2 has an unstructured N-terminal 
phosphorylation domain, which is hyperphosphorylated in response to DNA 
damage and during certain phases of the cell cycle. This phosphorylation is 
important in regulating not only RPA conformation and possibly DNA binding 
activity, but for RPA’s role in DNA repair and replication. There is extensive 
literature on RPA phosphorylation that will be discussed in more 
detail20,112,189,191,195,199,203-268. RPA2 also has a central DNA binding domain, 
DBD-D, which is also part of the trimerization core, and a C-terminal winged 
helix domain involved in protein-protein interactions. RPA3 is mostly important 
for heterotrimer stability, containing DBD-E that is part of the trimerization core. 
Though structural results suggest that it can bind ssDNA, it has not been 
observed269,270.  
RPA plays a role in processes that generate ssDNA, and its function in 
the cell is mediated through protein partners. Many proteins have been 
identified that interact with RPA1, including p53, ATRIP, MRE11, RAD9, 
RAD17, WRN, FANCJ, BLM, and XPG187,189,271. Many of these interact 
through an acidic alpha helical domain that bind a basic cleft of the N-terminus 
of RPA1 and are involved in DNA repair or the DDR. RPA also interacts with 
replication factors polymerase alpha, PCNA, and DNA2, the NER protein XPA, 
the BER protein Ung2, DSB repair proteins RAD52, RAD51, BRCA1, and 
plays a role in MMR and telomere maintenance187,189,271.  
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RPA-DNA binding  
Human RPA binding DNA has been extensively studied. RPA binds 
ssDNA with much higher affinity than dsDNA or RNA (at least three orders of 
magnitude greater), with 5’-3’ polarity188,190,191,196,272-274 and an association 
constant of 109-1011 M-1 275,276. It has a 10-50 fold preference for polypyrimidine 
sequences over polypurine sequences276,277, and binds with a length 
dependence such that it binds more strongly to 30 nucleotide oligos compared 
to 10 nucleotide oligos271. RPA protein binds ssDNA with low cooperativity, 
and the major ssDNA binding affinity is attributed to DBD-A and DBD-B in 
RPA1, with a short linker between them allowing greater binding affinity278. 
A model for RPA binding suggests that RPA binds ssDNA sequentially, 
5’-3’, alphabetically through DBDs A-D, with the complex becoming more 
stable as more DNA is bound188-191,271. RPA1’s DBD-A and DBD-B bind first, 
with a binding footprint of eight nucleotides. This eight nucleotide binding 
footprint has primarily been observed with glutaraldehyde crosslinking, 
suggesting it is unstable and likely a precursor to longer binding modes190,275. 
RPA1’s DBD-C then binds, to make the total segment 12-23 nucleotides. 
Finally RPA2’s DBD-D binds, bringing the footprint 25-30 nucleotides. This 30 
nucleotide segment is the most well characterized and stable191.  
More recent studies suggest that RPA binding is more dynamic than 
this sequential model. Thermodynamic analyses suggested that there are only 
18-20 and 28-30 nucleotide binding modes, likely representing three of four of 
the DBDs bound, and that the smaller binding modes are unstable and 
temporary271,279,280. Studying yeast RPA, Gibb et al281 found that without other 
unbound proteins present, RPA remains stably bound to ssDNA for long 
periods of time and rarely dissociates. In contrast, RPA rapidly dissociates and 
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is exchanged when there is unbound RPA, scRAD51, or E. coli SSB, present 
in solution. They proposed that RPA dissociation involves a partially 
dissociated intermediate that exposes a small section of ssDNA to allow other 
proteins access, which could then carry out DNA metabolic processes like 
recombination or repair. Another study280 found that human RPA rapidly 
diffuses along ssDNA, allowing other proteins access and also productively 
promoting the destabilization of hairpins adjacent to ssDNA. 
Though RPA binds ssDNA with much greater affinity, it does bind 
dsDNA. When RPA binds dsDNA, it can destabilize the duplex, disrupting the 
bonds between two strands282-284. RPA also has a preference for ultraviolet 
radiation (UV) and cisplatin damaged dsDNA compared to undamaged dsDNA, 
likely due to this destabilizing activity285-289. Conversely, RPA has a reduced 
affinity for damaged ssDNA compared to undamaged ssDNA283,290.  
RPA and the DNA Damage Response 
Due to its role as an ssDNA binding protein, and its interactions with 
other proteins involved in DNA metabolism, RPA has been identified as an 
important player in the DDR. In addition to its role in the DNA repair pathways 
themselves, RPA is involved in DNA damage and cell cycle checkpoints, 
which delay the cell cycle so that DNA can be repaired, or induce cell death in 
cells with irreparable damage. Failure of the DDR leads to genomic instability.  
As described previously, RPA interacts with important players in the 
DDR. When ssDNA is generated during replication stress or other kinds of 
DNA damage, RPA binds the ssDNA and then recruits ATR through ATRIP20. 
The RAD17-RFC complex, which requires RPA-ssDNA for its recruitment, 
loads the 9-1-1 sliding clamp complex onto DNA17,19-21. 9-1-1 has structural 
similarity to PCNA and plays a role in DNA repair. ATR becomes active 
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through interaction with TopBP1, which is recruited to damage through binding 
Rad9 of the 9-1-1 complex17,19-21. Thus, RPA is important in recruitment and 
activation of ATR20. RPA also colocalizes and interacts with MRN, which may 
connect it to the ATM kinase as well.  
A recent study by Toledo et al22 elucidated part of the role of RPA in 
genome stability. Stalled forks in ATR-deficient cells were found to have 
nucleus-wide breakage due to the excess of ssDNA generated by 
unscheduled origin firing that exhausts the pool of RPA. The authors suggest 
that ATR suppresses dormant origins, which protects against this breakage by 
preventing the exhaustion of RPA. If there is too much ssDNA during 
replication stress the nuclear pool of RPA is exhausted, which leads to DSBs. 
Cells with less RPA are less tolerant of replication stress, and cells with 
overexpressed RPA are more tolerant. The ATR damage checkpoint was 
found to help prevent this exhaustion by inhibiting origin firing, which would 
generate more ssDNA. RPA normally acts to stabilize stalled forks and 
activate damage checkpoints through ATR, and after damage allows restart of 
replication20,205,233,291. 
RPA-RAD52 interaction 
The RPA1 and RPA2 subunits are thought to be responsible for its 
interaction with RAD52292-294—thus connecting the central proteins of this 
thesis. The RPA2 subunit contains a C-terminal winged helix domain that 
interacts with a positively charged alpha helix in RAD52 (residues 257-274 of 
RAD52). This helix contains an Arg-Gln-Lys sequence similar to sequences in 
SMARCAL1, Tipin, Ung2, and XPA, that also interact with the RPA2 C-
terminus189,294,295. In addition to the RPA2 interaction, human RAD52 is 
thought to interact with DBD-A and DBD-B of RPA1292,294,296. Budding yeast 
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contain an additional acidic helix domain in RAD52 not found in humans, 
which is crucial for RAD52’s RPA interaction through RPA1 and recruitment to 
repair centers297.  
The interaction between RPA and RAD52 has been shown to be 
functionally significant. For example, Park et al298 found that RAD52 mutants 
that lack an interaction domain (amino acids 221-280 of RAD52) fail to 
enhance HR in monkey cells, while overexpressed RAD52 containing this 
segment does enhance HR. Grimme et al295 found using FRET ssDNA 
annealing assays that the RAD52-RPA interaction facilitated binding of 
hRAD52 to RPA-ssDNA, and counteracts RPA’s helix destabilizing activity. 
Another study by Jackson et al292 showed that RPA-RPA52 complexes have a 
five to 18-fold higher affinity for ssDNA than either protein alone, even using a 
RAD52 mutant lacking its own DNA binding domain. Nevertheless, although 
human RAD52 clearly interacts with RPA, a central player in DNA repair, the 
function of RAD52 in humans and other vertebrates is still not well defined. 
Other human SSBs 
There is a homolog to RPA2, RPA4, which replaces the canonical 
RPA2 in a form of RPA known as alternative–RPA (a-RPA)299. RPA4 interacts 
with RPA3 and RPA1, but not RPA2299,300, and only has complete coding 
sequences in primates and horse, with other mammals containing a 
pseudogene or related sequences301. Like RPA2, RPA4 contains an N-
terminal putative phosphorylation domain300. RPA4 is expressed in quiescent 
cells and in all normal human tissues, but at different levels in different tissues, 
and its expression is reduced in cancerous tissues and cell lines299,302  
a-RPA has similar ssDNA binding properties to RPA; it binds ssDNA 
with high affinity and low cooperativity, and forms similar solution structures to 
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RPA199,303,304. While a-RPA has only a slightly reduced binding affinity than 
RPA for undamaged DNA, it has a higher affinity than RPA for damaged DNA 
and shows a ten-fold greater preference for damaged DNA than RPA. a-RPA 
is not functional in replication, and acts as a dominant negative, inhibiting 
replication by canonical RPA. RPA4 does not support proliferation or S phase 
progression301. 
While a-RPA does not support replication, it has been shown to be 
capable of supporting DNA repair, as it is functional in both NER and 
recombination300-302. RPA4 localizes to foci after treatment with camptothcin 
(CPT), colocalizing with γ-H2AX and p-CHK2. CPT is a topoisomerase poison 
that causes replication stress and replication-associated breaks. It also 
interacts with RAD51 and RAD52, and supports RAD51 in vitro strand 
exchange301,302.  
Two other SSB proteins, hSSB1 and hSSB2, have also recently been 
described in humans305-321. These proteins have more structural similarity to 
archael SSBs than to RPA. They form SOSS complexes with two other 
proteins, INTS3, and a previously uncharacterized protein. hSSB1 forms foci 
in response to DSBs but does not form replication foci, and is phosphorylated 
by ATM313. hSSB1/2 and their SOSS partners have been shown to play a role 
in HR repair and ATM checkpoint signaling, as cells defective in these proteins 
have hypersensitivity to damaging agents, chromosomal instability, reduced 
HR and RAD51 recruitment, and reduced ATM-dependent 
phosphorylation306,308,311,313. hSSB1 has also been suggested to regulate 
resection through promoting MRN and Exo1 nuclease activity and 
recruitment309,310,318.  
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hSSB1 and other SOSS complex proteins have also been suggested to 
regulate checkpoints, similar to RPA. hSSB1 has been found to bind p21 and 
to affect the G1/S and G2/M transitions potentially through p21314; it also 
interacts with p53, stabilizing it and allowing p53-dependent p21 
transcription317. hSSB1 relocates to damaged replication forks305 and 
facilitates repair and restart stalled forks, through promotion of ATR and CHK1 
activity and Mre11 and Rad51 recruitment305; in RPA-depleted cells hSSB1 
can recruit and activate ATR-ATRIP307. Finally, deletion of the hSSB homologs 
in mice leads to repair and growth defects and lethality315, and these mouse 
homologs were shown to play a role in telomere protection316.  
The identification of RPA4 and the SOSS complex demonstrates that 
cells have a complicated network of regulations to DNA damage. How these 
proteins function in cells and their role and competition with canonical RPA is 
not well understood. In addition to these potential damage-specific SSBs in 
humans, another mechanism of regulation of SSBs response to DNA damage 
that is not yet well understood is hyperphosphorylation of the N-terminus  
of RPA2. 
RPA Phosphorylation 
The N terminus of RPA2 in humans is phosphorylated in response to 
DNA damage and at certain points in the cell cycle20,112,189,191,195,199,203-268. A 
common strategy for studying this phosphorylation involves mutation of 
putative phosphorylation sites to either alanine, which would act as a non-
phosphorylatable protein, or mutation of the sites to aspartate, which would 
add an acidic residue believed to mimic a phosphate group. While this study 
focuses on human RPA phosphorylation, yeast RPA has also been observed 
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to be phosphorylated in response to DNA damage on both the RPA1 and 
RPA2 subunits, which is dependent on the ATR homolog MEC1212,238,260,263.  
Two sites specifically on the RPA2 N-terminus are phosphorylated in a 
cell cycle-dependent manner during the G1/S transition and M phase by CDKs: 
S23 and S29195,218-221. S29 is phosphorylated in mitosis, and S23 is 
phosphorylated in the S and M cell cycle phases195,219,220,237,242,250,256. S23 and 
S29 are CDK consensus sites containing an S/T-P motif, and are 
phosphorylated by cyclin A-Cdk2 and Cyclin B-Cdk1 during DNA replication 
and mitosis, respectively189,199,219,220,234,242. As a result, the phopsho-S23/S29 
form of RPA is specific to mitosis195,204,220,240,250,257. The S phase 
phosphorylated form has been found to be associated with the replication 
initiation complex221. Dephosphorylation occurs during progression into G1 at 
mitotic exit, as RPA is relocated to the nucleus222,250. This may function to help 
remove RPA from chromosomes, since RPA is excluded from the 
chromosomes during mitosis250 and a decrease in dsDNA binding and duplex 
destabilizing activity is observed when RPA is phosphorylated at these sites240.  
Besides the two CDK-dependent phosphorylation sites, seven other 
sites have been identified as phosphorylation targets in the RPA2 N-terminus: 
S4, S8, S11, S12, S13, T21, and S33237,256. The specific kinase involved and 
which residues that kinase phosphorylates at what time point varies depending 
on which damaging agent is used and what phase of the cell cycle cells are 
in20,204,205,209,211,213,215,223,225,228,230,231,233,234,237-239,241,242,246-
252,254,256,257,259,261,262,264. Three kinases phosphorylate these sites: DNA-PK, 
ATM, and ATR. Although early studies indicated that ATR and ATM respond 
to replication stress and replication-independent DSBs, respectively, and 
DNA-PK functions in DSB repair by NHEJ, it is now clear that PIKKs have 
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overlapping roles and display crosstalk in various DNA damage response 
pathways205. There are four to nine identifiable isomers of 
hyperphosphorylated RPA after damge211. Evidence suggests that RPA 
phosphorylation is dependent upon RPA binding to chromatin and on 
replication, as treatment with aphidicolin (which arrests DNA replication) 
inhibits CPT-induced RPA hyperphosphorylation209,237,239,248. RPA binding to 
DNA is believed to cause a conformational change that promotes efficient 
phosphorylation.  
DNA-PK, ATM, and ATR each have been implicated in RPA 
hyperphosphorylation, though which kinase is responsible may differ 
depending on the type of damage. The pattern of hyperphosphorylation differs 
depending on damaging agent used238,244,256. There has been controversy 
over whether RPA is hyperphosphorylated in response to IR, with some 
studies observing this phosphorylation203,217,250 and others suggesting that the 
hyperphosphorylation response is limited to agents that generate larger 
amounts of ssDNA204,234,250. DNA-PK, which has been implicated in both 
NHEJ and HR repair, contributes to RPA hyperphosphorylation237,242. DNA-PK 
has been observed to phosphorylate in vitro each phosphorylation site in the 
N-terminus of RPA2237,256, and to phosphorylate RPA in cells at multiple sites 
after treatment with CPT, etoposide (ETO, a topoisomerase poison), IR, and 
UV204,205,209,231,233,247,248,250,254. It has been observed to interact in vitro with 
RPA1248. Cells with DNA-PK defects have similar phenotypes to those with 
RPA phospho-mutants, further demonstrating its important role in RPA 
phosphorylation205. ATM is also believed to contribute to RPA 
hyperphosphorylation, including after IR, UV, and ETO209,234,239,250,257, but 
possibly not after CPT treatment247. Defects in RPA phosphorylation have 
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been observed in A-T cells, which are deficient in ATM, supporting a role for 
ATM in RPA phosphorylation234,239,261. Finally, ATR is not only recruited by 
RPA, but plays a role in RPA hyperphosphorylation20. Phosphorylation of RPA 
by ATR is dependent on ssDNA and stimulated by ATRIP251,262. ATR has 
been implicated in RPA hyperphosphorylation after IR, CPT, UV, and 
hydroxyurea (HU, which depletes nucleotide pools thereby causing replication 
stress) treatment233,241,247,252,262,264. Interestingly, ATR kinase activity has been 
suggested to be needed for ATR and RPA foci formation after IR262. While 
many studies have been published on RPA hyperphosphorylation by these 
kinases, the relative contributions of each kinase after different damaging 
agents, and the role of each phosphorylation site, are not well defined.  
Beyond these nine better-characterized sites of phosphorylation in the 
RPA2 N-terminus, additional residues on RPA may be phosphorylated. 
Phosphorylation of RPA1 has been observed in yeast260,263 and humans238. 
ATR was observed to phosphorylate the S52, S72, and S174, S/Q consensus 
sites on RPA2 in vitro, but the contribution of these sites in vivo was not 
determined241. Another study found five new potential phosphorylation sites on 
RPA2, including T98, and five sites on RPA1238, while another suggested 
there are up to eight unidentified phosphorylation sites on RPA2211. Finally, the 
PHOSIDA and PhosphoSitePlus databases show human RPA1, RPA2 and 
RPA3 contain 28, 19 and 4 potential phosphorylation sites, respectively, that 
were measured at least once by mass spectrometry225,228.  
Phosphorylation at certain residues on RPA2 may be primed by 
phosphorylation at others. For example, hyperphosphorylation has been 
suggested to be dependent on CDK phosphorylation at S23 and S29 in some 
cases204,234,242. However, other studies did not see this effect of S23 and S29 
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on hyperphosphorylation250,259, which may be due to different damaging 
agents and systems used. S33 phosphorylation by ATR may also stimulate 
subsequent phosphorylation at other sites204,241,252. In another example, 
S23A/S29A or T21A/S33A mutants both inhibit S4/S8 phosphorylation after 
CPT, though 21/33 does so to a greater extent204. Additionally, S4/S8 and T21 
phosphorylation may exhibit reciprocal priming effects204,233, while S33 
phosphorylation regulates S4/S8 phosphorylation204, but not vice versa233. In 
contrast, other studies have shown that S4/S8 phosphorylation does not 
depend on other sites, and that T21 and S33 do not trigger RPA2 
phosphorylation after CPT247. Interestingly, one study found that 
phosphorylation could be primed in trans: phosphorylation of one RPA 
promoted phosphorylation on another204. Thus, while it is likely that priming at 
some sites does occur, the exact relationships are still unclear. 
Effect on hyperphosphorylation of RPA-DNA binding 
 There is evidence for a relationship between phosphorylation of RPA 
and its DNA binding activity, though it is not well-defined and there have been 
some contradictory results207,223,240,244. In one study, no difference in 
hyperphosphorylated and non-phosphorylated RPA binding to pyrimidine-rich 
ssDNA sequences was observed, but hyperphosphorylated RPA (hypRPA) 
had decreased binding to purine-rich ssDNA and dsDNA244. Simarlarly, IR-
induced hypRPA exhibited decreased binding to ssDNA compared to non-
phosphorylated RPA in crude mouse cell extracts223 and a lower affinity to 
DNA with 5’ or 3’ tails has been observed for phosphorylated RPA compared 
to RPA235. In contrast, using a mixed sequence 25-nucleotide oligomer, a 
relative increase in ssDNA binding by hypRPA over RPA was observed216. 
Other studies described little effect of RPA phosphorylation on ssDNA binding: 
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the mitotic phosphorylated form and mutations of mitotic sites shows no 
difference in ssDNA binding between pRPA and RPA240,259, and deletion of the 
N-terminus (amino acids 1-40) of RPA2 or mutations of the phosphorylation 
sites to alanine or aspartate each had only modest effect ssDNA binding 
activity265. Thus, while it is possible that phosphorylation of RPA may regulate 
its DNA binding, how it does so is still unclear and may be dependent on the 
length and sequences of nucleotides used. It has been suggested that a 
decrease in ssDNA binding, may facilitate binding of other repair proteins to 
the ssDNA, but this decrease in binding has not been observed consistently.  
Studies investigating phosphorylated RPA binding to dsDNA have been 
more consistent, demonstrating a reduction in RPA-dsDNA binding upon 
phosphorylation. Mitotically phosphorylated RPA binds less efficiently to 
dsDNA compared to non-phosphorylated RPA240. This was proposed to 
facilitate removal of RPA from DNA in mitosis, and reduce RPA duplex 
destabilization. Similar to this finding, the addition of multiple negative charges 
to the RPA2 phosphorylation domain reduces RPA-dsDNA duplex 
destabilization, while deletion of the phosphorylation domain or mutation to 
alanine did not effect helix destabilization206. This duplex destabilization defect 
was also observed with deletion of RPA1 N-terminal domain, suggesting a 
functional link between these domains206. Upon damage to dsDNA this effect 
was shown to be reversed: a higher affinity for cisplatin-damaged duplex DNA 
binding has been found for hypRPA compared to RPA, suggesting that 
hypRPA may signal DNA damage to other repair proteins244.  
RPA recruitment and phosphorylation 
There is some evidence that RPA phosphorylation affects RPA foci 
formation, though the published data is unclear. RPA replication foci, in 
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general, show no difference between RPA2-WT and RPA2-alanine mutants, 
while RPA2-aspartate mutants have been observed to have defects. For 
example, an RPA2-A (S8/S11/S12/S13/T21/S23/S29/S33) mutant was shown 
to have normal distribution and to associate with replication centers in 
untreated cells, while an RPA2-D mutant at the same sites did not associated 
with replication centers, despite still immunoprecipitating with RPA1 and being 
able to support DNA replication in an SV40 in vitro reaction253, Similarly, other 
RPA2-D mutants (S4D/S8D/S11D/S12D/S13D/T21D/S33D and T21D/S33D) 
had defective RPA2 S-phase-specific foci, while a S4D/S8D/S11D/S12D/S13D 
mutant had a more minor defect in forming normal S-phase foci241. Mutation of 
these sites to alanine did not result in a defect in association with replication 
centers241. In agreement with these results, in untreated cells no difference 
between RPA2-WT and an S23A/S29A204 mutant or T21A/S33A252 mutant foci 
was observed204,252. Looking at endogenous protein, hypRPA does not appear 
to localize to chromatin in untreated cells: no S4/S8 foci are observed in 
untreated cells249, mitotically phosphorylated RPA do not localize to 
chromosomes250 and an antibody specific to p-S4/S8 did not show 
phosphorylated RPA at replication centers253. Complementing these studies, 
depletion of ATR, DNA-PK, ATM, or treatment with caffeine did not affect 
RPA2 foci formation in untreated cells247. In sum, these data suggest that in 
untreated cells RPA can be recruited without phosphorylation and that 
phosphorylation prevents RPA recruitment to replication foci. 
In cells with DNA damage, both phospho-mimic and 
unphosphorylatable RPA are recruited normally. Expressing a kinase-dead 
mutant of ATR does not affect RPA2 recruitment to chromatin after damage 
with UV or HU, though hyperphosphorylation is reduced241,264, and 
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hyperphosphorylation has been observed to occur after initial localization of 
RPA to damage sites247,249. Expressing kinase inactive ATR or treatment with 
caffeine reduces RPA foci formation two hours after 50Gy IR, however, 
mutation in two ATR RPA phosphorylation sites does not affect RPA IR-
induced foci (IRIF) so this effect may be an indirect effect of ATR inactivation 
and not specific to RPA phosphorylation, or the sites mutated were sufficient 
for the effect262. Looking at RPA mutants directly, after treatment with CPT, 
HU, or IR, there are normal levels of RPA foci in both RPA2-A and RPA2-D 
(S8, S11, S12, S13, T21, S23, S29, S33) mutants253. Similarly, an RPA2-A 
mutant containing alanine substitutions at all of the damage-inducible 
phosphorylation sites (S4A/S8A/S11A/S12A/S13A/T21A/S33A) did not result 
in a defect in association with damage foci after UV and HU, although this 
mutant did not slow replication as well as WT in response to UV, similar to 
ATR deficiency241. These observations support the model that RPA is 
phosphorylated before recruitment to DNA.  
In seeming contrast to these findings, there is evidence that RPA 
phosphorylation affects RPA foci kinetics after damage. In one study, 
depletion of ATR or treatment with caffeine abrogated RPA2 foci formation 
after CPT, though there was normal RPA2 foci formation in DNA-PK and ATM 
deficient cells after CPT treatment247. Feng et al found that an RPA2-D mutant 
(T21D/S33D) formed foci normally after HU, but these foci persisted during 
recovery, which is likely due to unresolved damage, as γH2AX foci also 
persist112. Though some studies241,253 show phosphorylation prevents 
association of RPA with the replication machinery after stress, they did not see 
a defect in T21D/33D association with BrdU replication centers112. In another 
study, RPA2-T21A/S33A mutant cells had normal DNA replication without 
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stress, but after stress had abnormally high levels of chromatin bound RPA, 
defective recovery from stress, and higher levels of ssDNA formation252. Lee 
et al found that depletion of PP4R2 (a phosphatase that targets RPA2) 
resulted in fewer RPA foci at early time points (up to 1.5 hours) after CPT 
treatment, but at later time points (four hours) there was no difference 
compared to control cells230. Consistent with this finding, an RPA2-D mutant 
(S8, S23, S29, S33) showed a significant delay in RPA2-focus formation after 
CPT230. One paper observed a similar fraction of cells with RPA2 foci, but 
those foci were of greater intensity immediately after and eight hours after 
treatment with CPT in a S23A/S29A mutant204. It’s possible that the model that 
RPA is hyperphosphorylated independent of recruitment is still consistent with 
these findings, and that RPA hyperphosphorylation’s effect on repair is 
responsible for differences seen. This is also consistent with an unaltered DNA 
binding affinity of hypRPA compared with RPA to ssDNA. RPA 
hyperphosphorylation promotes DNA repair, and as a result levels of ssDNA, 
which would alter RPA foci kinetics. Thus, it’s unlikely for RPA phosphorylation 
mutants to have no effect at all on RPA foci kinetics. 
RPA phosphorylation, DNA repair, and replication stress 
Current models suggest that RPA phosphorylation and 
dephosphorylation are important in regulating RPA’s role in the repair of 
damaged DNA. Defects in RPA phosphorylation alter the response to 
replication stress and lead to sustained damage. Several studies have shown 
that RPA phosphorylation defects lead to sensitivity to DNA damaging agents; 
for example, RPA2-D (S8/S23/S29/S33) mutants have increased CPT 
sensitivity230 and HU and UV sensitivity112, while RPA2-A mutants have 
increased chromosomal aberrations and decreased survival after HU249.  
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RPA phosphorylation defects have also been shown to affect damage 
repair, resulting in persistent damage and ssDNA. For example, after 
treatment with CPT, RPA2-A (S23/S29) mutant cells had more intense RPA2 
and γH2AX staining compared to RPA2-WT cells 204, RPA2-A (S4/S8) mutant 
cells have sustained H2AX phosphorylation after HU and enter mitosis with 
unrepaired damage233, while an RPA2-D (T21/S33) mutant and PP2A-
depleted cells also have persistent DNA damage foci of RPA and γH2AX in 
HU recovery112. Similarly, RPA2-A (S4/S8/S11/S12/S13/T21/S33) mutant cells 
have higher frequencies of chromatid and chromosome breaks, radial 
structures, and decreased cell survival after HU, and hypRPA associated with 
ssDNA after HU, supporting a role for RPA phosphorylation during replication 
stress and recovery249. In agreement with this, more DSBs were measured by 
the COMET assay in an RPA2-A (S4/S8/S11/S12/S13/T21/S33) mutant 
compared to RPA2-WT cells after CPT268 and in RPA2-D (T21/S33) after 
HU112. RPA2-D and RPA2-A can associate with damage foci, as they are 
shown to co-localize with γH2AX253, implying that although RPA can localize to 
breaks and sites of stress, RPA recruitment of downstream factors is impaired 
when the regulation of hyperphosphorylation is impaired, leading to persistent 
breaks. Curiously, one study found that RPA2-WT cells had more γH2AX by 
western blot after stress compared to an RPA-S33A or RPA-T21A/S33A 
mutants, which was argued to be the result of more breaks generated during 
replication during stress recovery252. This may be due to different assays used, 
as other studies looked at γH2AX foci, phosphorylation by western, or due to 
different timepoints, mutants, or cell backgrounds used. 
Assays measuring homologous recombination more directly have 
shown a role for RPA phosphorylation in its regulation. RAD51 foci formation 
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is often reduced in RPA phosphorylation mutants. For example, compared to 
RPA2-WT cells, RPA2-A (S4/S8/S11/S12/S13/T21/S33) mutant cells have 
fewer RAD51 foci after HU, though not after IR, and hypRPA2 colocalizes with 
RAD51 in response to HU249. Dephosphorylation is also important for HR, as 
PP4R2-depleted or RPA2-D (S4/S23/S29/S33) mutant cells also 
have reduced RAD51 foci after CPT230. Notably, deficiency in RPA2 
hyperphosphorylation has no obvious effect on the fraction of cells with 
RAD51 foci in untreated cells249. The DR-GFP assay has also been used to 
study the effect of RPA hyperphophorylation with similar results. Synchronized 
cells treated with HU in S phase have decreased DR-GFP HR in RPA2-A 
(4/8/11/12/13/21/33) mutant cells compared to WT, but phospho-mutant cells 
are normal in HR of I-SceI-induced breaks in this assay249. Another study did 
see an effect on endonuclease breaks, as cells depleted of PP4 phosphatase 
subunits or expressing an RPA2-D mutant (S8/S23/S29/S33) show lower HR 
induced by I-SceI compared to control cells230. Further, mutation in the p53 
phosphorylation sites that regulate its interaction with phosphorylated RPA 
also reduced DRGFP-HR268. Interestingly, it was shown that aberrant HR was 
increased in RPA-phospho mutant cells, as measured by UV-induced sister 
chromatid exchanges (SCEs), which were increased in RPA2-A (S4/S8) 
mutant cells compared to RPA2-WT cells231. This effect has also been seen 
for DNA-PK-KD (kinase dead) but not DNA-PK null cells after HU205.  
The effect of RPA phosphorylation on unstressed DNA replication has 
also been studied. RPA2-D mutants and hypRPA have been suggested to be 
deficient in their association with replication centers in cells241,253, and 
phosphorylation of RPA2 has been suggested to inhibit DNA replication213,244. 
HypRPA has also been shown to have deficient interactions with pol-alpha 
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primase209,240, which would limit its role in replication. In contrast, other in vivo 
and in vitro studies have not seen deficient replication or localization of RPA to 
foci without damage112,243,252,253,259. While the effect of RPA phosphorylation 
on replication without damage is unclear, after DNA damage, it is generally 
accepted that RPA phosphorylation and dephosphorylation promote 
replication-associated repair207.  
RPA phosphorylation promotes RPA function in recovery from 
replication stress. HypRPA colocalizes with ssDNA after HU, supporting the 
role of RPA phosphorylation in replication stress recovery249. Further, 
phosphorylation mutants are deficient in recovery from stress. For example, 
RPA2-A (T21/S33) mutant cells are deficient in recovery from HU, with more 
RPA bound to chromatin, reduced BrdU incorporation, higher levels of ssDNA 
formation, and increased apoptosis compared to RPA2-WT cells252. 
Dephosphorylation is also needed, as DNA synthesis after IR is impaired in 
PP4R2-depleted, and RPA2-D (S8/S33 and S8/S23/S29/S33) mutant cells230. 
Additionally single molecule fiber analysis in RPA2-A (T21/S33 and S23/S29) 
mutant, RPA2-D (T21/S33) mutant, and PP4R2-depleted cells shows reduced 
synthesis at replication forks during HU-induced replication stress and 
recovery from stress compared to WT cells236.  
Some studies have shown different effects of RPA phosphorylation on 
replication recovery after stress. Feng et al found that RPA2-D (T21/S33) cells 
have normal RPA2 foci after damage, and have normal DNA replication levels 
after HU treatment, as measured by thymidine incorporation112; while there 
were elevated levels of radioactive thymidine incorporation after HU treatment 
in RPA2-A (T21/S33) cells112. This RPA2-A effect was argued to implicate 
RPA phosphorylation in the intra-S checkpoint. The discrepancy with other 
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studies listed above, which described reduced nucleotide analog incorporation 
(BrdU) in phospho-mutants, may be due to the use of a low concentration of 
HU, 0.2mM, compared to between 1.5 and 5 mM for the other studies. In a 
different study, Olson et al using flow cytometry analysis did not see a defect 
in replication resumption after 1mM HU release in RPA2-A mutant 
(S4/S8/S11/S12/S13/T21/S23/S29/S33) cells, though similar to Feng et al they 
saw an elevated levels of DNA synthesis by thymidine incorporation after UV 
treatment241. This may also be due to differing methods and treatment with UV 
as opposed to high concentrations of HU241. Another argument against the 
function of hypRPA in replication stress recovery could be made by the 
observation by Vassin et al, that an RPA pS4/S8 antibody did not colocalize to 
areas of BrdU incorporation after CPT treatment, but their analysis was not 
rigourous253. Nevertheless, it is clear that disruption of RPA phosphorylation 
and dephosphorylation does affect recovery from replication stress. 
In line with defects in DSB repair and replication stress response, 
altered regulation of RPA phosphorylation leads to altered cell cycle 
distributions after DNA damage. Some groups have also implicated RPA 
phosphorylation directly in checkpoint responses, with phosphorylation 
mutants failing to stall the cell cycle to allow damage to be repaired. RPA2-A 
(S23/S29) mutant cells mutants have a delayed G2/M transition, delayed 
mitotic exit, and increased apoptosis204,257; RPA2-A mutant (S4/S8) cells have 
increased mitotic entry with unrepaired damage231,233, and fail to arrest 
following replication stress, with defective G2/M arrest after ETO and cisplatin 
treatment, premature replication fork restart, failure to block late origin firing, 
and increased mitotic catastrophe205. PP4R2-silenced and RPA2-D mutant 
(S8/S23/S29/S33) cells have an extended G2/M checkpoint230, though another 
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study found no effect of RPA phosphorylation on checkpoint and cell cycle 
distribution in RPA2-D (T21/S33) mutant cells112. In one report, replication-
induced Chk1 phosphorylation was defective in DNA-PKcs and RPA2-A 
(S4/S8) mutants233, which was argued to be because RPA2 S4/S8 
phosphorylation regulates replication checkpoint signaling via MRE11 and 
TopBP1 phosphorylation, as an RPA2-A (S4/S8) mutant has reduced 
phosphorylation of MRE11 and TobBP1233. Other studies have found no effect 
on Chk1 phosphorylation in RPA2-A mutant cells, after HU or UV treatment241.  
RPA phosphorylation also regulates DNA repair by altering protein 
interactions. For example, RPA’s interaction with the MRN complex is 
dependent on the regulation of its phosphorylation, although results of these 
studies are contradictory 245,267. Robison et al found that RPA and MRE11 
colocalize in response to HU and UV, both become phosphorylated, and a co-
IP showed this interaction is abrogated by phosphatase treatment, suggesting 
that phosphorylation of these proteins promotes their interaction245. Oakley et 
al showed that purified RPA interacts with Mre11 and Nbs1 through the RPA1 
N-terminus, but in this case a phosphomimetic RPA2 mutant is deficient in this 
interaction267, while an alanine mutant had increased colocalization with MRN 
after etoposide267. The differences between these results may be due to the 
different damaging agents methods used, or because Robison et al used a 
phosphatase to look at the effect of phosphorylation which would be non-
specific, while Oakley et al used purified proteins, phosphorylation mutants, 
and RPA bound to ssDNA for their IP. Thus, although the direction in which 
RPA phosphorylation affects its MRN interaction is unclear, it is likely that this 
interaction is somehow regulated by phosphorylation. 
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Another example of phosphorylation altering RPA-protein interactions 
involves the p53 tumor suppressor. Phosphorylation of RPA by DNA-PK and 
phosphorylation of p53 by ATR and ATM after DNA damage disrupts the p53-
RPA complex, which is needed for HR repair268. Disruption of the release of 
the RPA-p53 complex reduces HR repair of DSBs, while phopshorylation of 
either protein alone shows no effect268. It was also shown that ssDNA and an 
RPA2-D mutant displace p53 in binding RPA1, leading to a model that after 
damage RPA2 phosphorylation results in the RPA2 N-terminus interacting with 
RPA1, displacing p53 and dissociating the p53-RPA complex210. 
Key to HR repair of DNA breaks are the RAD51 and RAD52 proteins, 
and phosphorylation also regulates RPA’s interaction with these proteins. A 
co-IP showed that RPA’s interaction with RAD51 and RAD52 after UV and 
CPT is promoted by hyperphosphorylation255. RAD51 and RAD52 have higher 
affinity for hypRPA in an in vitro binding assay as well255. hypRPA co-localizes 
with RAD52 in foci255, while RAD52 focus formation is reduced in RPA2-A 
mutant cells268. An in vitro study further investigated the interaction of hypRPA 
and RAD52, and found that hyperphosphorylaiton of RPA promotes formation 
of a complex with monomeric RAD52 and causes transfer of ssDNA from RPA 
to RAD52216. The RPA-ssDNA-Rad52 complex was found to be more stable 
when it included hypRPA compared to unphosphorylated RPA, and more 
RAD52 crosslinks to ssDNA when the RPA in the complex is 
hyperphosphorylated216.  Other studies have confirmed that 
hyperphosphorylation promotes RPA’s interaction with RAD51: RAD51 
preferentially co-immunoprecipitates with an RPA2-D mutant230 and RAD51 in 
vitro preferentially pulls down hypRPA with little non-phosphorylated 
RPA2255,268. 
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The HR protein PALB2 also interacts preferentially with hypRPA: 
hypRPA’s ability to stimulate fork recovery has been suggested to be 
mediated through PALB2, and RPA phosphorylation increases localization of 
PALB2 and BRCA2 to RPA nuclear foci after replication stress236. hypRPA 
also recruited PALB2 to ssDNA in vitro236. Another protein involved in the 
regulation of repair, the ATR kinase, not only phosphorylates RPA but 
phosphorylation has been shown to improve its interaction with RPA: ATR 
binds more efficiently with hypRPA after damage, and hypRPA co-localizes 
with ATR in foci255. Thus, hyperphosphorylation of RPA regulates its role in 
DNA repair partially through regulating protein interactions.  
A current model proposes that RPA undergoes a conformational 
change upon phosphorylation. Using scanning transmission electron 
microscopy, it was shown that formation of the extended RPA-30 nucleotide 
ssDNA complex correlates with increased phosphorylation208. Another study 
compared native and hypRPA using mass spectrometry, fluorescence 
spectroscopy, and limited proteolysis235. The authors found a conformational 
change upon hyperphosphorylation of RPA in which three residues in DBD-B 
of RPA1 were shielded in hypRPA,235 leading to a model in whice the RPA2 N-
terminus interacts with DBD-B of RPA1 in a phosphorylation dependent 
manner235. Other studies have supported this model that phosphorylation of 
the N-terminus of RPA2 results in RPA2 binding to RPA1, displacing RPA1 
from ssDNA or other proteins. The binding of RPA2 to RPA1 would release 
the RPA1 N-terminus from ssDNA and then allow DNA damage response 
proteins to interact with RPA1 instead, or hypRPA2 may compete for binding 
of RPA1 with damage repair proteins to allow them to bind to other proteins. 
Supporting this hypothesis, the interactions with some proteins that interact 
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with RPA1 are altered after RPA is phosphorylated, including MRN, RAD9322, 
p53, ATRIP and DNA-PK210,240,245,248,267,322. P53 binds to the N-terminus of 
RPA-1, and p53 is displaced by ssDNA and RPA2-D mutant protein, 
supporting this hypothesis210. A functional link between these two RPA 
domains was also demonstrated, as a phosphomimetic RPA2 mutant shares a 
similar defect in DNA duplex destabilization as a mutant with the RPA1 N-
terminus deleted206. Further, NMR studies showed evidence for a direct 
interaction between the RPA1 N-terminus and phosphomimetic mutant RPA2 
mutant206.   
RPA regulation by phosphatases 
In addition to regulation of phosphorylation by kinases, 
dephosphorylation of RPA by phosphatases is also important for RPA 
regulation and DNA repair, as mentioned previously. The PP2A phosphatase 
has numerous substrates involved in DNA repair, replication and cell cycle 
progression323-325. Feng et al showed that RPA is dephosphorylated by PP2A 
phosphatase during recovery from HU112; the catalytic subunit of PP2A binds 
to RPA2 after damage and can dephosphorylate RPA2 in vitro112. Further, 
RPA2-T21/S33 phosphomimetic mutant cells had increased HU and UV 
sensitivity and persistent DNA damage foci of RPA and γH2AX112  
The PP4 phosphatase also dephosphorylates RPA2. PP4C–PP4R2–
PP4R3β forms the PP4 heterotrimeric complex, which is involved in the DSB 
response; PP4C and PP4R2 form a heterodimeric complex in vivo and in vitro, 
which then recruits PP4R3α or PP4R3β. Lee et al showed that PP4R2, the 
regulatory subunit, mediates RPA2 dephosphorylation by recruiting the PP4C 
catalytic subunit230. PP4 dephosphorylates RPA2 in vitro, and depletion of 
PP4R2 in cells alters the pattern of RPA2 phosphorylation, inhibits HR, 
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reduces RAD51 foci formation, extends the G2/M checkpoint, and causes 
hypersensitivity to DNA damage230. Further, cells expressing a 
phosphomimetic RPA2-D mutant cells (S8/S33/S23/S29) are comparable in 
these defects to those depleted of PP4230. RPA2 interacts with PP4C and 
PP4R2 (not with PP4R3β) after treatment with CPT230. Silencing PP4C and 
PP4R2 increases RPA phosphorylation after CPT and IR, which is not 
dependent on H2AX, another target of PP4C230, and these effects are not due 
to kinase activity of ATR or DNA-PK230. These data are consistent with a role 
of the PP4 phosphatase in regulating RPA2 phosphorylation. In agreement 
with this study, Murphy et al found that after treatment with CPT, cells deficient 
in PP4R2 showed an increase in levels of hyperphosphorylated RPA, with 
slowed replication fork movement during stress and recovery236. Thus, 
regulation not only by kinases but also by phosphatases through 
dephosphorylation is important in regulating RPA2 phosphorylation and DNA 
damage. 
These findings are in line with similar studies that show that 
phosphatases regulate other proteins involved in DNA repair, replication, and 
cell cycle progression. PP4C dephosphorylates other critical DNA repair 
factors, including H2AX, KAP-1, and 53BP1230,232,326-329. PP4 has also been 
shown to be involved DSB repair through both HR and NHEJ232.  
Recent unpublished data from our lab suggest that BRCA1 controls 
RPA2 phosphorylation through phosphatases in response to replication stress. 
BRCA1-deficient cells have a marked reduction and delay in phosphorylated 
RPA2 expression after treatment with hydroxyurea, and a consequent 
reduction in the recruitment of pRPA2 to DNA damage foci. A constitutive 
association between BRCA1 and the catalytic subunit of PP2A in vivo 
           47
dissociates after DNA damage. Thus, RPA2 phosphorylation status is 
regulated by a BRCA1-PP2A complex that dissociates upon damage to 
promote RPA2 phosphorylation and coordinate timely HR. Taken together, 
these data suggest that regulation of RPA phosphorylation is regulated both 
by phosphorylation and dephosphorylation, and this switch is important in the 
regulation of DNA repair. 
In summary, RPA is an essential protein in eukaryotes, as ssDNA is 
produced through numerous cellular processes. RPA plays a key role in the 
repair of DNA damage, and its interactions with both DNA and repair proteins 
allow it to regulate repair processes. RPA is itself regulated by phosphorylation, 
which is clearly important in the repair of DNA damage, but the mechanisms 
and precise regulation of RPA phosphorylation requires further clarification. Of 
interest to this thesis, is how RPA phosphorylation affects mediators of 
RAD51-homologous recombination. In the next section, we describe in more 
detail the RAD51 and the RAD51 mediators. 
RAD52 AND MEDIATIORS OF RECOMBINATION 
 RAD52 has two main functions (Figure 3). One is as an ssDNA 
annealer, base-pairing complementary ssDNAs. The other is as a mediater, 
facilitationg formation of RAD51 filaments on RPA bound ssDNA and 
promoting RAD51-exchange. While both  human and yeast RAD52 proteins 
clearly anneal ssDNA in vivo and in vitro, RAD52’s role as a mediator in 
humans and other vertebrates has been called into question. Following is a 
discussion of the key players in mediation in vertebrates: RAD51, BRCA2, and 
RAD52. 
 Two main in vitro assays are used to assess RAD51 function: the 
strand exchange assay and the D-loop assay. The strand exchange assay 
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Figure 3: RAD52 domains and function. a. RAD52 domains. In the N-
terminal half of the protein, RAD52 interacts with DNA and itself to form higher 
order structures. In the C-terminal half, RAD52 interacts with RPA and RAD51, 
pointing to its role as a mediator. b. RAD52 functions. RAD52 acts as a 
mediator, promoting RAD51 filament formation on RPA-ssDNA, and strand 
invasion. RAD52 also acts as an annealer, base-pairing complementary 
ssDNA bound by RPA. c. Proposed annealing pathways. RAD52 annealing 
function may be important to Single-Strand Annealing (SSA), Synthesis-
Dependent Strand Annealing (SDSA), or Second End Capture.  
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takes ssDNA, or a duplex with an ssDNA overhang, and incubates it with a 
dsDNA duplex that contains a strand homologous to the ssDNA. Strand 
exchange, catalyzed by a recombinase, involves the ssDNA or overhang 
invading the homologous dsDNA duplex and displacing the bound 
complementary strand. Similarly, in the D-loop assay, ssDNA or an ssDNA 
overhang is added to a plasmid containing a region of homology to the ssDNA. 
D-loops are formed when the ssDNA invades the duplex, base pairing to the 
complementary region of the plasmid, and displacing the other strands.  
RAD51  
An essential protein for HR, the RAD51 recombinase is a homolog of 
RecA from bacteria. These recombinases form nucleoprotein filaments on 
DNA and catalyze homology search and strand exchange. RAD51 is needed 
for both mitotic and meiotic recombination, while DMC1, the other eukaryotic 
recombinase, is involved only in meiotic recombination. RAD51 loss is lethal 
early in mouse embryogenesis40,330,331 likely due to its role in DNA repair in 
replicating cells through HR, and disruption of RAD51 in vertebrate cells leads 
to increases in chromosome aberrations. In cells, RAD51 forms repair foci at 
ssDNA sites in response to DNA damage332.  Formation of a RAD51 filament 
leads to repair by HR and suppresses SSA and alt-NHEJ; SSA is 
demonstrably increased while HR is reduced in RAD51- and BRCA2-deficient 
cells93,333,334.  
The crystal structure of RecA filaments shed light on how strand 
exchange works335 and this mechanism is likely conserved in eukaryotes. 
RecA-ssDNA with ATP forms a helical filament that binds to dsDNA, searches 
for homology, and then catalyzes the exchange of the complementary strand, 
producing a new heteroduplex. Chen et al found that ssDNA bound with 
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RAD51 has units of three nucleotides that are B-form in structure, and 
between these triplets the DNA is stretched. Homology search in the duplex is 
believed to occur by random collisions, and the complementary strand in the 
dsDNA interacts primarily through base pairing, so that heteroduplex formation 
is solely dependent on base-complementarity. ATP hydrolysis promotes the 
dissociation of the new heteroduplex DNA and the displaced strand. DNA in 
yeast and human RAD51 filaments is also extended significantly compared to 
B form DNA, which is thought to facilitate homology sampling, though the 
polarity of pairing and invasion are opposite that of RecA.  
RAD51, like RecA, contains ATPase activity, though its ATP hydrolysis 
rate is slower. In comparison to RecA, hRAD51 protein also exhibits lower 
strand-exchange activity in vitro. For homology search and strand exchange, 
RAD51 ATP binding but not hydrolysis is required336. ATP hydrolysis is 
needed for dissociation of the recombinase from newly formed heteroduplex 
DNA. As a consequence, the use of a nonhydrolyzable nucleotide analogue337, 
calcium ions338, or a RAD51 mutants lacking ATPase activity337, leads to the 
stabilization of the presynaptic filament and also enhanced recombinase 
activity in vitro. Turnover from ATP hydrolysis could promote recycling of 
recombinases within the cell, and make the primer in the D-loop available for 
DNA repair synthesis339. Mouse ES cells with an ATPase-dead (K133R) 
mutation of RAD51 have increased sensitivity to MMC and IR, reduced SCE 
efficiency, and defective HR340. Expression of an ATP-binding mutant of 
RAD51 causes a greater than 90-fold shift to SSA over HR, and expression of 
an ATP hydrolysis mutant of RAD51 resulted in more extensive gene 
conversion, which increases genetic loss during HDR93. These studies 
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demonstrate that although in vitro ATPase activity is not required for exchange 
activity, it is likely important for functional HR in cells. 
Certain factors have been shown to affect RAD51 exchange activity. 
The effect of Ca2+ of modulating its ATPase activity is unique to human 
RAD51338. When Mg2+ is included in in vitro reactions, the hRAD51-ATP-
ssDNA filament is quickly converted to an inactive hRAD51-ADP-ssDNA form, 
due to relatively rapid ATP hydrolysis and slow dissociation of ADP, while 
inclusion of Ca2+ maintains the active hRAD51-ATP-ssDNA filament by 
reducing the ATP hydrolysis rate. The efficiency of in vitro recombination by 
hRAD51 protein can also be significantly enhanced by reducing RAD51 
binding to dsDNA by addition of 100 mM ammonium sulfate341. Finally, RAD51 
activity is stimulated by the presence of high salt, which favors co-aggregation 
of the nucleoprotein filaments with dsDNA, destabilizes RAD51 interactions 
with dsDNA, and causing a RAD51 conformational change that leads to 
extended filaments342.  
The formation of the RAD51 filament on ssDNA and D-loop 
intermediates are both reversible, through antirecombination and 
anticrossover pathways. The RAD51-ssDNA filament is reversible through 
yeast Srs2, and human proteins implicated in this function include FBH1, PARI, 
BLM, FANCJ, RECQ5. Nascent D-loops can be reversed through mismatch 
repair proteins, which reject D-loops when heterology is detected by these 
proteins. Extended D-loops can also be reversed, which promotes SDSA and 
NCOs. Yeast Srs2 and human RECQ5 have been implicated in this process, 
as have human RTEL1, FANCM, and BLM (yeast Sgs1). 
RPA plays a role in the strand exchange reaction as well, both inhibiting 
and promoting the reaction. It is believed to prevent secondary structure 
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formation in ssDNA, and to bind the displaced strand preventing reversal of 
the reaction. However, in in vitro biochemical reactions, RPA added prior to 
RAD51 inhibits exchange, by inhibiting formation of RAD51 filaments on 
ssDNA. This can be overcome by mediators157. There are several mediators of 
RAD51 exchange in eukaryotes, including BRCA2 and RAD52. 
BRCA2 
BRCA2 is the primary mediator of RAD51 filament formation in humans 
and other vertebrates157,158. Mutations in BRCA2 cause a predisposition to 
cancer, meiotic defects, DNA damage sensitivity, defective replication and 
checkpoints, and increased choromosomal instability, evidenced by increased 
chromosomal breaks, translocations, exchanges and abnormal structures39,343-
346. Hypomorphic biallelic mutations in BRCA2 cause Fanconi Anemia—
BRCA2 is also known as FANCD1. Early studies showed that BRCA2 
interacts with RAD51, is important for RAD51 recruitment to foci, and is 
important in HR333,344,347-350. Like loss of RAD51, deficiency in BRCA2 leads to 
reduced HDR and increased SSA93. BRCA2 also functions to stabilize stalled 
replication forks through RAD5139.  
BRCA2 is a large protein of 3418 amino acids80. At the N-terminus, 
BRCA2 interacts with PALB2. Between amino acids 1009 and 2083, BRCA2 
contains eight BRC repeats, which are important for its interaction with RAD51. 
Closer toward the C-terminus lies its DNA-binding domain, consisting of a 
helical domain, three OB folds, and a tower domain, which facilitates BRCA2 
binding to both ssDNA and dsDNA and interacts with DSS1. At the C-terminus 
is BRCA2’s nuclear localization signal, as well as a CDK phosphorylation site 
that mediates its RAD51 interaction80. 
           55
 Protein partners of BRCA2 are important for its function in HR. PALB2 
functions to facilitate BRCA2 mediation, as it stabilizes RAD51 binding to 
ssDNA and promotes the formation of D-loops351,352. PALB2 mutations are 
also associated with breast cancer, and biallelic mutations result in Fanconi 
Anemia. BRCA2 also relies on the DSS1 protein: BRCA2 mutants that do not 
bind DSS1 have HR defects, and DSS1 is thought to promote BRCA2 loading 
of RAD51 and BRCA2 stability43,158,353. 
 The BRC repeats of BRCA2 mediate its interaction with RAD51. There 
is great variability in the number of BRC repeats between species. There is 
also poor sequence identity between BRC repeats within a species, and 
different BRC repeats are thought to have diverging functions. BRC1-4 bind 
free RAD51 at high affinity, reduce RAD51 ATPase activity, target RAD51 to 
ssDNA instead of dsDNA, promote RAD51 nucleation, and stimulate 
exchange354. The second set of BRC repeats, BRC5-8, lacks these activities, 
binding free RAD51 with low affinity but the RAD51-ssDNA filament with high 
affinity, stabilizing the filament and facilitating filament extension354. 
Interestingly, fusions of BRCA2 BRC repeats to RPA1 in BRCA2-mutant cells 
improved HDR and suppressed mutagenic repair through SSA, and also 
restored RAD51 foci formation355. This supports the idea that the main function 
of BRCA2 is in HR, specifically bringing RAD51 to DNA. 
The C-terminal interaction of BRCA2 with RAD51 is regulated by CDK 
phosphorylation at S3291 at the G2/M transition356. This interaction stabilizes 
RAD51 filaments. Interestingly, mutation of the S3291 site shows little or no 
DNA damage sensitivity or HR defect44,357,358. However, this site is thought to 
be important for BRCA2 to stabilize nascent DNA: RAD51 binding to this site 
           56
has been implicated in the protection of nascent strands at the replication 
fork44. 
Recently, several groups purified BRCA2 and characterized it 
biochemically157,158,359,360. They confirmed that BRCA2 binds RAD51 through 
its BRC repeats, binding up to six RAD51 proteins at a time157,158. Prior studies 
using BRC fragments, and the U. maydis and C. elegans orthologs of BRCA2 
(Brh2 and BRC-2, respectively) suggested a role for BRCA2 in DSB repair 
through RAD51344,348,355,361-368. Reports of full length BRCA2 purification 
showed that BRCA2 prefers binding ssDNA to dsDNA, with a slight preference 
for tailed substrates157,359. Electron microscopy data showed that BRCA2 
specifically recognizes dsDNA with ssDNA overhangs, but not blunt dsDNA 
ends. BRCA2 was found to form rod-shaped complexes, which based on their 
dimension and mass were suggested to be dimers359. Also, there was no 
complex of BRCA2-RAD51-ssDNA observed, suggesting that BRCA2 leads 
RAD51 to ssDNA and does not become a stable part of filament359.  
Based on these reports and previous studies, BRCA2 is proposed to 
have four main mechanisms of promoting RAD51 function360. First, BRCA2 
prevents RAD51 binding to dsDNA, which inhibits exchange157,359. Second, it 
stimulates binding of RAD51 to ssDNA or to dsDNA with ssDNA tails157,359. 
Third, it enables RAD51 to bind ssDNA in presence of RPA157,158,359. And 
fourth, BRCA2 inhibits RAD51-ssDNA dissociation by inhibiting ATP 
hydrolysis157,158. While other mediators, such as Brh2 in U. maydis and 
RecFOR in bacteria, have been shown to localize recombinase filaments to 
the ssDNA/dsDNA junction, this was not observed for BRCA2368-370. 
In one of the reports of purified full-length BRCA2, Jensen et al showed 
that BRCA2 binds RAD51, DMC1, and yRad51, but not RecA, RPA, SSB, or 
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RAD52. They showed that BRCA2 stimulates strand exchange by RAD51, at 
an optimal one to three RAD51:nucleotide ratio. In the exchange assay, when 
RAD51 was added to the tailed substrate and dsDNA at the same time, rather 
than being incubated with the ssDNA tail first, there were only background 
levels of exchange. However, the addition of BRCA2 promoted exchange in 
these conditions, confirming that BRCA2 directs RAD51 to ssDNA, or limits its 
binding to dsDNA, or both. This effect is even seen in the presence of RPA 
added at same time as the other proteins, though this reduces levels of 
exchange. At a concentration that saturates both ssDNA and dsDNA with 
RAD51, exchange is normally inhibited because of RAD51 binding the dsDNA, 
even when RAD51 is first incubated with ssDNA and then the dsDNA is 
added; BRCA2 also stimulated exchange in this case (in these assays RPA 
was not included). The authors further showed this ability of BRCA2 to direct 
RAD51 to dsDNA by EMSA analysis157.  
In exchange assays where the ssDNA representing the resected strand 
is incubated with RPA prior to the addition of RAD51 and BRCA2, BRCA2 
promoted RAD51 exchange157. It mediated exchange when the ssDNA was 3’ 
tailed and 5’ tailed equally, but did not mediate exchange with untailed ssDNA 
quite as well. BRCA2 stimulated RAD51-exchange up to twenty fold, but it did 
not stimulate RecA exchange, suggesting its interaction with RAD51 is 
important for this function and is species specific. BRCA2 lacking polarity in 
mediation of exchange differs from Brh2 and RecFOR368,371,372. Replacing 
RPA with SSB did not affect BRCA2 stimulation; this observation, in 
conjunction with the data showing that BRCA2 does not interact with RPA, 
implies that BRCA2 does not need to interact with RPA to facilitate 
exchange157.  
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Jensen et al also looked at the differences between BRCA2 and RAD52. 
While U. maydis and C. elegans BRCA2 orthologs can anneal ssDNA in 
presence of RPA365,373 BRCA2 did not anneal RPA-coated ssDNA—in 
humans this function appears to be specific to RAD52. Although scRAD52 
promotes scRAD51-exchange on scRPA-ssDNA, both hRAD52 and scRAD52 
did not mediate exchange with hRPA and hRAD51, while BRCA2 did. This 
suggests this mediation activity is species-specific, and is primarily carried out 
by BRCA2 in humans157. In the next section, we discuss the role of RAD52 in 
humans, which despite its inability to promote RAD51 filament formation on 
RPA-ssDNA in these assays, still plays a role in HR. 
RAD52 phenotypes  
hRAD52 was initially identified as a homolog of RAD52 in S. cerevisiae, 
which was known to be required for HR repair of DSBs. The human RAD52 
gene is 418 amino acids (mouse is 420), sharing 30% identity and 58% 
similarity amino acid sequence with scRAD52374, primarily in the N-terminal 
region of the protein (human and mouse share 69% identity and 80% 
similarity) (Figure 3). The N-terminus is responsible for binding to DNA and for 
forming oligomers. Toward the C-terminus, where the human and yeast 
sequences diverge, RAD52 interacts with RPA and RAD51. Low amounts 
of RAD52 RNA were observed in adult mouse tissues, while a relatively high 
level of gene expression was observed in the testis and thymus, suggesting 
that the mammalian RAD52 protein, like its homolog from yeast, plays a role in 
recombination374. 
S. cerevisiae RAD52 is known to mediate the exchange of RPA for 
RAD51, promoting RAD51 filament formation on RPA-coated ssDNA and 
stimulating RAD51 strand invasion155,156. It is known to bind DNA375, RAD51376, 
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RPA377,378, to target Rad51 to ssDNA379, and to facilitate RPA displacement by 
RAD51380. Deletion of RAD52 leads to severe DSB repair and meiosis defects 
in yeast. S. cerevisiae RAD52 not only promotes Rad51 filament formation, 
but also functions in RAD51-independent ssDNA annealing for second-end 
capture, SDSA, and SSA, which is likely why yeast rad52 mutants have more 
extreme phenotypes than rad51 mutants180. 
Despite their similarities, RAD52 does not have a strong HR phenotype 
in vertebrates, as it does in yeast93,381, which is likely due to the presence of 
BRCA2. In organisms that do have both a BRCA2 homolog and RAD52, like U. 
maydis, chicken, and mice, RAD52 disruption also leads to limited or no 
defects in HR or DNA repair; interestingly, C. elegans do not have RAD52 
homolog, only containing BRCA2159,160,382. Nevertheless, there are some 
effects of RAD52 in cells and organisms, suggesting it does indeed play a role.  
RAD52 knockouts in chicken and mice failed to show a strong 
phenotype159,160. RAD52 deletion mutants of the chicken B-cell line DT40 were 
not hypersensitive to DNA damage induced by IR, MMS, or cisplatin, and 
there was no effect on growth rate and cloning efficiency160. Furthermore, 
intrachromosomal recombination, measured by immunoglobulin gene 
conversion, and IRIF of RAD51, were unaffected in RAD52-deleted cells 
compared to WT cells160. Targeted integration frequencies, however, were 
consistently reduced in RAD52-deleted cells, showing a clear role for RAD52 
in genetic recombination160. This phenotype was noted to be similar to that of 
the yeast S. pombe, where mutation of RAD51 and RAD54 leads to 
hypersensitivity to radiation and targeted integration deficiency, but deficiency 
in the RAD52 homolog rad22 has a less severe defect383. Similar to the 
chicken cells, mouse RAD52 mutants lack a strong HR phenotype159. RAD52-
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deleted embryonic stem (ES) cells were not hypersensitive to DSB agents, 
and RAD52-null mice showed no abnormalities in viability, fertility, and the 
immune system, calling into question the importance of RAD52 in HR159. 
However, inactivation of RAD52 in mouse ES cells did cause a reduced 
frequency of HR measured by gene targeting159. Finally, I-SceI reporter 
constucts in RAD52-null mouse cells show no detectable HDR defect, 
although SSA is dependent on RAD5293. In sum, these data suggest that 
though RAD52 is not critical to DSB repair in chicken and mouse, it does still 
play some role in HR and is important in SSA.  
 Further supporting some role in the HR pathway despite RAD52’s lack 
of severe phenotype, RAD52 still interacts with key players in HR. Several 
studies showed RAD52 interacts with RAD51 by IP, colocalization, and in vitro 
assays298,376,381,384-386, and it interacts with RPA1 and RPA2 as described 
previously292-294,298. These interactions map to the C-terminal half of RAD52 
(Figure 3), where it does not share homology with yeast Rad52, implying the 
interactions, and possibly the functional significance of these interactions, are 
species specific.  
Studies of RAD52 overexpression have shown effects on HR readouts, 
again supporting a role for RAD52 in homology-directed DNA repair. Early 
studies showed that overexpressing RAD52 in monkey cells conferred 
resistance to IR and increased levels of HR387, and that RAD52 mutants that 
lacked its interaction domain with RPA (amino acids 221-280 of RAD52) failed 
to enhance HR in monkey cells298. Mouse cells overexpressing a RAD52-GFP 
fusion show both increased survival and an increased number of RAD51 foci 
after MMS and IR384, and RAD52 overexpression has also been found to 
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inhibit gene targeting and stimulate HR between separate transfected 
plasmids388.  
Double mutants of RAD52 with other HR factors have also pointed to a 
role for RAD52 in HR. In chicken DT40 cells, conditional mutants deficient in 
both RAD52 and XRCC3 are non-viable and have extensive chromosomal 
breaks, whereas rad52 and xrcc3 single mutants grew well389. Double mutants 
of RAD52 and RAD54 in mice have normal haemopoietic depression in bone 
marrow and micronuclei formation with MMC treatment, but a deficiency of 
RAD52 exacerbates the MMC survival of RAD54 mutant mice and also has a 
distinct effect on the survival of bone marrow cells after exposure to IR390. As 
will be discussed in more detail later, RAD52 is also synthetically lethal with 
BRCA2, BRCA1, PALB2, and the RAD51 paralogs, and acts independently of 
these proteins162,391,392.  
RAD52 is regulated by post-translational modifications in yeast and 
humans. Studies in yeast have shown that RAD52 is regulated by sumoylation, 
which is induced by DNA damage and involved in regulating RAD52 stability 
and activity393-396. Similarly, hRAD52 associates with the sumo-conjugating 
enzymes UBL1 and UBE2I in yeast two hybrid assays397,398. Further, in human 
cells, PTEN was shown to interact with RAD52 by IP and colocalization, and 
also colocalized with γH2AX, and depletion of PTEN reduced RAD52 
sumoylation399, supporting that RAD52 in humans is also regulated by 
sumoylation. RAD52 is also regulated by tyrosine phosphorylation; 
phosphorylation reduces RAD52 affinity for dsDNA and increases its ssDNA 
annealing rate, overcoming the inhibition of dsDNA on annealing400. This site 
is likely phosphorylated by c-abl401 in response to IR, and is important for 
RAD52 foci formation in response to IR. 
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RAD52 foci are induced and immobilized to a greater extent by HU, 
which stalls replication forks, than by IR, suggesting its role is related to 
replication damage386. Interestingly, RAD52 has been shown to interact with 
MUS81 and to regulate its role in replication stress402. MUS81 generates 
DSBs during replication in checkpoint deficient cells, but the mechanism and 
its effects are not well understood. MUS81-induced DSBs, when CHK1 is 
inhibited, are independent of RAD51, and instead depend on RAD52. 
Depletion of RAD52 rescues chromosome instability after replication fork 
stalling in CHK1-deficient cells, and leads to the ability of stalled forks to 
restart and to more de novo origin firing in these conditions. Recovery from 
replication stress in RAD52-depleted cells requires MUS81, and loss of both 
these proteins results in increased RAD51 foci formation that is toxic. Thus, a 
RAD52/MUS81-dependency exists in checkpoint-deficient cells, and this 
suggests that RAD52 is associated with cleavage at stalled forks in vivo and in 
vitro402. 
 RAD52 has also been suggested to interact with helicases in cells. 
WRN, a RECQ homolog, interacts physically with RAD52 in vivo at arrested 
replication forks and in vitro403. Biochemically RAD52 both inhibits and 
enhances WRN helicase activity, while WRN increases RAD52-mediated 
strand annealing403. RAD52 also interacts with human RECQ5 to promote 
SDSA; Paliwal et al show that the RECQ5 helicase, which can disrupt RAD51 
filaments, promotes NCO during DSB repair through HR168. It counteracts the 
inhibition by RAD51 on RAD52 annealing in vitro and in vivo, and deficiency in 
RECQ5 leads to increased occupancy of RAD51 at DSBs168. RECQ5 
deficiency causes elevated levels of SCEs in untreated cells when Holliday 
junction dissolution is impaired (by BLM deficiency), and in response to CPT 
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RECQ5-deficiency alone elevates SCEs, while depleting both BLM and 
RECQ5 increases SCEs even more168. These data suggest that RECQ5 has a 
role in CO suppression even in the presence of BLM if the load of DNA 
damage exceeds a certain threshold, and that RECQ5 and BLM act in two 
different pathways to suppress CO formation during HR. The authors suggest 
that RECQ5 acts in SDSA post-synaptically to prevent aberrant RAD51 
filament formation on the extended invading strand, thus limiting crossovers. 
They also show a role for RAD52 in this pathway. Including an ATP-hydrolysis 
dead RAD51 mutant before RAD52 in vitro inhibits RAD52 annealing of RPA-
ssDNA, and wild-type RAD51 also inhibits annealing but to a lesser extent. 
This inhibition was lost when RECQ5 was included, likely by disrupting RAD51 
filaments since RECQ mutants (helicase deficient and RAD51-interacting 
mutant) did not alleviate inhibition; WRN and FBH1 also did not relieve 
inhibition168. 
Interestingly, alternative splice variants of hRAD52 have been identified 
that code for RAD52 proteins containing mostly the conserved N-terminal 
half404-406. Expression of two mouse RAD52 splice variants in CHO tissue 
culture cells elevates the frequency of recombination that uses a sister 
chromatid template406. A yeast homolog (Rad59) is also composed mostly of 
this domain, yeast do not contain splice variants. It has been suggested that 
RAD52 splice variants could function like yeast Rad59 in vertebrate cells404-406.  
In summary, the role of RAD52 in vertebrate cells and organisms is not 
well understood. Its function as an annealer has been shown to be important 
in the SSA pathway, and is also potentially important for SDSA and second 
end capture downstream in HR (Figure 3). Its function as a RAD51 mediator is 
likely only important in the absence of the BRCA pathway, as will be discussed 
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in more detail later on. Studies into the in vitro biochemical function of RAD52 
help shed light on its role in cells; the next section focuses on these studies.  
RAD52 structure and biochemistry 
As described previously, RAD52 binds RPA and RAD51 through 
domains in the C-terminal half of the protein. At its N-terminus are the RAD52 
DNA binding and self-association domains, where it contains 70% homology 
with the yeast protein, and these also catalyze homologous DNA pairing. From 
the N- to the C-terminus are the DNA-binding domain (residues 25–65), the 
RAD52 heptameric ring binding domain (125–185), the RPA32 binding domain 
(220–280), and Rad51-binding domain (290–340)292(Figure 3). Some studies 
suggest while the N-terminal self-association domain mediates the assembly 
of monomers into rings, a C-terminal domain of the protein mediates higher 
order self-association of the rings407,408. RAD52-DNA filaments are proposed 
to contain either stacked rings or rings arranged side by side409.  
 Looking at RAD52 rings by electron microscopy, it was shown that 
RAD52 forms rings with 10nm diameter and a hole at the center410. ssDNA-
hRAD52 complexes have RAD52 distributed along the length of the DNA with 
a beads on a string appearance, and at higher RAD52 concentrations, “super 
rings” of 30nm are observed with the ssDNA collapsed on itself410. These rings 
were shown using transmission electron microscopy and scanning 
transmission electron microscopy to be heptameric with a large central 
channel411. RAD52 binds DNA non-cooperatively, and in contrast to how it 
binds ssDNA, dsDNA-RAD52 has some protein free regions410. RAD52 is 
proposed to bind four nucleotides per monomer of ring412-414. 
Crystal structures of N-terminal RAD52 truncations have been 
analyzed. These truncated forms of RAD52 form an undecameric ring with a 
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highly positively charged groove around the ring and extensive subunit 
contacts412,413. Though the truncations form an undecamer and full length 
RAD52 forms a heptamer, both rings are about the same size407,411,412. Each 
RAD52 monomer has a β-β-β-α fold412, and a mutational analysis revealed 
that the amino acid residues located between the β-β-β-α fold and a hairpin 
loop are essential for ssDNA and dsDNA binding. Amino acids 79-156 make 
up a stem region of the β-β-β-α fold, while residues flanking both ends of the 
stem form a domed cap with a flat top412. Negative charges are found at the 
top of the domed cap, near the channel of the ring, while most of the bottom 
half of the ring is positively charged412. The region between the stem and the 
loop in the RAD52 monomer is most positively charged and aligned outside 
the ring412. The central channel of RAD52 does not contain any basic residues, 
suggesting RAD52 binds DNA along outside of the ring, and not within the 
channel412. A study of the crystal structure of the N-terminus identified a 
potential second DNA binding site in hRAD52415. This new binding sites 
includes residues from Lys102 to Arg173, which are exposed on the surface of 
the crystal structure of the N-terminal domain of RAD52. It is located at the rim 
of the stem region and edge of domed cap region, while the earlier established 
sites are clustered at the bottom of the groove between the stem and domed 
cap regions415. Singleton et al413 propose that the large, positively charged 
groove that runs along the surface of the ring suggests a mechanism by which 
RAD52 presents the single strand for reannealing with complementary ssDNA, 
with ssDNA bound to RAD52 having bases facing outward, and RAD52 
forming a ternary complex with ssDNA and dsDNA413.  
This model is supported by a report from Van Dyck et al, who show 
using tailed duplex DNA molecules that purified hRAD52 protein binds 
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resected DSBs and promotes associations between complementary DNA 
termini416. Heteroduplex intermediates of these recombination reactions 
visualized by electron microscopy reveal the specific binding of multiple rings 
of RAD52 to the resected termini and the formation of large protein complexes 
at heteroduplex joints formed by RAD52-mediated annealing416. This study 
suggests that RAD52 rings are active in SSA, and strengthens the argument 
that SSA is driven by RAD52-directed DNA–DNA contacts in which ssDNA lies 
exposed on the surface of the protein416. 
hRAD52 binds ssDNA and dsDNA, though it does not bind dsDNA as 
well as ssDNA410,417,418. In one study, hRAD52 was found to bind preferentially 
to the ends of duplex DNA with 300 nucleotides of 5’ or 3’ tails, and was 
suggested to have a higher affinity or greater stability on tailed dsDNA419; thus, 
RAD52 binds structures found at DSBs. Mutational analysis with DNA binding 
assays suggested that specific aromatic and basic side-chains, R55, Y65, F79, 
Y81, K152 and R156, are most important for mediating the interaction of 
hRad52 with DNA, which mostly agrees with the crystal structure420. A study 
looking at truncation mutants (amino acids 1–212, blocking higher order 
oligomers and 1–85, blocking 10nm ring formation) suggested that DNA 
binding depends on neither ring-shaped oligomers nor higher order oligomers, 
but that formation of oligomers consisting of multiple RAD52 rings is important 
for activities involving simultaneous interaction with more than one DNA 
molecule408. 
Parsons et al414 showed that RAD52 binds ssDNA and tailed duplex 
DNA molecules via precise interactions with the terminal base. DNA in ssDNA-
RAD52 complexes exhibit a four-nucleotide repeat hypersensitivity pattern 
when probed with hydroxyl radicals, which is due to the interaction of RAD52 
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with either a 5' or a 3' terminus of the ssDNA, and is sequence independent 
and phased precisely from the terminal nucleotide414. This hypersensitivity is 
observed for 36 nucleotides, consistent with the length of DNA that is 
protected by RAD52 in nuclease protection assays. The authors propose that 
RAD52 binds DNA breaks via specific interactions with the terminal base, 
leading to the formation of a precisely organized ssDNA-RAD52 complex in 
which the DNA lies on an exposed surface of the protein414. This protein-DNA 
arrangement may facilitate the DNA-DNA interactions necessary for RAD52-
mediated annealing of complementary DNA strands414. 
As mentioned previously, RAD52 has been shown to be important for 
annealing in vivo, and studies also show that RAD52 is effective at annealing 
in vitro. Unlike BRCA2, RAD52 is able to overcome RPA inhibition to anneal 
ssDNA157. RAD52 annealing has been suggested not only to be important in 
SSA, but also may play a role in second end capture, SDSA, or BIR, which is 
supported by studies in yeast and with human protein177,421.  
Early studies demonstrated that RAD52 is efficient at annealing 
complementary DNAs in vitro413,416,418. It has been shown that RAD52 
promoted annealing can be followed by branch migration, displacing another 
strand downstream418. As described earlier, purified hRAD52 binds tailed 
duplex DNA molecules and promotes associations between complementary 
DNA termini, with annealing likely driven by RAD52 rings directing DNA-DNA 
contacts with the ssDNA exposed on the surface of the protein416. Interestingly, 
tyrosine phosphorylation reduces RAD52 affinity for dsDNA and increases the 
ssDNA annealing rate, overcoming annealing inhibition by dsDNA400 and WRN 
increases RAD52-mediated strand annealing403; thus, there is complex 
regulation of RAD52 annealing. 
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 More detailed studies shed light on the mechanism of RAD52 annealing. 
Rothenberg et al422 proposed that RAD52-annealing proceeds in successive 
steps involving rearrangements of the ssDNA–hRAD52 complex. After initial 
pairing, further search for extended homology occurs without dissociation of 
DNA and RAD52, which is driven by the interaction of two overlapping 
nucleoprotein complexes. The authors propose a model in which ssDNA 
release and dsDNA zippering are coordinated through successive 
rearrangement of overlapping nucleoprotein complexes422. Another study of 
annealiny by Grimme et al295 studied RAD52-annealing using fluorescence 
resonance energy transfer (FRET). They found that RAD52 bound ssDNA or 
ssDNA-RPA in two modes: at low RAD52 concentration, the ssDNA wrapped 
around circumference of protein ring, while at high RAD52 concentration, the 
ssDNA was stretched between multiple RAD52 rings295. In annealing assays 
where RPA was included, RAD52 mutants with impaired RPA binding 
(RQK/AAA (261-263) and 1-212 truncation) competed with RPA for ssDNA 
binding and failed to counteract RPA duplex destabilization; the rate and 
extent of annealing was reduced in these mutants. In annealing assays 
without RPA, the rate and extent of annealing increased with RAD52 
concentration up to 8nM, beyond that the rate of annealing was reduced but 
the extent remained the same; in this scenario the RAD52-RQK mutant 
behaved similarly to RAD52-WT, while the rate was reduced with the 1-212 
truncation though the extent was similar to RAD52-WT. ssDNA annealing was 
fastest when the concentration of DNA molecules used was the one in which it 
is wrapped around individual RAD52 protein rings (low concentration), 
suggesting that optimal annealing occurs at conditions where both strands are 
bound by RAD52 and that homology search and annealing occur through two 
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RAD52-ssDNA complexes or two hRAD52-ssDNA-RPA complexes rather than 
a RAD52-ssDNA(-RPA) complex and free ssDNA295. 
Studies of human RAD52 have suggested that it can also promote 
second-end capture and SDSA. In a reconstituted system, RAD54 can cause 
dissociation of joint molecules through its ATP-dependent branch migration 
activity423. In a reaction analogous to SDSA, RAD52 anneals the extended 
invaded strand after it dissociates from the D-loop with a second 
complementary tail, though it is dispensable for this activity in the absence of 
RPA423. RAD52 can also promote formation of a “double D-loop,” annealing 
the displaced strand of a D-loop to another complementary ssDNA, which 
would be analogous to second end capture/dHJ formation of DSBR423. RAD54 
was capable of dissociating double D-loops as well423. Additionally, DNA repair 
synthesis catalyzed by human DNA polymerase η (which has been suggested 
to play a role in HR repair) acting upon priming strand of a D-loop leads to 
capture and annealing of the second end of a resect DSB, and this reaction is 
mediated by RAD52176. This second-end capture was not seen with other 
polymerases, or RAD51 instead of RAD52. The RAD52-dependent reaction is 
stimulated by RPA, and following repair synthesis and second-end capture, de 
novo synthesis from the captured second end occured176. Taken together, 
these studies suggest that RAD52 may function in cells to anneal during 
SDSA and second end capture. 
While it is clear biochemically that RAD52 functions as an annealier, the 
role of RAD52 as a mediator of RAD51 filament formation and strand 
exchange in humans and other vertebrates is controversial. The prevailing 
view seems to be that DNA strand exchange by hRAD51 is not affected by 
RAD52 when RPA is present157. RAD52’s relative unimportance as a mediator 
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is consistent with no or mild effects of RAD52 deficiency159,160. Nevertheless, 
as there is some recombination phenotype in vivo, RAD52 has also been 
shown to have some activity in biochemical reactions of exchange and strand 
invasion.  
hRAD51 promotes homologous pairing and DNA strand exchange in 
vitro on its own in certain conditions424-426. A one to three, RAD51 to nucleotide 
ratio is optimal for exchange425. hRAD51 initiates joint molecule formation 
preferentially at the 5’ end of the complementary strand of the linear duplex, 
and heteroduplex DNA is subsequently formed by the 5’ to 3’ transfer of this 
strand to the ssDNA425. Thus, the heteroduplex forms with a 3’ to 5’ polarity 
(polarity of transfer is defined relative to ssDNA on which nucleoprotein 
filament assembled), which is analogous to scRad51 but opposite to RecA425. 
RAD51 reactions are stimulated by RPA at low RPA concentrations when RPA 
is added before RAD51425. However, hRAD51 requires a mediator to 
overcome inhibition by RPA added before RAD51 at higher concentrations, 
and to prevent RAD51 binding to dsDNA, which inhibits the reaction. At sub-
optimal RAD51 concentrations (1:6 RAD51:nucleotide) few joint molecules are 
formed by RAD51 in the absence of RPA, but preincubation with low 
concentrations of RPA prior to RAD51 addition stimulates efficiency of joint 
molecule formation, while high RPA concentrations inhibit exchange427. 
However, at a one to three RAD51 to nucleotide concentration, there is no 
stimulation by low concentrations of RPA427. There is also a stimulatory effect 
at suboptimal RAD51 concentrations with bacterial SSB, and there is RAD51 
stimulation at low RPA concentration with optimal RAD51 concentration at low 
temperatures (0 and 22 degrees); these data suggest that RPA stimulates 
RAD51 exchange by removing secondary structure427. Another study by 
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McIlwraith et al428 also shows that RAD51 stimulates D-loop formation, though 
less efficiently than RecA, and requires magnesium and ATP to do so. They 
also found that RPA (added after RAD51) does not stimulate the reaction 
when RAD51 is added in excess, but RPA did stimulate D-loop formation 
when using sub-optimal Rad51 concentrations. At higher RPA concentrations, 
RPA inhibited the reaction428. Thus, there is a complex relationship between 
RPA and RAD51 in strand exchange and D-loop formation. 
 Some studies have found that RAD52 can stimulate strand exchange or 
D-loop formation on its own when incubated with ssDNA before the addition of 
dsDNA, and at concentrations of RAD52 that saturate the ssDNA, and this 
activity was localized to the N-terminus of RAD52385,409,412,415,429. Other studies 
have disputed this observation428. The effect of RAD52 is possibly executed by 
its annealing activity, but it has not been shown to overcome RPA inhibition. 
The in vivo relevance of these observations is not clear. 
Stimulation of RAD51 activity by RAD52 using human proteins has 
been observed when RPA is not included, or when RAD51 is added at 
suboptimal concentrations157,417. At substoichiometric RAD51 concentrations 
(1:6 RAD51:nucleotide), RAD52 stimulates joint molecule formation by 
RAD51; this effect is greater when RAD52 is incubated with the ssDNA before 
the addition RAD51 than when the proteins are added simultaneously or 
RAD51 is added first. Preincubation of RAD51 and RAD52 before adding 
ssDNA is worse than adding RAD51 alone, suggesting that in this case the 
RAD52 may sequester the RAD51 from DNA417.  
 Using stoichiometric amounts of RAD51, RAD52 is inhibitory to 
hRAD51 joint molecule formation (2.1uM RAD52:10uM RAD51, no inhibition 
observed at 0.6uM RAD52)427. Adding RAD52, then RPA at low 
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concentrations (0.3-0.6 uM RPA), then RAD51 (10uM), then labeled duplex, 
removed this inhibition427. However, at higher RPA concentrations (1.2uM) 
adding RPA inhibits the reaction even more than RAD52, and RAD52 does not 
overcome this inhibition427. Adding excess heterologous dsDNA also removes 
the RAD52 inhibition, which was proposed to be due to the prevention of 
RAD51 binding to the dsDNA. Including excess heterologous DNA also 
allowed RAD51 and RAD52 preincubated together to form joint 
molecules417,427. RPA and RAD52 do not stimulate RAD51 D-loops when 
RAD51 is added in excess, but they do stimulate D-loop formation when using 
suboptimal RAD51 concentrations428. The N-terminal fragment of RAD52 (1-
209), using suboptimal conditions, also stimulates RAD51 in presence of RPA 
and ammonium sulfate413. Thus, RAD52 cannot overcome RPA inhibition of 
RAD51 exchange, but it does stimulate RAD51 activity at suboptimal 
conditions. 
 One study found that there is higher homologous pairing activity in 
presence of both hRAD51 and hRAD52 than either alone using suboptimal 
RAD51 concentrations385. A mutant of RAD51 that does not interact with 
RAD52 reduced homologous pairing in these conditions, but has normal 
activity compared to WT-RAD51 in the absence of RAD52. This suggests that 
the interaction between these two proteins is important for RAD52 stimulation 
when it is present385. 
It has been suggested that RAD52 may promote RAD51 binding to 
ssDNA430,431. Interestingly, RAD52 binds RAD51-ssDNA filaments by EMSA 
analysis and by gold antibodies in electron microscopy410. At saturating 
concentrations of RAD51, it was able to displace RAD52 from ssDNA, but 
dsDNA-RAD52 was more resistant to RAD51 nucleoprotein filament 
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formation410, suggesting that RAD52 could potentially direct RAD51 to ssDNA 
in some conditions.  
Stimulation of RAD51 exchange and D-loop formation by RAD52 has 
been observed in some cases, but RAD52 has not been observed to remove 
facilitate RAD51 filament formation on RPA-ssDNA, an important step in vivo. 
Furthermore, mutants of RAD52 do not have strong HR phenotypes. As a 
result, RAD52-RAD51 mediator function in humans and other vertebrates is 
not believed to be essential to HR, but its residual activity is likely still 
biologically relevant, particularly in the context of BRCA deficiency, as will be 
described in the following section. 
RAD52-BRCA synthetic lethality 
hRAD52 can anneal in vivo93 and in vitro157 but RAD52 deficiency does 
not cause phenotype expected of an protein important for HR repair, like 
hypersensitivity to DNA damage or depletion in HR, and RAD52 is inefficient 
at promoting RAD51-exchange in vitro. S. cerevisiae Rad52 mutants have 
more severe defects than Rad51 mutants, believed to be due to its dual role 
as a mediator and an annealer. It appears that the functions of scRad52 have 
split between BRCA2, which can mediate and not anneal, and hRAD52, which 
can anneal and not mediate effectively161. The lack of strong phenotype in 
vertebrate RAD52 mutants suggests that annealing is not important to 
homology-directed DSB repair, or that there is some redundancy or way to 
compensate for the loss of RAD52.  
Despite RAD52’s apparent lack of mediator activity in humans, recent 
evidence suggests that hRAD52 provides an alternative mediator pathway to 
BRCA2 (Figure 4)161,162. In BRCA2-deficient human cancer cell lines, depletion 
of RAD52 reduces cell survival and proliferation, thus there is a synthetic lethal 
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Figure 4: Synthetic lethality: Two mediator pathways in humans. BRCA2, 
BRCA1, and PALB2 form the primary RAD51 mediator pathway in human 
cells. In cells that lack the BRCA pathway, RAD52 can act as a backup 
mediator, promoting RAD51 function and HR. 
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relationship between the two proteins162. In cells lacking both BRCA2 and 
RAD52 there is increased chromosomal instability, evidenced by telomere end 
associations and radials, pointing to HR deficiency as the cause of the 
synthetic lethality. RAD52 functions independently of BRCA2, since its 
localization to damage and with RPA2 and ssDNA is no different between 
BRCA2-complemented and BRCA2-deficient cells, and RAD52 interacts with 
RAD51 independently of BRCA2162. Additionally, RAD52 was necessary for 
RAD51-mediated HR in BRCA2-deficient cells162. Depleting RAD52 in 
EUFA423 cells, which are BRCA2-deficient, reduces RAD51 foci formation, 
and expressing RAD52 in Capan-1 cells, which are deficient in BRCA2 and 
RAD52, increases levels of RAD52 foci. DR-GFP HR is also dependent on 
RAD52 in BRCA2-deficient cells. These results suggest that RAD52 provides 
a backup HR pathway in human cells: when BRCA2 is present, RAD52 has 
little effect on HR and viability, whereas in BRCA2-deficient cells, RAD52 is 
important for viability and for HR162. This suggests that residual RAD52 
mediator activity is sufficient for survival in cells lacking BRCA2  
Lok et al showed that not only is RAD52 synthetically lethal with BRCA2, 
but with BRCA1 and PALB2392. Double knockdown of RAD52 and either 
BRCA1 or PALB2 reduces plating efficiency in MCF7 and U2OS cells392. 
There is a further reduction in RAD51 foci with BRCA1-RAD52 double 
knockdown compared to BRCA1 knockdown, and DR-GFP HR is further 
reduced in BRCA1- and PALB2-depleted cells also depleted of RAD52. 
Similar to its independence from BRCA2 status, RAD52 foci formation is 
normal in the absence of BRCA1392. Further supporting the independence of 
the RAD52 pathway, Van Veelen et al found that in mammalian cells, though 
RAD52 is not required for foci formation of RAD51 and RAD54, RAD52 foci 
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formation is not influenced by a mutation in the RAD51 paralog-mutated 
(XRCC2, XRCC3, RAD51C) and BRCA2-mutated cell lines tested391. 
Evidence from Wray et al also supports the independence of the RAD52 
pathway, as that RAD51 colocalizes with a BRCA2-interacting protein (BCCIP) 
early after IR and with RAD52 at later timepoints, with little colocalization of 
BCCIP and RAD52386.  These results suggest that RAD52 promotes RAD51 
recruitment and HR in the absence of and independent of the BRCA pathway. 
Thus, evidence points to RAD52 acting in an alternative, or backup, mediator 
pathway in humans, independent of BRCA pathway. 
It is possible that RAD52 performs its mediator functions in conjunction 
with other proteins, and there are factors that would allow it to perform this role 
if included in reactions in vitro. Candidates for partners of RAD52 include the 
RAD51 paralogs, however recent evidence suggests that they are epistatic to 
the BRCA pathway rather than the RAD52 pathway. RAD52 is synthetically 
lethal in chicken DT40 with XRCC3, a RAD51 paralog389, BRCA2 is epistatic 
to the RAD51 paralogs in response to DNA damage as measured by cellular 
survival after MMC432, and RAD51 paralog complexes are epistatic to BRCA2 
and synthetically lethal with RAD52 in human cells433, suggesting the paralogs 
function with the BRCA pathway and not with RAD52. One study did find that 
RAD52 (as well as BRCA1, SFR1, SWS1, and XRCC3) is epistatic to BRCA2 
in DT40 cells434, as measured by cell growth and CPT and cisplatin sensitivity. 
There was no effect on RAD51 after IR when RAD52 was depleted on top of 
BRCA2 depletion, however, this did increase sensitivity to Olaparib, a PARP 
inhibitor434. The majority of evidence, however, supports an independent role 
for RAD52. So far the factors needed for RAD52 mediation in cells and in 
biochemical assays have not been determined. 
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In cancer patients carrying BRCA mutations only, tumor cells are 
BRCA-deficient (usually heterozygous BRCAmut/-), while normal cells are 
proficient in HR, containing one functional and one nonfunctional copy of 
BRCA1 or BRCA2. Thus, targeting a protein, such as RAD52, that is 
synthetically lethal with BRCA2 would result in death specifically of tumor cells. 
The synthetic lethal relationship between Poly (ADP Ribose) Polymerase 
(PARP) and the BRCA proteins provides a proof of principle example that 
synthetic lethality with BRCA proteins may be utilized for cancer treatment. 
PARP depletion has been shown to be lethal to cells lacking BRCA1 or 
BRCA2435,436, and inhibition of PARP is being exploited to selectively kill 
tumors in patients with BRCA mutations437-440.   
The PARP family consists of 17 proteins, each containing a conserved 
catalytic domain which is responsible for poly (ADP-ribose) polymerization441, 
which generates long chains of poly (ADP) ribose on target proteins, a process 
known as PARylation. PARP proteins are important in genomic stability, DNA 
repair, cell cycle progression, and apoptosis441. PARP1 and PARP2 
specifically have been shown to be involved in single strand break (SSB) 
repair (SSBR), and also facilitate HR and fork restart by promoting MRE11, 
RPA, and RAD51 recruitment to collapsed replication forks441-447. Mouse 
knockouts of PARP1 or PARP2 are viable and fertile and do not develop early 
onset tumors448. However, PARP1 knockout mice and normal cells treated 
with PARP inhibitors do exhibit defective SSBR, increased HR and increased 
SCE, suggesting that HR may be vital to repairing lesions in PARP deficient 
cells435,449-453 
The current model for the synthetic lethality relationship between PARP 
and HR hinges on PARP’s role in the repair of SSBs454,455, though recent 
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evidence suggests that the interaction is more complicated. PARP inhibition 
leads to the accumulation of SSBs, which stall replication forks and lead to the 
formation of DSBs435,436,456.  These DSBs are normally repaired by the HR 
pathway, but cannot be repaired effectively in BRCA-deficient cells456. Thus, 
PARP inhibition in HR-deficient cells results in synthetic lethality, as the 
resulting DNA damage induces apoptosis or other forms of cell death. This 
model focuses on PARP’s role in SSBR, but its function in HR-mediated 
restart of stalled replication forks447 as well as in alt-NHEJ457 may contribute to 
the sensitivity of BRCA-deficient cells to PARP inhibitors458.  Another 
mechanism has been proposed in which PARP inhibitors trap PARP on a SSB 
intermediate459, which may then be converted to a more toxic lesion during 
replication458.  PARP proteins are also involved in DNA methylation, 
transcription, chromatin modification, and cell death pathways, and these 
functions may contribute to the sensitization of BRCA-deficient cells as well441. 
Sensitivity to PARP inhibitors has also been demonstrated in cells deficient in 
other HR genes, supporting the hypothesis that BRCA-mutant cells are 
sensitive to PARP inhibitors specifically because of HR deficiency460. Currently, 
many PARP inhibitors are in early phase clinical trials439,461,462.   
PARP therefore provides an established example of the clinical 
implications of synthetic lethality with the BRCA pathway. Targeting RAD52 
may therefore similarly be effective in treating tumors in patients with BRCA 
mutations or other HR defects. 
Other mediators 
Beyond BRCA2 and RAD52, other proteins play a role in mediating and 
supporting RAD51 function. These include the RAD51 paralogs, PALB2 (as 
described), SWS1, SWSAP1, RAD54, RAD54B, SWI5, and SFR463. There are 
           79
five RAD51 paralogs in humans: RAD51B, RAD51C, RAD51D, XRCC2, and 
XRCC3, which are likely tumor suppressor proteins and are analogous to the 
yeast Rad55 and Rad57 proteins. They have 20-30% amino acid sequence 
similarity to RAD51 and each other, mostly at the Walker A and B motifs, 
which are responsible for ATP-binding. RAD51 paralogs form two major 
complexes: BCDX2 (RAD51B, RAD51C, RAD51D, XRCC2), and CX3 
(RAD51C, XRCC3) 464-466. RAD51 interacts with the RAD51 paralogs466-468, 
but their functions in HR are not well understood. Cells deficient in the 
paralogs in mammals have reduced RAD51 foci formation469-472, increased 
chromosomal abnormalities, increased sensitivity to damaging agents, 
reduced HR-mediated gene targeting and DSB repair, and reduced 
SCEs470,473-476. Disruption of these genes in mice leads to early embryonic 
lethality with accumulation of unrepaired DNA damage477-479. Though these 
proteins have been implicated as mediators of the RAD51 recombinase, their 
precise roles remain unclear, as part of their phenotype may be due to other 
roles in the cell such as control of centrosome integrity and function in 
checkpoint signaling480.  
The RAD51 paralog complexes have been shown to promote exchange 
activity in vitro. The CX3 complex catalyzes the formation of D-loops on its 
own in vitro481. Directly supporting a role as RAD51 mediators, the BC 
subcomplex partially alleviates the competition by RPA with RAD51 for 
substrate binding, thereby stimulating RAD51-filament formation and strand 
exchange, though this enhancement was more evident in the formation of joint 
molecules than the final exchanged product482,483. Beyond roles in mediation, 
paralogs have also have been suggested to have functions downstream in HR, 
           80
such as regulating gene conversion tract length484,485 and playing a role in 
Holliday junction resolution486,487. 
The different RAD51 paralog complexes have been shown to function 
differently in HR. The BCDX2 complex acts downstream of BRCA2 
recruitment and upstream of RAD51, while the CX3 complex functions 
downstream of RAD51 recruitment, but still affects HR433; both are epistatic to 
BRCA2 and synthetically lethal with RAD52433. Double depletion of the 
paralogs with RAD52 reduces plating efficiency (51D and X3), RAD51 foci 
(51D), and DR-GFP HR. Depletion of all complex members reduces DR-GFP 
HR, but depleting both complexes does not further deplete HR, so they likely 
function in the same pathway433. Other studies have also found that BRCA2 is 
epistatic to the paralogs in response to DNA damage by cellular survival after 
MMC432.  
SWS1, an ortholog of the yeast Shu complex, and SWSAP1, which 
interacts with SWS1 and has a predicted RecA-core, have also been proposed 
to act as recombination mediators488,489. SWS1 also interacts with RAD51D, 
while SWSAP1 interacts with RAD51 and most of the paralogs and its 
depletion causes defects in HR. The hSWS1-SWSAP1 complex binds ssDNA 
and exhibits DNA-stimulated ATPase activity. These proteins are not well 
characterized, but their interactions have lead to the suggestion that they may 
be mediators as well. 
The RAD54 protein, a Swi/Snf family protein that translocates on DNA, 
is also important in HR through numerous mechanisms. Humans have two 
RAD54 homologs: RAD54 and RAD54B. These proteins have been implicated 
as mediators through stimulation of RAD51 filament formation, homology 
search, and strand exchange, and disruption of RAD51 binding to dsDNA, and 
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also function in chromatin remodeling, branch migration of Holliday junctions, 
and resolution of Holliday junctions through endonuclease interactions165. 
Human RAD54 has been shown to associate with RAD51, promote its 
recruitment, and stimulate its DNA pairing490-492.  
RAD51AP1 enhances joint molecule formation through Rad51, but its 
exact role is unclear. It interacts with PALB2, and PALB2 stimulates joint 
molecule formation351,352, though it is believed to promote an interaction with 
the dsDNA target and stabilizing the D-loop rather than promoting RAD51 
filaments352,463. Interestingly, PALB2 has also been shown to interact with the 
RAD51C paralog467. 
Finally, the SWI5-SFR1 complex, related to the S. pombe Swi5-Sfr1 
and S. cerevisiae Sae3-Mei5 complexes, may act as a mediator. These 
proteins function only in meiosis in budding yeast. In mouse, Swi5 and Sfr1 
are nuclear proteins; deletion mutants in ES cells are sensitive to DNA 
damaging agents, have increased chromosomal aberrations, and reduced 
PARP-inhibitor-induced SCE, supporting a role for the complex in homology 
based DSB repair493. Expression of a BRC repeat has been shown to inhibit 
RAD51 focus formation and to decrease HR in mammalian cells, likely by 
sequestering RAD51 in cells340,346,349,494; in Sfr1 and Swi5 deleted cells, 
though their loss does not decrease HR frequency on their own, expression of 
the BRC repeat reduced HR in Sfr1 and Swi5 deleted cells even more than in 
WT cells, again implicating these proteins in a role supporting RAD51493. In 
humans cells, SWI5-SFR1 depletion reduces RAD51 foci and also enhances 
sensitivity to IR495; in vitro the complex interacts with RAD51 and stimulates 
RAD51-strand exchange by stabilizing the filament496 paradoxically by 
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enhancing ATP hydrolysis by RAD51 and facilitating the release of ADP from 
the presynaptic filament to keep it in its active ATP bound form497.  
These effects are interesting due to the role of the Swi5-Sfr1 complex in 
S. pombe, which may be relevant to the mediator proteins in human cells. 
While S. cerevisiae Rad52 protein promotes Rad51-dependent DNA-strand 
exchange on RPA-coated DNA by itself, S. pombe Rad52 (Rad22) cannot. 
Though Rad22 is important to overcome the inhibitory effect of RPA, it 
requires the Swi5–Sfr1 complex in a downstream step to stabilize the Rad51 
filament, so it can progress to strand exchange480,498,499. Although this is 
possibly due differences between S. pombe and S. cerevisiae RAD51, it could 
be because of differences in Rad52 mediator activity between budding and 
fission yeast. Similar to RAD52 knock-outs, mouse cells in which 
the Swi5 or Sfr1 are knocked out are viable and display no defect in HR. Thus, 
it is plausible that RAD52 in humans and other mammals requires the SWI5-
SFR1 complex to perform its mediator function480,498,499.  
Thesis aims 
 RAD52 provides a backup pathway to BRCA2 in human cells as a 
RAD51-mediator. However, the factors important to this pathway have yet to 
be uncovered. There may be factors that allow RAD52 to perform its mediator 
role more efficiently in vitro, and RPA is a good candidate. RPA is an 
important interacting partner of RAD52, and studies of its 
hyperphosphorylation leave much to be uncovered. In this thesis, we look at 
the effect of RPA hyperphosphorylation on the RAD52-mediator pathway both 
in vivo and in in vitro assays. 
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CHAPTER TWO 
RPA HYPERPHOSPHORYLATION PROMOTES RAD52 MEDIATOR 
FUNCTION IN HUMAN CELLS THROUGH IMPROVED RPA-RAD52 
ASSOCIATION 
INTRODUCTION 
Double strand breaks (DSBs) are the most deleterious type of DNA 
damage and arise during endogenous processes, such as DNA replication, or 
after exposure or DNA damaging agents, such as ionizing radiation or 
topoisomerase poisons. DSBs are resolved by two main pathways: 
homologous recombination (HR) and nonhomologous end joining (NHEJ).  
In HR, DSBs are resected to generate single-stranded DNA (ssDNA) 
overhangs, which are bound by the heterotrimeric ssDNA binding complex, 
RPA1-3,72.  RPA is exchanged for RAD51, which then performs homology 
search and strand invasion. S. cerevisiae RAD52 mediates the exchange of 
RPA for RAD51, promoting RAD51 filament formation on RPA-coated ssDNA 
and stimulating RAD51 strand invasion155,156. BRCA2 performs this mediator 
function in humans157,158. Moreover, RAD52 mouse knockouts show little 
phenotype or sensitivity to DSB-inducing agents, hRAD52 is inefficient at 
displacing RPA and stimulating strand exchange in vitro, and hRAD52 is not 
essential for RAD51 function or HR157,159,160. Thus the role of human RAD52 
and its ability to function as a RAD51 mediator in HR is unclear. 
Nevertheless, recent evidence suggests that hRAD52 provides an 
alternative mediator pathway to BRCA2161,162.  In BRCA2-deficient human 
cancer cell lines, depletion of RAD52 reduces cell survival and proliferation, 
such that there is a synthetic lethal relationship between the two proteins162. 
RAD52 is necessary for RAD51-mediated HR in BRCA2-deficient cells162, and 
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RAD52 functions independently of BRCA2, since its localization to damage is 
not affected by the presence of the BRCA2 protein, and it interacts with 
RAD51 independently of BRCA2162. These results suggest that RAD52 
provides a backup HR pathway in human cells: when BRCA2 is present, 
RAD52 has little effect on HR and viability, whereas in BRCA2-deficient cells, 
RAD52 is important for viability and for HR162. What factors are required for 
this backup pathway are currently unknown. 
hRAD52 has been shown to interact with the RPA2 subunit of the RPA 
complex, and this interaction facilitates HR in mammalian cells298. RPA2 is 
hyperphosphorylated in response to DNA damage, which is important for 
RAD51 recruitment and HR249,253. Dephosphorylation of RPA2 by PP4 and 
PP2A phosphatases is also needed for HR112,230. How RPA phosphorylation 
affects RAD52 function is not well understood. In vitro evidence suggests that 
more RAD52 associates in RPA-RAD52-ssDNA complex when RPA is 
phosphorylated, and pRPA promotes RAD52 contacts with ssDNA216.
 This study aims to address if and how RPA phosphorylation affects 
RAD52 function. We are interested in this relationship as a potential 
mechanism to target RAD52 function, since targeting RAD52 may lead to 
tumor specific synthetic lethality in patients. The main questions we address 
are whether RPA phosphorylation affects RAD52-mediated HR directly, and 
whether phosphorylation affects RPA’s interaction with RAD52. Using human 
cell lines expressing RPA-phosphorylation mutants we investigate RAD52-
dependent HR using endonuclease-induced recombination assays and 
RAD51 foci formation assays. We also look at the how the interaction of RPA 
and RAD52 is affected by RPA hyperphosphorylation by IP and colocalization.  
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RESULTS 
RAD52-mediated HR is promoted by RPA hyperphosphorylation 
In order to study the effect of RPA hyperphosphorylation on RAD52-
mediated HR, we used MCF7 breast carcinoma cells stably expressing myc-
tagged RPA2 phosphorylation mutants, which are similar to systems used in 
other studies of RPA phosphorylation (Figure 5). These cells express either 
wild-type RPA2 (RPA2-WT), RPA2 with all of the phosphorylation sites 
mutated to alanine (RPA2-A), or with most of the sites mutated to aspartate 
(RPA2-D), mimicking non-phosphorylatable and constitutively phosphorylated 
RPA2, respectively. Alanine is structurally similar to serine, lacking the 
hydroxyl group that is phosphorylated, and therefore acts as a phospho-dead 
analog. Aspartate has a carboxyl group that can mimic the negative charge of 
a phosphate group, though aspartate substitutions do not always perfectly 
mimic a phosphorylated protein. The exogenous RPA2-WT and RPA2-
mutants each have a C-terminal myc tag. We depleted endogenous RPA2 
using siRNA to study the effects of each exogenous RPA specifically. As in 
previous studies, these RPA mutants still interact with RPA1 and RPA3 by 
immunoprecipitation and colocalization (Figure 5B). Although some studies 
saw an effect on the cell cycle by expressing RPA phosphorylation mutants, in 
these cell lines cell cycle distributions were normal after endogenous RPA2 
depletion, suggesting that RPA phosphorylation mutants do not affect the 
normal cell cycle. Expression of the RPA2-D mutant was very low in all clones 
tested, and unpublished data from our lab suggests that RPA phosphorylation 
plays a role in regulating RPA protein stability or turnover. Thus, it is possible 
that effects seen in the RPA2-D line are due to low expression of RPA and not 
due to mutation of the phosphorylation sites.  
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Figure 5: Methods—RPA phosphorylation mutants a. RPA phosphorylation 
mutants. Either RPA2-WT, RPA2-A (non-phosphorylatable) or RPA2-D 
(phospho-mimic) were stably expressed in MCF7 cells. b. IP pull down with 
myc antibody, showing RPA2-WT, -A, and –D, exogenous proteins interact 
with RPA1 and RPA2. 
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Each of these cell lines also expresses the DR-GFP construct to 
measure levels of HR (Figure 5). In the DR-GFP assay, which was developed 
in the Jasin lab, a site-specific DSB is induced in DR-GFP cells by transfecting 
the I-SceI endonuclease. The I-SceI site is located in a truncated GFP gene 
(SceGFP), and generates early stop codons so there is no functional GFP 
expressed. Downstream of the SceGFP gene is an iGFP gene that is also 
truncated. When an I-SceI break in SceGFP is repaired by HR with the iGFP 
gene on the sister chromatid and gene conversion occurs, a functional GFP 
gene results and is expressed475. The percentage of cells expressing GFP can 
then be determined using flow cytometry analysis. 
Our first set of experiments suggests that RPA phosphorylation 
facilitates RAD52-dependent HR. Consistent with earlier reports, cells 
expressing RPA2 phosphorylation mutants have reduced HR as measured by 
the DR-GFP assay (Figure 6A), confirming that RPA phosphorylation and 
dephosphorylation are important for HR. In order to study RAD52-dependent 
HR, we depleted BRCA2 with siRNA (Figure 6C). Evidence suggests that the 
remaining DR-GFP HR and RAD51 foci in these cells is dependent on 
RAD52162. As expected, depletion of BRCA2 significantly reduces levels of HR 
(Figure 6B). In these conditions, we also see reduced HR in the RPA 
phosphorylation mutant cell lines compared to RPA2-WT (Figure 6B). This 
suggests that RPA phosphorylation and dephosphorylation are not only 
important in the BRCA pathway of HR, but also for the RAD52-dependent 
pathway. 
In order to confirm the effect of RPA phosphorylation on RAD52-
dependent HR, we next looked at RAD51 foci formation. The RAD51 
recombinase is recruited to foci in normal cells and in response to DNA 
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Figure 6. RPA phosphorylation is important for RAD52-dependent HR. a. 
MCF7 DR-GFP cells expressing RPA2-WT or phospho-mutant RPA2 (RPA2-A 
and RPA2-D) were depleted of endogenous RPA2 by siRNA and also 
transfected with siNT or siBRCA2. 48 hours later, cells were transfected with 
the I-SceI endonuclease. 72 hours after that, 105 cells per condition were 
tested by flow cytometry for expression of GFP. Experiments were normalized 
to RPA-WT siNT treated cells. Error bars represent SEM. n=5 (*: p< .05 by t-
test). b. siBRCA2 data, or RAD52-dependent HR events, plotted on different 
scale. c. Western blots confirming depletion of BRCA2 and endogenous RPA2
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damage that causes DSBs. Levels of RAD51 foci are reduced in cells that 
have impaired HR. In order to generate DSBs we treated cells for 4 hours with 
4 μM camptothecin (CPT). Camptothecin is a topoisomerase I inhibitor, which 
stabilizes the topoisomerase bound to DNA and prevents religation, thus 
generating a break in DNA, that is converted to a DSB when encountered by 
the replication fork. We looked at RAD51 foci by immunofluorescence, and the 
percentage of cells with greater than five RAD51 foci were counted as positive. 
In cells treated with non-targeting siRNA with BRCA2-dependent RAD51 
recruitment intact, we again see a dependence of RAD51 recruitment on RPA 
phosphorylation: RPA2-A cells have reduced RAD51 foci in both untreated 
cells and in cells treated with CPT compared to RPA2-WT cells, in agreement 
with previous reports that RPA phosphorylation is important for RAD51 
recruitment and HR (Figure 7A and 7B). In cells depleted of BRCA2, where 
RAD51 foci formation is dependent on RAD52, we again see reduced RAD51 
foci formation in the RPA2-A cells compared to RPA2-WT cells. This suggests 
that RPA phosphorylation is necessary for RAD52-dependent recruitment of 
RAD51 and subsequent HR. 
Since it appears that RAD52-dependent HR is promoted by RPA 
phosphorylation and dephosphorylation, we looked at the effect of RPA 
phosphorylation mutants on RAD52 foci recruitment, as RAD52-dependent HR 
may be defective due to a failure to recruit RAD52. RAD52 is difficult to detect 
by immunofluorescence, so RAD52 tagged with GFP was expressed in MCF7 
cells expressing RPA phosphorylation mutants or RPA2-WT, and after 6 hours 
with 4 μM CPT (or no treatment in control cells), the cells were fixed and 
imaged on the confocal microscope. The number of cells with greater than five 
RAD52-GFP foci per condition were counted and normalized to RPA2-WT 
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Figure 7. RPA phosphorylation is important for RAD52-dependent RAD51 
foci.  MCF7 cells expressing RPA2-WT or phospho-mutant RPA2 (RPA2-A) 
were depleted of endogenous RPA2 by electroporation of siRPA. 48 hours 
later cells were depleted of BRCA2 by Lipofectamine RNAiMax transfection of 
siBRCA2. 24 hours after that, cells were plated on glass slides. The next day, 
cells were treated with CPT for 4 hours, then fixed with formaldehyde and 
permeabilized with Triton X-100. Cells were stained with RAD51 primary 
antibody, fluorescent secondary antibody, and then imaged on the confocal 
microscope. a. 300 cells were counted per condition in each experiment, and 
cells with >5 RAD51 foci were counted as positive for RAD51. Error bars 
represent SEM. n=3 (*: p< .05 by t-test). b. Representative images for data in 
a. c. Western blots confirming depletion of RPA2 and BRCA2.
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untreated controls. After treatment with CPT, there was no difference in the 
percentage of cells with RAD52-GFP foci between RPA2-WT, RPA2-A, and 
RPA2-D cells (Figure 8). The levels of RPA foci in each cell line were also not 
significantly different. This suggests that after damage, RPA phosphorylation 
and dephosphorylation do not affect the recruitment of RAD52. RAD52 is 
either able to interact sufficiently with the RPA mutants for its recruitment, or 
RAD52 is recruited independently of RPA. Interestingly, in RPA2-D cells, 
RAD52-GFP foci levels are elevated in the absence of damage compared to 
RPA2-WT and RPA2-A cells, which have similar levels of RAD52-GFP foci. 
RPA2-D untreated cells have RAD52-GFP foci levels similar to the levels of 
foci in CPT-treated cells of both RPA2-WT and RPA2-mutant lines, and there 
is no increase in the number of cells with RAD52-GFP foci after damage 
treatment in RPA2-D cells. This suggests some deficiency in RPA2-D cells, 
perhaps that RPA2-D signals to RAD52 that there is damage in untreated cells, 
leading to RAD52 recruitment. 
To investigate why RAD52 is more efficient at HR and RAD51-
recruitment in RPA2-WT compared to RPA2-phosphomutant cells, we looked 
at colocalization of RAD52-GFP with RAD51. More RAD52-GFP colocalizes 
with RAD51 in the RPA2-WT line compared to the RPA2-A line with and 
without BRCA2-depletion after DNA damage (Figure 9A and 9B). Furthermore, 
the percentage of cells with RAD52-GFP foci in which those foci are 
colocalized with RAD51 is reduced in RPA2-A cells compared to RPA2-WT 
cells (Figure 9D), and the percent of cells with RAD51 foci in which those foci 
are colocalized with RAD52-GFP is also reduced in RPA2-A cells, though not 
significantly (Figure 9E). Interestingly, we did not observe any RAD52-RAD51 
colocalization in unperturbed cells, suggesting that the interaction between 
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Figure 8. RAD52 recruitment after damage is unaffected by RPA 
phosphorylation. MCF7 cells expressing RPA2-WT or phospho-mutant 
RPA2 (RPA2-A and RPA2-D) were depleted of endogenous RPA2 by 
electroporation of siRPA and RAD52-GFP was expressed, also by 
electroporation. 48 hours later cells were plated on glass slides; 24 hours after 
that they were fixed with formaldehyde and permeabilized 24 hours later. Cells 
were imaged on the confocal microscope. a. 300 cells were counted per 
condition in each experiment, and cells with >5 RAD52-GFP foci were counted 
as positive for RAD52. Error bars represent SEM. n=5 (*: p< .05 by t-test). b. 
Representative images for data in A.  
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Figure 9. RPA phosphorylation promotes RAD51-RAD52 colocalization.  
MCF7 cells expressing RPA2-WT or phospho-mutant RPA2 (RPA2-A) were 
depleted of endogenous RPA2 by electroporation of siRPA2 and RAD52-GFP 
was expressed. 48 hours later cells were depleted of BRCA2 by Lipofectamine 
RNAiMax transfection of siBRCA2. 24 hours after that, cells were plated on 
glass slides. The next day, cells were treated with CPT for 4 hours, then fixed 
with formaldehyde and permeabilized with Triton X-100. Cells were stained 
with RAD51 primary antibody, fluorescent secondary antibody, and then 
imaged on the confocal microscope. a. 300 cells were counted per condition in 
each experiment, and cells with >5 RAD51 foci colocalized with RAD52-GFP 
were counted as positive for colocalization. Error bars represent SEM. n=3 (*: 
p< .05 by t-test). b. Representative images for data in a. c. Western blot 
confirming BRCA2 and endogenous RPA knockdown, and RAD52-GFP 
expression. d. The percent of cells with RAD52-GFP foci in which >5 of those 
foci are colocalized with RAD51. e. The percent of cells with RAD51 foci in 
which >5 of those foci are colocalized with RAD52-GFP. 
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RAD51 and RAD52 is DNA damage dependent in both RPA2-WT and RPA2-
A cells. Thus, although RAD52 forms foci in RPA-phosphorylation mutants, it 
fails to recruit RAD51 normally, resulting in lower levels of HR. 
RAD52-RPA interaction is promoted by RPA hyperphosphorylation 
Our results indicate that RPA hyperphosphorylation promotes RAD52 
function in HR. RPA and RAD52 interact, and this interaction has been 
suggested to be important for RAD52 function. There is some evidence that 
RPA hyperphosphorylation promotes the interaction of RAD52 and RPA216,255, 
which could possibly explain the differences we see in RPA2-WT and RPA-
phosphomutant cells in RAD52-dependent HR and RAD51 foci. Thus, we 
looked at the effect of RPA phosphorylation on the interaction of RAD52 and 
RPA.  
Using immunofluorescence of the RPA2-myc tagged proteins and 
RAD52-GFP foci, we looked at the co-localization of RAD52-GFP and RPA2 
(with a myc antibody) (Figure 10). We calculated the percentage of cells that 
had RAD52-GFP foci in which at least five of those foci were colocalized with 
RPA. The RPA2-A and RPA2-D mutants did not colocalize with RAD52-GFP 
as well as the RPA2-WT protein did in untreated cells after treatment with CPT, 
although this result was only significant for the RPA2-D cells. Interestingly, 
despite the elevated levels of RAD52 foci in RPA2-D untreated cells, relatively 
few of those foci colocalize with RPA, suggesting that RPA dephosphorylation 
is important for effective interactions between RPA and RAD52.  
RPA2-phosphorylation mutants have defective colocalization with 
RAD52, suggesting that proper regulation of RPA phosphorylation is important 
for their interaction. Therefore, we looked at the association of RPA and 
RAD52 by immunoprecipitation (IP). Consistent with a disruption in the 
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Figure 10. RPA phosphorylation promotes RPA-RAD52 association.  a. 
MCF7 cells expressing RPA2-WT or phospho-mutant RPA2 (RPA2-A or 
RPA2-D) were depleted of endogenous RPA2 by electroporation of siRPA2 
and RAD52-GFP was expressed. 48 hours later cells were plated on glass 
slides. The next day, cells were treated with CPT for 6 hours, then fixed with 
formaldehyde and permeabilized with Triton X-100. Cells were stained with 
myc primary antibody, fluorescent secondary antibody, and then imaged on 
the confocal microscope. 300 cells were counted per condition in each 
experiment, and cells with >5 RAD52-GFP foci colocalized with RAD52-GFP 
were counted as positive for colocalization. Plotted are the percent of cells 
with RAD52-GFP in which >5 of those foci are colocalized with RPA2-myc. 
Error bars represent SEM. n=5 (*: p< .05 by t-test). b. Representative images 
for data in a. c. Co-immunoprecipitation pull down with myc (RPA2) antibody. 
           102
 A
 
B
 
6h
 4
µM
 C
PT
 
W
T 
   
   
   
   
A 
in
pu
t 
W
B
: R
A
D
52
 
W
T 
   
   
   
  A
 IP
   
W
B
: m
yc
 (R
PA
) 
m
yc
 (R
PA
)  
   
   
   
 Ig
G
 
B
 
R
A
D
52
-G
FP
  R
PA
-m
yc
 
4µ
M
 C
PT
 6
H
 
R
PA
-W
T 
R
PA
-A
 
R
PA
-D
 
U
nt
re
at
ed
 (U
T)
 
           103
association between RPA and RAD52 in phosphorylation-defective cells, more 
RAD52 immunoprecipitates with RPA2-WT than RPA2-A after CPT treatment, 
using an antibody against the RPA-myc tag to IP. Thus, although RAD52 can 
be recruited to foci regardless of RPA phosphorylation status, RPA 
phosphorylation improves RAD52 association with RPA. RAD52 association is 
different between RPA2-WT and the mutants, with RAD52 interacting with 
RPA more efficiently in RPA2-WT cells. RPA’s association with RAD52 is 
therefore dependent on phosphorylation and dephosphorylation. In cells in 
which RPA phosphorylation is defective, RPA fails to associate properly with 
RAD52, which does not affect RAD52 recruitment but does result in the failure 
of RAD52 to recruit RAD51 and thereby promote HR. 
MATERIALS AND METHODS 
Note: MCF7 cell lines expressing RPA2-myc proteins were generated by 
Rohini Roy, who also determined cell cycle distributions and confirmed 
immunoprecipitation of the RPA2-myc proteins with RPA1 and RPA3 in these 
cells. Alison Carley performed all other experiments in this thesis. 
MCF7 cell lines 
RPA-myc cell lines were generated by electroporating linearized 
plasmids into MCF7 cells, a breast adenocarcinoma cell line, containing the 
DR-GFP reporter construct. Cells were grown in blasticidin and resistant 
colonies were expanded and tested for expression of RPA mutant cell lines. 
Cells were maintained in DMEM with 100U/mL penicillin, 100 μg/mL 
streptomycin, 10% BGS, 20 mM Hepes, and 15 μg/ml blasticidin. RPA2-WT (-
A, -D) plasmids were generated from the pEF6 by insertion into the XbaI and 
BstBI sites of the pEF6/Myc-HisA vector (Invitrogen). Expression of the His6 
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tag from pEF6/Myc-HisA was prevented by mutating the ATG codon at 
position 1863 to a TGA codon. 
DR-GFP assay: As described by Pierce et al. The DR-GFP system was 
developed in the Jasin lab and has been used extensively since then. Briefly, 
gene conversion events in cells containing this substrate result in expression 
of GFP protein, which can then be assayed by flow cytometry. DR–GFP 
contains two mutated GFP genes oriented as direct repeats and separated by 
a drug selection marker. SceGFP is mutated to contain a recognition site for 
the endonuclease I-SceI, the substitution of the recognition site also generates 
in-frame stop codons. The second mutated GFP is downstream of SceGFP, 
termed iGFP, a 5′ and 3′-truncated GFP gene. When the I-SceI nuclease is 
expressed, it results in a DSB in the SceGFP site. Upon a gene conversion 
event between Sce-GFP and iGFP on the same chromatid or sister chromatid, 
a functional GFP gene results and is expressed475.  
Transfections 
• DR-GFP: 1 million cells were transfected with 2μg each siRPA and 
siBRCA2 (or siNT control) using the Amaxa electroporation system. 48 
hours later, the 2μg pCMV-ISceI-3xNLS plasmid along with 0.5 μg each 
siRNA were transfected using the Lipofectamine 2000 reagent (Life 
Technologies). 72 hours later, the cells were harvested and percentages of 
GFP-positive cells per 100,000 cells were determined by flow cytometry 
(FACSCalibur; Becton, Dickinson).  
• RPA-myc -RAD52-GFP foci: 1.5 million cells were transfected with 4.5 μg 
RAD52-GFP plasmid and 2 μg siRPA (or siNT control). Cells were plated 
on 8 well glass slides 48 hours later, then treated with 4μM camptothecin 
for 6 hours the next day fixed 72 hours later. Foci were imaged as 
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described below in immunofluorescence. (RAD52-GFP plasmid: RAD52 
was C-terminally tagged with GFP by cloning Rad52 cDNA into the 
pEGFP-C1 vector; Kitao H and Yuan ZM. JBC 2002.) 
• RAD51-RAD52 foci: 1.5 million cells were transfected with 4.5 μg RAD52-
GFP plasmid and 0.75μg siRPA (or siNT control). 48 hours later, 0.75 μg 
siBRCA2 was transfected using Lipofectamine RNAiMax from Life 
Technologies. Cells were plated on glass slides 24 hours later, then treated 
with 4μM camptothecin the next day and fixed. 
• siRNAs were obtained from Dharmacon as follows:  
• siRPA: 2 sequences mixed in equal amounts:  
sense sequence: 
 AAC UGG AUC UAA CUG GGU ACC UU 
 GCU UCU AGG AAG UAG GUU UCA UU 
• siBRCA2: ON-TARGETplus SMARTpool from Dharmacon (L-
003462-00) 
target sequences: 
 GAA ACG GAC UUG CUA UUU A 
 GGU AUC AGA UGC UUC AUU A 
 GAA GAA UGC AGG UUU AAU A 
 UAA GGA ACG UCA AGA GAU A 
• siNT: ON-TARGETplus SMARTpool from Dharmacon (D-001810-
10) 
target sequences: 
 UGG UUU ACA UGU CGA CUA A 
 UGG UUU ACA UGU UGU GUG A 
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 UGG UUU ACA UGU UUU CUG A 
 UGG UUU ACA UGU UUU CCU A 
Western blots 
• Preparation of protein lysates: Cells were trypsinized and pelleted by 
centrifugation. They were lysed using RIPA buffer containing 1X protease 
inhibitor cocktail (HaltTM Protease Inhibitor Cocktail, ThermoScientific) and 
incubated on ice for 5 minutes. Lysates were then sonicated and incubated 
on ice for 30 minutes. Lysates were then centrifuged at 16.1 RCF for 20 
minutes, and the supernatant was collected. Protein concentrations were 
determined by using Bio-Rad Protein Assay Dye Reagent Concentrate and 
comparing against a BSA protein standard curve, measured on a Tecan 
Infinite M200 reader. 
• Western blot: 20-100μg of protein lysates were loaded onto pre-cast gels 
from Life Technologies (NuPAGE® Novex® 10% Bis-Tris SDS page gels 
were run in NuPAGE® MOPS SDS running buffer for all proteins except 
BRCA2; 3-8% Tris-Acetate gels run in NuPAGE® Tris-Acetate running 
buffer for BRCA2 and SMC-1) in Novex Mini-Cell or Midi apparatus at 110 
V for 2 hours. Gels were then transferred onto Nitrocellulose membranes 
using transfer buffer (1.4% glycine, 0.3% tris-base, 20% methanol) at 40V 
overnight in a Mini-PROTEAN® Tetra System (Bio-Rad). Membranes were 
stained with Ponceau S solution to verify even transfer, and then blocked in 
5% milk in TBS-T(tris-buffered saline with 0.1% tween) or Odyssey TBS 
blocking solution for 1 hour.  Membranes were incubated in primary 
antibodies diluted in 5% milk TBS-T (2.5% for BRCA2) or Odyssey TBS 
blocking solution with 1% tween overnight. Antibody was removed and the 
membrane was washed 3 times for 10 minutes in TBS-T. Membranes were 
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then incubated in secondary antibodies for 1 hour, and then again washed 
3 times with TBS-T. Membranes incubated in HRP secondary were then 
incubated in Western Lightning ® Plus-ECL (Perkin Elmer) for 5 minutes, 
and then exposed to autoradiography film. Membranes incubated in IRD 
secondary were imaged on the Odyssey CLx System (Li-Cor).  
• Antibodies: 
• RPA2 (cell signaling RPA2 (4E4) Rat mAb #2208) 1:1000 
• pRPA (abcam  Anti-RPA32/RPA2 (phospho S4 + S8) antibody 
(ab87277)) 1:400 
• myc (cell signaling myc rb polyclonal #2272) 1:400 
• myc (Myc-Tag (9B11) Mouse mAb #2276) 1:1000 
• RAD52 (rb polyclonal RAD52 Antibody H-300, sc-8350) 1:500 
• RAD52 (ms monoclonal Rad52 Antibody F-7, sc-365341) 1:500 
• BRCA2  (BRCA2 Mouse mAb, OP-95, EMD Millipore) 1:300 
• SMC-1 (rabbit polyclonal, Bethyl Laboratories) 1:5000 
• Actin (mouse monoclonal, EMD Millipore MAB1501) 
• Secondary: Pierce goat anti-mouse and goat anti-rabbit HRP 
conjugated; Li-or IRDye® 800CW Goat anti-Mouse, IRDye® 
800CW Goat anti-Rabbit, IRDye® 800CW Goat anti-Rat IgG  
Immunoprecipitation 
MCF7 cells were incubated in 4μM CPT for 6 hours. Nuclear lysates 
were collected using the Universal Magnetic Co-IP kit (Active Motif).  Protein 
A/G SpinTrapTM Buffer Kit (GE Healthcare) was used to immunoprecipitate 
proteins as follows: Protein A Magnetic Sepharose Beads (GE Healthcare) 
were equilibrated by resuspension in 500 μl binding buffer, which was then 
removed. Beads were incubated with 10 μg primary antibody (myc mouse, cell 
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signaling #2276) for 4 hours. They were washed in 500 μl binding buffer, then 
in crosslink solution A. The beads were crosslinked to the primary antibody 
twice in 500 μl crosslink solution A with 50mM DMP for 30 minutes, with a 
wash in crosslink solution A in between.  After crosslinking, the beads were 
washed in 500 μl crosslink solution A. They were blocked for 15 minutes in 
crosslink solution B, and unbound antibody was then eluted for 10 minutes at 
50 degrees in elution buffer. Antibody-crosslinked beads were washed twice in 
500 μl wash buffer, and then nuclear lysates were added to the beads and 
incubated for 3 hours. Unbound lysates were removed, and the antibody- and 
protein-bound beads were then washed twice with wash buffer. Bound protein 
was eluted in twice for 10 minutes in elution buffer. The eluate was 
concentrated using Amicon® Ultra 0.5 mL Centrifugal Filters (Ultracel® 10K, 
Millipore), and run on western blots as described above. Binding and wash 
buffer (50mM Tris, 150 mM NaCL pH 7.5); Elution Buffer (0.1 M glycine-HCl , 
pH 2.9); Crosslink Solution A (200 mM triethanolamine pH 8.9); Crosslink 
Solution B (100 mM ethanolamine, pH 8.9).  
Confocal Microscopy and Immunofluorescence 
Cells were simultaneously fixed and permeabilized in 0.5% triton and 
0.5% formaldehyde diluted in PBS for 15 minutes. They were then blocked at 
4 degrees overnight in 5% BGS in PBS. The following morning, they were 
incubated in primary antibody for 3 hours at room temperature. Cells were 
washed 3 times for 5 minutes in 0.5% triton in PBS, and then incubated in 
secondary antibody for 1 hour. Cells were washed again 3 times for 5 minutes 
in 0.5% triton in PBS. Mounting Medium with DAPI (Vectashield) was added, 
and then coverslips. Cells were imaged on a Zeiss confocal microscope.  
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• Antibodies: 
• myc (Myc-Tag (9B11) Mouse mAb #2276) 1:2000 
• RAD51 (rabbit monoclonal, abcam ab133534) 1:2500 
• Secondary: goat anti mouse Alexa Fluor® 568 (Life technologies), 
Goat anti-Rabbit, Alexa Fluor® 555 conjugate 
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CHAPTER THREE 
INVESTIGATING THE EFFECT OF RPA HYPERPHOSPHORYLATION ON 
ITS IN VITRO FUNCTIONS 
INTRODUCTION 
While our studies in Chapter Two show that RPA hyperphosphorylation 
is important for RAD52 mediator function in cells, the effect of RPA 
phosphorylation on RAD52 mediator function in vitro has not been determined 
previously. Thus, to complement these studies, we looked at in vitro assays of 
recombination. Human RAD52 has been shown to be inefficient at acting as a 
mediator of RAD51 filament formation and strand invasion on RPA-coated 
ssDNA, but it is possible that if phosphorylated RPA were included it would 
allow RAD52 to function as a mediator in vitro. Several lines of evidence 
suggest this may be true: the interaction of RPA and RAD52 is improved with 
RPA phosphorylation as shown in chapter two and published work255, hypRPA 
promotes RAD52 contacts with ssDNA in RPA-RAD52-ssDNA complexes216, 
the interaction between RPA and RAD52 is functionally significant as RAD52 
mutants that do not interact with RPA fail enhance HR in monkey cells while 
RAD52-WT does298, and the RAD52-RPA interaction facilitates binding of 
RAD52 to RPA-ssDNA, and this interaction is necessary for RAD52 to 
counteract RPA’s helix destabilizing activity295. Biochemically, RAD52 has 
been shown have annealing activity and RAD51-mediation activity in the 
absence of RPA or in suboptimal conditions for RAD51, but it has not been 
shown to remove RPA from ssDNA to allow RAD51 filament formation157. 
Phosphorylated RPA is present in cells at DNA damage but has not been 
studied in in vitro strand exchange assays to date. The effect of RPA 
phosphorylation on RAD51 exchange itself also has not previously been 
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determined, though other studies have found that hyperphosphorylation 
promotes RPA’s interaction with RAD51: RAD51 preferentially co-
immunoprecipitates with an RPA2-D mutant230 and RAD51 in vitro pulled down 
hypRPA with little non-phosphorylated RPA2255,268. Thus, it is possible that 
RPA phosphorylation may affect RAD51 exchange on its own. 
The relationship between RPA phosphorylation and RPA DNA binding 
is not clear, as there have been mixed reports207,223,240,244. In one study, no 
difference in hyperphosphorylated and non-phosphorylated RPA binding to 
pyrimidine-rich ssDNA sequences was observed, but hyperphosphorylated 
RPA (hypRPA) had decreased binding to purine-rich ssDNA and dsDNA244. 
Simarlarly, IR-induced hypRPA exhibited decreased binding to ssDNA 
compared to non-phosphorylated RPA in crude mouse cell extracts223, while in 
contrast, using a mixed sequence 25 nucleotide oligomer, a relative increase 
in ssDNA binding by hypRPA over RPA was observed216. Other studies have 
seen no difference in ssDNA binding240,259,265. Thus, while it is possible that 
phosphorylation of RPA may regulate its DNA binding, how it does so is still 
unclear. Studies investigating phosphorylated RPA binding to dsDNA have 
been more consistent, finding a reduction in pRPA dsDNA binding206,240, such 
that phosphorylation has been proposed to reduce RPA duplex destabilization, 
while a higher affinity of RPA for damaged dsDNA has been observed244, 
leading to the proposal that hypRPA may signal DNA damage to other repair 
proteins.  
We have evaluated the effect of RPA phosphorylation on various 
biochemical activities. Since published data are inconsistent, we first looked at 
RPA and hypRPA binding to ssDNA. We then investigated the effect of RPA 
phosphorylation on RAD51 strand exchange. Since our experiments show that 
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RPA phosphorylation promotes RAD52 mediator function in cells, we looked at 
RAD52 mediator activity using ssDNA coated with unphosphorylated versus 
phosphorylated RPA2, as using phosphorylated RPA may allow RAD52 to 
promote RAD51 strand exchange. Finally, we looked at the effect of RPA 
phosphorylation on RAD52 annealing activity, as the promotion of RAD52 
activity and RPA interaction by RPA phosphorylation may not be limited to its 
mediator function. 
RESULTS 
RPA ssDNA-binding is not significantly affected by phosphorylation 
 To study the effects of RPA phosphorylation, we used purified RPA and 
RPA that had been purified, hyperphosphorylated using HeLa cell extracts, 
and then re-purified, in the Borgstahl lab. We used purified RAD51 and RAD52 
from the Jensen lab. We verified their purity (Figure 11A) and phosphorylation 
status of RPA (Figure 11B) using antibodies specific to the S4/S8 epitope on 
RPA. 
We compared DNA binding of RPA and pRPA with 5nM of 80 
nucleotide ssDNA oligomer. There was no significant consistent difference 
observed in DNA binding between the two proteins—they saturated the DNA 
at the same concentration, though in some cases either RPA or pRPA bound 
ssDNA at a slightly lower concentration, this effect was not seen consistently 
and there was not a significant difference (Figure 11C and 11D).  
RAD51 strand exchange is not affected by RPA phosphorylation in vitro 
Strand exchange and annealing experiments were modeled on those in 
Jensen et al157, which characterized the biochemical function of full length 
BRCA2, using one-third the concentrations of nucleotides and protein in our 
assays. We first verified the strand exchange activity of RAD51. RAD51 was 
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Figure 11. RPA phosphorylation does not affect DNA binding.  a. 
Coomassie stain of purified RPA, pRPA, RAD51 and RAD52. b. Western blots 
of purified RPA, pRPA. c. ssDNA binding EMSA. RPA and pRPA were 
incubated with an 80-nucleotide ssDNA oligo with an infrared label for five 
minutes, cross-linked with glutaraldehyde, run on an agarose gel, and imaged 
on a Li-Cor Odyssey machine. d. Quantification of c. Bands were measured 
using Image Studio, points represent the percent of ssDNA signal bound by 
protein as a fraction of the total of the signal in each lane. Error bars represent 
SEM, n=3. 
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incubated with DNA containing a 3’ overhang (a 167 nucleotide oligo base-
paired at the 5’ end with a 40 nucleotide oligo). After 5 minutes, dsDNA was 
added, one of the strands of which is homologous to the end of the 3’ 
overhang and is radiolabeled with 32P. After 30 minutes, the reaction was 
stopped and the samples were run on a polyacrylamide gel, imaged on a 
phosphorimager, and analyzed. The shifted band is the strand exchange 
product, and the amount of this product as a percentage of the signal in the 
lane as a whole was calculated. In agreement with published results, RAD51 
activity was greatest around 73.3 nM, a 1:3 RAD51:nculeotide ratio, and 
activity was reduced at higher concentrations (Figure 12). RAD51 generally 
produced between 15 and 30 percent strand exchange products at this 
concentration. 
We then looked at the effect of RPA phosphorylation on RAD51 
exchange in vitro. Published studies show that incubation of ssDNA or DNA 
overhangs with RPA before the addition of RAD51 inhibits RAD51 exchange, 
due to the inability of RAD51 to form filaments by displacing RPA. For these 
experiments, we incubated RPA (or hypRPA) with the 3’ overhang substrate 
for five minutes before adding RAD51 (Figure 13A). Adding increasing 
amounts of RPA up to 33nM reduced exchange activity, which is analogous to 
the concentration where inhibition was seen in the report by Jensen et al. 
There was no significant difference in the amount of inhibition by RPA versus 
hypRPA on RAD51 exchange inhibition (Figure 13). Thus, RPA 
phosphorylation does not prevent it from inhibiting RAD51-filament formation. 
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Figure 12. RAD51 strand exchange. a. Strand exchange protocol for b. and 
c. b. Autoradiogram of reaction. 3’ overhang ssDNA was incubated with 
RAD51 for 5 minutes, labeled complementary dsDNA was then added for 30 
minutes. The reaction was stopped, run on a polyacrylamide gel, and imaged 
on a phosphorimager. c. Quantification of b. Bands were quantified, and the 
signal of the exchange product as a percent of the total signal in each lane 
was determined and plotted. Error bars represent S.D., n=3. 
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Figure 13. RPA phosphorylation doesn’t affect RAD51 strand exchange a. 
Strand exchange protocol for b. and c. b. Autoradiogram of reaction with RPA 
and pRPA. 3’ overhang ssDNA was incubated with RPA or pRPA for 5 
minutes, RAD51 was added for 5 minutes, then labeled complementary 
dsDNA was then added for 30 minutes. The reaction was stopped, run on a 
polyacrylamide gel, and imaged on a phosphorimager. c. Quantification of b. 
Bands were quantified, and the signal of the exchange product as a percent of 
the total signal in each lane was determined and plotted. Error bars represent 
S.D., n=3. 
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RAD52-mediated strand exchange is not promoted by RPA 
phosphorylation in vitro 
 Finally, we looked at the effect of RPA phosphorylation on RAD52’s 
ability to stimulate RAD51 filament formation and exchange on RPA-covered 
ssDNA. For these experiments, we incubated the overhang DNA with RPA or 
phosphorylated RPA for five minutes, then added RAD52 and incubated for 
five minutes, then added RAD51 and incubated for five minutes, and finally 
added the labeled dsDNA (Figure 14A). RAD52 did not promote RAD51 
exchange in the presence of RPA or phosphorylated RPA, and it did not 
promote RAD51 exchange in the absence of RPA (Figure 14B top and Figure 
14C). The presence of some exchange activity with RPA and hypRPA alone is 
curious (Figure 14B, bottom lane 1 and 6 compared to 11), as RPA and 
hypRPA should inhibit exchange. It is possible this is duplex destabilization 
activity, however in Figure 13 we see that these concentrations do not 
promote more activity and actually inhibit RAD51 exchange compared to lower 
concentrations—adding more RPA in these conditions (up to 90nM) lead to 
the loss of inhibition (not shown), likely due to duplex destabilization activity. 
Nevertheless, we can still compare the effect of RAD52 on RPA inhibition, and 
we see no difference between RPA and hypRPA in their inhibition of RAD52 
mediator function—there is no promotion of RAD51 exchange in either case. 
We also do not see strand exchange by RAD52 protein on its own as some 
previous publications observed (Figure 14B bottom, lanes 11-15). We 
conclude that there may be a factor in the cell not present in these reactions 
that allows hypRPA to promote RAD52 function, and that another factor or 
other conditions may exist that allows RAD52 to promote RAD51 exchange on 
RPA-ssDNA.  
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Figure 14. RPA phosphorylation doesn’t affect RAD52-mediated strand 
exchange a. Strand exchange protocol for b. and c. b. Autoradiogram of 
reaction with and without RAD51. 3’ overhang ssDNA was incubated with RPA, 
pRPA, or RPA buffer for 5 minutes, RAD52 or RAD52 buffer was added for 5 
minutes, RAD51 or RAD51 buffer was added for 5 minutes, then labeled 
complementary dsDNA was then added for 30 minutes. The reaction was 
stopped, run on a polyacrylamide gel, and imaged on a phosphorimager. c. 
Quantification of b. +RAD51. d. Quantification of b. -RAD51. For c. and d., 
bands were quantified, and the signal of the exchange product as a percent of 
the total signal in each lane was determined and plotted. Error bars represent 
S.D., n=3. 
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RAD52-mediated annealing is not promoted by RPA phosphorylation in 
vitro 
 It is also possible that RPA phosphorylation affects RAD52 annealing 
activity. This is supported by evidence that RPA phosphorylation promotes 
RAD52-ssDNA contacts and the RPA-RAD52 interaction. To study this we 
used an in vitro strand-annealing assay with purified RAD52, RPA and 
hypRPA. We incubated complementary ssDNAs (one radiolabeled) separately 
with RPA or hypRPA for five minutes, then added RAD52 for five minutes, and 
then mixed the two solutions to allow annealing and stopped the reaction at 1, 
5, 15, and 30 minutes (Figure 15A). RPA and hypRPA on their own reduced 
annealing compared to the control with no protein (Figure 15B, bottom). When 
RAD52 was incubated without RPA or hypRPA, in promoted almost 100 
percent exchange (Figure 15B top, lanes 9-12). Adding RPA or hypRPA 
before RAD52 inhibited RAD52 annealing, and there was no significant 
difference between them (Figure 15B top, lanes 1-4 vs. 5-8). Thus, RPA 
phosphorylation does not promote RAD52 mediator function or annealing in 
vitro under the conditions tested. 
MATERIALS AND METHODS 
Purification of proteins: 
RPA and phosphorylated RPA were purified in Gloria Borgstahl’s lab as 
described previously (Deng et al, Biochemistry, 2009)216. To generate 
phosphorylated RPA, RPA was purified as previously described and then 
mixed with HeLa extracts supplemented with an ATP regenerating system, 
ssDNA, and phosphatase inhibitors. The phosphorylated RPA was then 
purified again in the same was as previously.  
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Figure 15. RPA phosphorylation doesn’t affect RAD52-mediated strand 
annealing a. Strand annealing protocol for b. and c. b. Autoradiogram of 
reaction. Complementary ssDNAs in separate tubes were incubated with RPA, 
pRPA, or buffer for 5 minutes, RAD52 was added for 5 minutes, and then the 
ssDNAs were mixed. Aliquotes were added to stop buffer at 1, 5, 15, and 30 
minutes, run on a polyacrylamide gel, and imaged on a phosphorimager. c. 
Quantification of b. Bands were quantified, and the signal of the annealed 
product as a percent of the total signal in each lane was determined and 
plotted. Error bars represent S.D., n=3. 
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RAD51 and RAD52 were purified in Ryan Jensen’s lab as described 
previously (Jensen et al, Nature, 2009)157.  
DNA binding 
RPA and pRPA were incubated at indicated concentrations in 35mM 
HEPES pH 7.5, 1mM DTT, and 5nM 80mer (5’ IRD700 labeled oligo with 
sequence: TT TGT TAA AAT TCG CGT TAA ATT TTT GTT AAA TCA GCT 
CAT TTT TTA ACC AAT AGG CCG AAA TCG GCA AAA TCC CTT ATA, 
ordered from IDT HPLC purified) at 37 degrees for 5 min. Reactions were then 
cross-linked for 10 minutes at room temperature with 0.2% gluteraldehyde, 
and stopped with 100mM Tris pH 8.0. Reactions were loaded on a 1% 
agarose gel for 2 hours, and imaged on a Li-Cor Odyssey CLx. 
DNA strand exchange and single-stranded DNA annealing assays  
Based on experiments in Jensen et al., Nature, 2010, and performed as 
follows: 
Oligonucleotide substrates were obtained from Sigma or IDT and were purified 
by polyacrylamide gel electrophoresis (PAGE). The following oligonucleotides 
were used:  
RJ-167-mer 
(5’,CTGCTTTATCAAGATAATTTTTCGACTCATCAGAAATATCCGTTTCCTAT
ATTTATTCCTATTATGTTTTATTCATTTACTTATTCTTTATGTTCATTTTTTAT
ATCCTTTACTTTATTTTCTCTGTTTATTCATTTACTTATTTTGTATTATCCTT
ATCTTATTTA-3′);  
RJ-PHIX-42-1 
(5′,CGGATATTTCTGATGAGTCGAAAAATTATCTTGATAAAGCAG-3′);  
RJ-Oligo1 (5′,TAATACAAAATAAGTAAATGAATAAACAGAGAAAATAAAG-3′); 
RJ-Oligo2 (5′,CTTTATTTTCTCTGTTTATTCATTTACTTATTTTGTATTA-3′).  
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To generate the 3′ tailed DNA substrate, RJ-167-mer annealed at a 1:1 molar 
ratio to RJ-PHIX-42-1. The dsDNA was generated by radio-labelling RJ-Oligo1 
with 32P at the 5′-end and annealing it to RJ-Oligo2. The ssDNA substrate was 
RJ-167-mer radio-labelled with 32P at the 5′-end. 
DNA strand exchange assays 
 The assay buffer contained 25 mM Tris acetate (pH 7.5), 1 mM MgCl2, 
2 mM CaCl2, 0.1 µg/µl BSA, 2 mM ATP and 1 mM DTT. All pre-incubations and 
reactions were at 37 °C. The DNA substrates and proteins were at the 
following concentrations unless otherwise indicated in the figure legend: 
p/RPA (33 nM); RAD51 (73 nM); 3′ tail (1.3 nM molecules); and dsDNA 
(1.3 nM molecules). Where proteins were omitted, storage buffer was 
substituted. The reaction was terminated with Proteinase K in 0.5% SDS for 
10 min. The reactions were loaded on a precast 6% polyacrylamide gel in TBE 
buffer (Life Technologies) and electrophoresis was at 30 V for 120 min. The 
gel was then dried and exposed to PhosphorImager screen overnight. The 
screens were scanned on a Fujifilm FLA-7000 phosphorimager and bands 
quantified using Quantity One. The percentage of exchange product was 
calculated as the radio-labelled product divided by the total radio-labelled input 
DNA in each lane. 
Single-stranded DNA annealing assays: 
Cold 167-mer at 4 nM (molecules) and 5′ radio-labelled oligo 1 at 2 nM 
(molecules) were each incubated separately in 10 µl reactions containing 
25 mM Tris acetate (pH 7.5), 1 mM MgCl2, and 1 mM DTT for 5 min with 
RPA(50 nM), pRPA(50 nM) or storage buffer. The 40-mer is complementary to 
the 167-mer at the 3′ end. All incubations were at 37 °C. The oligonucleotides 
were then incubated with either RAD52 (100 nM) or protein storage buffer for 
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5 min. The two separate reactions were then mixed and incubated for 1, 5, 15 
or 30 min to allow for annealing. At the indicated time points aliquots were 
removed and added to stop buffer (4 mg/ml proteinase K, 1% SDS and 0.2 µM 
unlabelled Oligo2 (complementary to Oligo1) for 15 min. Loading dye was then 
added to the samples and they were run on precast 6% polyacrylamide gels in 
TBE buffer (Life Technologies) for 2 h at 30 V. The gels were dried onto 
Whatman paper and exposed to a PhosphorImager screen overnight. The 
screens were scanned on a Fujifilm FLA-7000 phosphorimager and bands 
quantified using Quantity One. The percentage of annealed product was 
calculated as the radio-labelled product divided by the total radio-labelled input 
DNA in each lane. 
Protein buffers 
RPA and pRPA: 30mM HEPES, 0.5% inositol, 0.5mM EDTA, 1mM DTT, 
250mM KCl.  Final pH is 7.8.   
RAD52:  50 mM Tris-Cl (pH=7.5), 200 mM KCl, 15% Glycerol, 10 mM Beta-
mercaptoethanol. 
RAD51:  20 mM HEPES (pH=7.5), 150 mM NaCl, 0.1 mM EDTA, 10% 
Glycerol, 2 mM B-me. 
  
  
           132
CHAPTER FOUR 
DISCUSSION 
RAD52’s function as an alternative mediator 
Studies of RAD52 in vertebrates show no or a limited role for RAD52 in 
HR, as there is little or no phenotype associated with RAD52 loss93,159,160, and 
BRCA2 is the primary mediator of RAD51 filament formation in humans and 
other vertebrates157,158. Despite RAD52’s apparent lack of mediator activity in 
humans, recent evidence suggests that hRAD52 provides an alternative 
mediator pathway to BRCA2161,162. In cells lacking both BRCA2 and RAD52 
there is increased chromosomal instability, pointing to HR deficiency, and 
RAD52 is necessary for RAD51-mediated HR in BRCA2-deficient cells162. 
RAD52 is also synthetically lethal with BRCA1 and PALB2392, and HR and 
RAD51 foci are dependent on RAD52 in BRCA1 and PALB2 depleted cells392. 
The RAD51 paralogs also likely function with BRCA2 and not with RAD52, 
since RAD52 is synthetically lethal in chicken DT40 cells with XRCC3389, 
BRCA2 is epistatic to the paralogs in response to DNA damage as measured 
by cellular survival after MMC432, and both paralog complexes are epistatic to 
BRCA2 and synthetically lethal with RAD52 in human cells433. Several lines of 
evidence suggest this RAD52-backup pathway functions independently of the 
BRCA pathway: RAD52 localization to damage and colocalization with RPA2 
and ssDNA is not affected by BRCA2-status162, RAD52 interacts with RAD51 
independently of BRCA2162, RAD52 foci formation is normal in the absence of 
BRCA1392 and the Rad51 paralogs (XRCC2, XRCC3, RAD51C)391, RAD52 
does not interact with BRCA2157, there is little colocalization of BCCIP (a 
BRCA2-interacting protein) and RAD52 while both localize with RAD51 
separately386, and synthetic lethality has been observed with BRCA1, BRCA2, 
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and PALB2, and RAD51 paralogs, resulting in reduction in HR and viability 
after DNA damage162,392,433. 
RPA hyperphosphorylation has been shown to play a role in the repair 
of replication associated DSBs through HR. Several studies have shown that 
RPA phosphorylation defects lead to sensitivity to DNA damaging 
agents112,230,249 and persistent DNA breaks112,204,233,249. Phosphorylation 
mutants can associate with damage sites253, supporting a model where RPA 
can localize to breaks and sites of stress without phosphorylation but RPA 
function at damage sites and recruitment of downstream factors is impaired 
when the regulation of hyperphosphorylation is defective. RPA 
phosphorylation has also been shown to play a role in HR, as RAD51 foci 
formation230,249 and HR by the DR-GFP assay230,249,268 are reduced in 
phosphorylation mutants, and aberrant SCEs are increased in phosphorylation 
mutants231. RPA phosphorylation also affects its interactions with HR and DNA 
damage response proteins including MRN245,267, p53210,268, RAD51230,255,268, 
PALB2236, and ATR255. Thus, RPA phosphorylation is important for the BRCA 
DNA repair pathway. However, the effect of RPA phosphorylation on the 
RAD52 mediator pathway was previously not well understood. 
There is published evidence that RPA phosphorylation is also important 
for the RAD52 pathway. RPA phosphorylation promotes its interaction with 
RAD52255, hypRPA co-localizes with RAD52 in foci255, and RAD52 focus 
formation is reduced in an RPA2-A mutant268. The RPA-ssDNA-RAD52 
complex is more stable when it includes hypRPA compared to 
unphosphorylated RPA, and more RAD52 cross-links to ssDNA when the RPA 
in the complex is hyperphosphorylated216. Our data in cells supports this 
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evidence that RPA phosphorylation promotes its interaction with RAD52 and 
RAD52 function as an alternative mediator. 
RAD52 mediator function in human cells is promoted by RPA 
phosphorylation 
In this study we showed that in BRCA2-deficient cells, RAD52-
dependent HR as measured by RAD51 foci and the DR-GFP assay are 
dependent on functional phosphorylation and dephosphorylation of RPA. This 
supports the importance of RPA and its phosphorylation in both the BRCA and 
RAD52 pathways of HR. While it is possible that these results are due to the 
effects of residual levels of BRCA2 protein, the relationship between RPA and 
RAD52, as well as our results and previous publications showing that 
phosphorylation regulates their interaction, suggests that RPA phosphorylation 
is important to RAD52 function.  
Furthermore, our results show that RPA phosphorylation promotes the 
association of RAD51 and RAD52 by colocalization, as there is more 
colocalization of RAD51 and RAD52 in RPA2-WT cells than in RPA2-A mutant 
cells. We show that the association of RAD51 and RAD52 is DNA-damage 
dependent, further supporting a role for RAD52 in facilitating RAD51 function 
in DNA repair. While we might expect that the percent of cells in which RAD52 
colocalizes with RAD51 should increase when BRCA2 is depleted, this was 
not observed, suggesting that in normal cells RAD52 colocalizes with RAD51, 
a fraction of this is due to RAD52 mediator function, and the absence of 
BRCA2 does not enhance its mediator activity. In both BRCA2-proficient and 
BRCA2-depleted cells, the percentage of cells with RAD52 foci that colocalize 
with RAD51 is reduced in RPA2-A cells compared to RPA2-WT, suggesting 
that RAD52 requires functional phosphorylation of RPA to recruit RAD51. 
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Although this result could also simply be due to the presence fewer RAD51 
foci in RPA2-A cells, considered in conjuction with the result that there are 
fewer RAD52-dependent (in BRCA2-depleted cells) RAD51 foci and less 
RAD52-dependent HR in RPA2-phosphomutant cells, it is clearer that RPA 
phosphorylation and dephosphorylation promote RAD52-dependent RAD51 
recruitment. Furthermore, although the result was not significant, a smaller 
percent of RAD51 foci colocalize with RAD52 in RPA-phosphomutant cells 
compared to RPA2-WT cells in both control and BRCA2-depleted cells. We do 
not see an increase in the percentage of cells with RAD51 foci that colocalize 
with RAD52 when BRCA2 is depleted, such that RAD52 recruitment of RAD51 
is not affected by BRCA2 loss, supporting its independence from the BRCA 
pathway. Also, it is possible that the levels of RAD51 foci are higher than they 
should be in these experiments, as overexpression of RAD52-GFP, which was 
also transfected in these experiments, has previously been shown to promote 
RAD51 foci formation and HR298,384,387,388. Finally, preliminary evidence not 
shown here indicate that RAD52-depletion does not cause a further reduction 
of DR-GFP recombination in RPA2-phosphomutant cells compared to RPA2-
WT cells, supporting our model in which RAD52 and RPA phosphorylation 
function in the same pathway. As a whole, these data show that RPA 
phosphorylation is important to RAD52 mediator function.  
Depleting RAD52 in BRCA2-depleted RPA phosphorylation mutant 
cells was not technically feasible using our system, however this would show 
directly that RPA phosphorylation mutants are important to RAD52 mediator 
function. We would expect RPA phosphorylation mutants to cause even more 
toxicity and HR deficiency in BRCA2 and RAD52 depleted cells compared to 
RPA2-WT cells. Other endpoints that we could use to show that RPA 
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phosphorylation is important to RAD52 function are the resolution of γH2AX 
foci and cell survival. 
RPA phosphorylation and RAD52-RPA interaction in human cells 
Unlike some previous publications, we saw no effect of RPA 
phosphorylation on levels of RPA foci204,241,252,253,262. We did see a reduction in 
the association of RAD52 with phosphorylation mutants by IP and 
colocalization, in agreement with published literature216,255. This suggests that 
the reduction in RAD52-dependent HR in phosphorylation mutants is due to 
impaired interactions between RAD52 and RPA. Paradoxically, though RPA 
phosphorylation promotes RAD52-dependent HR and improved its interaction 
with RAD52 in our studies and others, RAD52 foci form normally in RPA 
phosphorylation mutant cells after damage. It is possible that although RAD52 
is recruited to foci independently of RPA phosphorylation, either through its 
interactions with RPA or through its own DNA binding activity, that the 
association between RAD52 and RPA is not efficient with phosphorylation 
mutants, or that the lack of cycling between phosphorylation and 
dephosphorylation prevents a hand off of tighter ssDNA contacts from RPA to 
RAD52, thereby causing defective HR. It is also possible that RPA 
phosphorylation mutants fail to recruit other factors important for RAD52 to 
function, for example, RAD51. Interestingly, while after damage RAD52 forms 
foci normally in RPA phosphorylation mutant cells, in RPA2-D untreated cells 
there is an increase in RAD52 foci formation to the level of CPT-treated cells. 
This could mean that phospho-mimic RPA2 signals to RAD52 that there 
appears to be DNA damage in untreated cells, or there could be buildup of 
DNA damage even in untreated RPA2-D mutant cells due to the mimic of 
constitutive RPA2 phosphorylation that results in RAD52-recruitment. On the 
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whole, our data suggest that it is the faulty association between RAD52 and 
RPA that leads to the failure of RAD52 to recruit RAD51 and therby promote 
HR in BRCA2-depleted cells. 
It would be interesting to see if there is a difference in the interaction of 
RPA and RAD52 in the absence of BRCA2. The independence of the RAD52 
pathway, and the lack of effect of BRCA2 on RAD52 function, suggests that 
there would be no difference in this association between BRCA-proficient and 
deficient cells. Additionally, a reverse IP pulling down with a RAD52 antibody 
would confirm the interaction deficiency of the RPA phospho-mutant. There 
may be differences at different timepoints and with different DNA damaging 
agents. Experiments using phospho-specific antibodies would also confirm 
these results by IP and colocalization. Preliminary evidence not shown here 
suggests that endogenous phosphorylated RPA does not preferentially 
colocalize with RAD52, however this may be due to the specific timepoint 
studied or phospho-site used. We used a pS4/8 antibody for these 
experiments; it is possible that other phosphorylation sites mediate the 
RAD52-RPA interaction. Using phosphorylation mutants with mutations at 
individual damage sites, or using a series of different phospho-specific 
antibodies, to determine which phosphorylation sites are important, could 
resolve this issue. 
RPA phosphorylation and RAD52 biochemical mediation  
 We show that RAD51 is not able to replace RPA and form filaments on 
ssDNA on its own, as previously shown, and also that including 
phosphorylated RPA has no effect on this RPA inhibition. We also found that 
RPA phosphorylation does not promote RAD52 mediator function in vitro to 
allow RAD52 to mediate RAD51 filaments on RPA coated ssDNA like BRCA2 
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or yeast RAD52, under the conditions used. This suggests that there either 
there are other biochemical conditions necessary for hRAD52 mediator 
function, or there is a factor present in cells not included in the reaction that 
allows RAD52 to function as a mediator in the absence of BRCA2. This finding 
may also be attributable to a limitation of the assay: in cells, phosphorylation 
and dephosphorylation of RPA is needed for HR and this is under complex 
regulation, and phosphorylation at different sites may have different functions. 
Thus, the failure of phosphorylated RPA to promote RAD52-mediator function 
in our in vitro assays may be because phosphorylation of RPA needs to be 
cycled on and off to promote RAD52 function, or because we are lacking the 
specific phosphorylation pattern that promotes RAD52 function in cells. 
 It is possible that the reactions could be optimized further to show a 
difference between RPA and pRPA inhibition and its effect on RAD52 
mediation. Other publications showed greater RAD51 activity on its own (up to 
50%), and our background activity was high in the presence of RPA, possibly 
due to helix destabilization activity of RPA. Other conditions that may allow 
RAD52 to promote RAD51 mediation in vitro include adding RPA after RAD51 
and RAD52 or at lower concentrations, including RAD51 at suboptimal 
concentrations, or including ammonium sulfate or spermidine, which have 
been shown to improve RAD51 activity157,413,417,427,428. Nevertheless, we see 
no difference in RAD52 mediator activity between RPA and phosphorylated 
RPA.  
 It may be that even though including phosphorylated RPA does not 
allow RAD52 to remove RPA from ssDNA, that phosphorylation of RPA in 
cells promotes RAD52 function through some other mechanism, such as 
recruiting another factor. There may be other biochemical conditions that 
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would show this effect, and these results could be negative because we are 
not seeing enough activity of RAD51 on its own and have too much 
background of RPA on its own. Perhaps, as in cells there is clearly a need for 
phosphorylation and dephosphorylation, cycling phosphorylated RPA and 
nonphosphorylated RPA in vitro would promote the reaction. 
RPA phosphorylation and RAD52 annealing 
We also show that RPA phosphorylation does not promote RAD52 
annealing activity in vitro. It is possible that similar to RAD52 mediator function, 
there is some factor or condition in cells that allows RPA phosphorylation to 
promote RAD52 annealing, however there was no difference in the conditions 
tested. It would be interesting to see the effect of RPA phosphorylation on 
SSA in vivo. The impaired interaction between RPA and RAD52 in RPA 
phosphorylation mutants suggests that SSA in cells would be reduced in these 
phosphorylation mutants. 
Other potential partners of RAD52 in backup mediation 
RAD52 appears to be important for back-up mediation of RAD51 in 
human cells, however it has not been shown to be effective in vitro, suggesting 
a few possibilities. Some other function of RAD52, such as ssDNA annealing, 
and not RAD52-dependent promotion of RAD51 function, may be responsible 
for the synthetic lethal relationship. This is unlikely, since data including the 
dependence of RAD51 foci and HR on RAD52 in the absence of the BRCA 
pathway, suggests that RAD52 is acting as a mediator in the absence of 
BRCA2. Alternatively, RAD52’s inefficient yet present mediation of RAD51 that 
has been shown in vitro may be sufficient in vivo for the synthetic lethality. 
Finally, there may be some other factor in cells that has not been tested in in 
vitro assays that allows RAD52 to mediate RAD51 displacement of RPA. 
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 There are some candidates for RAD52 functional partners beyond RPA 
and RPA phosphorylation. Perhaps in vitro assays containing other known 
vertebrate SSBs, like a-RPA, or hSSB1 and hSSB2, will promote RAD52 
function. Evidence that these proteins are important specifically in DNA 
damage repair and not in DNA replication supports this hypothesis. RPA4 
replaces RPA2 in some RPA complexes in cells to form a-RPA, contains an N-
terminal putative phosphorylation domain199,299,300,302-304, preferentially binds 
damaged DNA301, supports DNA repair through recombination, localizes to 
damage, interacts with RAD51 and RAD52, and supports RAD51 strand 
exchange in vitro300-302. This suggests that it is important at DSB sites, and 
therefore could play a role in promoting RAD52 function. hSSB1 and 
hSSB2305-321 also function in the DNA damage response: hSSB1 forms foci in 
response to DSBs but not replication foci313, hSSB1/2 and their SOSS 
partners have been shown to play a role in HR repair and ATM checkpoint 
signaling, and cells defective in these proteins have hypersensitivity to 
damaging agents, chromosomal instability, reduced HR and RAD51 
recruitment, and reduced ATM-dependent phosphorylation306,308,311,313. hSSB1 
and hSSB2 are therefore potential partners of RAD52. RPA4 and hSSBs are 
not well characterized, but it would be interesting to study their interactions 
with RAD52 in cells and their effect on RAD52 mediator function in vitro. 
Beyond BRCA2 and RAD52, there are other proteins that play a role in 
mediating and supporting RAD51 function. These include the RAD51 paralogs, 
PALB2, SWS1, SWSAP1, RAD54, RAD54B, SWI5, and SFR1463. The RAD51 
paralogs and PALB2 have been suggested to be epistatic to BRCA2 and not 
RAD52, but these other proteins are potential RAD52 mediator partners. 
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SWS1, an ortholog of the yeast Shu complex, and SWSAP1, which 
interacts with SWS1 and has a predicted RecA-core, have been proposed to 
act as recombination mediators488,489. SWS1 also interacts with RAD51D, 
while SWSAP1 interacts with RAD51 and most of the RAD51 paralogs and its 
depletion causes defects in HR. These proteins may function epistatically with 
RAD52, although evidence that RAD52 is not epistatic to the RAD51 paralogs 
and that SWS1 and SWSAP1 function with the paralogs suggests otherwise. 
Similarly, double mutants of RAD52 and RAD54 in mice have exacerbated 
MMC survival reduced survival of bone marrow cells after IR390, suggesting 
these proteins are not epistatic. 
Finally, the SWI5-SFR1 complex, which is related to the S. pombe 
Swi5-Sfr1 and S. cerevisiae Sae3-Mei5 complexes, may act as a mediator and 
function with RAD52. These proteins function only in meiosis in budding yeast. 
In mouse, Swi5 and Sfr1 are nuclear proteins; deletion mutants in ES cells are 
sensitive to DNA damaging agents, have increased chromosomal aberrations, 
and reduced PARP-inhibitor-induced SCE supporting a role for the complex in 
homology based DSB repair493. Expression of a BRC repeat has been shown 
to inhibit RAD51 focus formation and to decrease HR in mammalian cells, 
likely by sequestering RAD51 in cells340,346,349,494; in Sfr1 and Swi5 deleted 
cells, though their loss did not decrease HR frequency on their own, 
expression of the BRC repeat reduced HR even more than in WT, again 
implicating these proteins in a role supporting RAD51493. In humans cells, 
SWI5-SFR1 depletion reduced RAD51 foci and also enhanced sensitivity to 
IR495; in vitro the complex interacts with RAD51 and stimulates RAD51-strand 
exchange by stabilizing the filament496 paradoxically by enhancing ATP 
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hydrolysis by RAD51 and facilitating the release of ADP from the presynaptic 
filament to keep it in its active ATP bound form497.  
These effects are interesting due to the function of the complex in S. 
pombe, which may be relevant to the mediator proteins in human cells. While 
S. cerevisiae Rad52 protein promotes Rad51-dependent DNA-strand 
exchange on RPA-coated DNA by itself, S. pombe Rad52 (Rad22) cannot. 
Though Rad22 is important to overcome the inhibitory effect of RPA, it 
requires the Swi5–Sfr1 complex in a downstream step to stabilize the Rad51 
filament, so it can progress to strand exchange480,498,499. Although it is possible 
this effect is due to differences between S. pombe and S. cerevisiae RAD51, it 
could be because of differences in Rad52 mediator activity between budding 
and fission yeast. Similar to RAD52 knockouts, mouse cells in which 
the Swi5 or Sfr1 are knocked out are viable and display no defect in HR. Thus, 
it is plausible that RAD52 in humans and other mammals requires the SWI5-
SFR1 complex to perform its mediator function.  
RAD52 roles in BRCA-proficient cells  
While RAD52 appears to play a backup mediator role in the absence of 
the BRCA pathway, its role in cells with a functional BRCA pathway is unclear. 
Despite RAD52’s lack of severe HR phenotype, there are some recombination 
phenotypes of RAD52, suggesting that RAD52 does play a role even in 
BRCA-competent cells. Targeted integration frequencies are reduced in 
RAD52-null chicken cells160, and inactivation of RAD52 in mouse ES cells 
causes a reduced frequency of HR160, showing a clear role for RAD52 in 
genetic recombination. RAD52-null mutant mouse cells have no detectable 
HDR defect measured with I-SceI reporter constructs93, but depletion of 
RAD52 has been shown reduce levels of HR repair of nuclease breaks in 
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some cases, although the effect is not as dramatic as would be expected for 
an essential HR protein162. Overexpressing RAD52 in monkey cells confers 
resistance to IR and increases levels of HR387, while in mouse cells 
overexpression increases survival and RAD51 foci after MMS and IR384 and 
inhibits gene targeting while stimulating HR between separate transfected 
plasmids388. Thus, mutations in RAD52 do affect HR. Furthermore hRAD52 
interacts with RAD51 and RPA292-294,298,376,381,384-386, though these interactions 
map to regions in which it does not share homology with yeast Rad52, 
suggesting species-specific functions of the interactions. RAD52’s synthetic 
lethality with factors in DNA repair also point to a role for RAD52. RAD52 foci 
are induced and immobilized to a greater extent by hydroxyurea, which stalls 
replication forks, than by ionizing radiation, suggesting its role is related to 
replication damage386.  
RAD52 annealing, which is effective in vitro and in vivo while BRCA2 
annealing is not, may play a role in BRCA-proficient cells. The SSA pathway is 
clearly dependent on RAD5293, and RAD52 has been proposed to be 
important for second-end capture, and for SDSA downstream in 
HR295,413,416,418,422. Yeast RAD52 mutations are more toxic than RAD51 
mutations, which is believed to be due to scRAD52’s dual function as both a 
mediator and an annealer. In contrast, loss of hRAD52 is not lethal to cells and 
BRCA2 is incapable of annealing RPA-ssDNA, suggesting that these 
annealing pathways are not necessary for functional DSB repair in cells, or 
that there is some redundancy in pathways or other proteins in cells that can 
compensate for the loss of RAD52. What factors function with RAD52 to 
promote its annealing and back-up mediation function in cells is unclear, as 
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most double knockouts tested suggest that RAD52 is synthetically lethal with 
the BRCA pathway including RAD51 paralogs.  
Insight into RAD52s function in BRCA-proficient cells comes from its 
interactions with other proteins. For example, MUS81-induced DSBs 
generated by CHK1 inhibition are independent of RAD51, and depend on 
RAD52. Recovery from replication stress in RAD52-depleted cells requires 
MUS81, and loss of both these proteins results in increased RAD51 foci 
formation that is toxic and massive cell death that can be suppressed by 
RAD51 depletion. Thus, a RAD52/MUS81-dependency exists in checkpoint-
deficient cells, and this suggests that RAD52 is associated with cleavage at 
stalled forks in vivo and in vitro402.  RAD52 has also been shown to interact 
with helicases in cells. Baynton et al403 find that WRN, a RECQ homolog, 
interacts with RAD52 in vivo at arrested replication forks and in vitro. 
Biochemically RAD52 both inhibits and enhances WRN helicase activity, while 
WRN increases RAD52-mediated strand annealing403. RAD52 also interacts 
with human RECQ5 to promote SDSA168. RECQ5 counteracts the inhibition by 
RAD51 on RAD52 annealing in vitro and in vivo, and deficiency in RECQ5 
leads to increased occupancy of RAD51 at DSBs. This suggests that RECQ5 
acts in SDSA post-synaptically to prevent aberrant RAD51 filament formation 
on the extended invading strand, thus limiting crossovers168. RAD52 also 
interacts with PTEN, regulating RAD52 sumoylation399. 
 In a reaction analogous to SDSA, RAD52 can anneal the extended 
invaded strand with a second complementary tail after it dissociates from the 
D-loop (dissociation is mediated by RAD54 in these experiments), though 
RAD52 was dispensable for this activity in the absence of RPA423. RAD52 can 
also promote the formation of a “double D-loop,” annealing the displaced 
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strand of a D-loop to another complementary ssDNA, which would be 
analogous to second end capture/dHJ formation of DSBR423. DNA repair 
synthesis catalyzed by human DNA polymerase η (which has been suggested 
to play a role in HR repair) acting upon priming strand of a D-loop leads to 
capture and annealing of the second end of a resected DSB, and this reaction 
is mediated by RAD52176. Thus, RAD52 may play an annealing role in second-
end capture and SDSA in cells, though the importance of this role in vivo is 
unclear. 
Interestingly, recent unpublished evidence from our lab suggests HelQ 
regulates RAD52 function in DSB repair by HR and SSA. HelQ depletion in 
U2OS cells reduces HR and SSA and leads to reduced RAD52-GFP foci 
formation after CPT. Depleting HelQ and RAD52 revealed no additive effect 
on either HR or SSA suggesting they are epistatic. HelQ acts downstream of 
RAD51 filament formation to facilitate RAD52 activity in second end capture—
no change was observed in foci formation of γH2AX, BRCA1, RPA2, and 
RAD51 after CPT treatment in HelQ-depleted cells, suggesting a role for HelQ 
downstream of resection and RAD51 filament formation. HelQ interacts with 
RPA2, pRPA2, and RAD52 after 2h CPT by IP. Loss of HelQ results in a 
greater frequency of long tract gene conversion, similar to RAD52 depletion, 
which is due to the inability of non-invading strand of the double-strand break 
to support appropriate termination of the short tract gene conversion by 
annealing, suggesting a role for HelQ in second-end capture. Finally, HelQ 
suppresses RAD52 mediator activity in HR, as depleting HelQ in BRCA2-
depleted cells resulted in an increase in HR by DR-GFP and RAD51 foci 
formation, and this recovery of RAD51 and HR can be attributed to the activity 
of the RAD52-mediated repair pathway, as the simultaneous depletion of HelQ, 
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Figure 16: Model for RAD52-mediated HR. In BRCA-deficient cells, RAD52 
mediates HR after a DSB. DSBs are resected to generate 3’ ssDNA 
overhangs, which are bound by RPA and pRPA. RAD52 is recruited to these 
damage sites independent of RPA phosphorylation, but proper regulation of 
RPA phosphorylation and dephosphorylation improves the RPA-RAD52 
association. This improved association allows RAD52 to successfully recruit 
RAD51, and to promote RAD51 filament formation and strand invasion. 
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BRCA2, and RAD52 blocked RAD51 foci formation. Taken together, these 
data suggest that HelQ appears to facilitate RAD52 dependent annealing 
activity while blocking RAD51 mediator activity in HR. 
CANCER THERAPIES 
In cancer patients carrying BRCA mutations only, tumor cells are BRCA 
deficient (usually heterozygous BRCAmut/-), while normal cells are proficient in 
HR, containing one functional and one nonfunctional copy of BRCA1 or 
BRCA2. Thus, targeting a protein such as RAD52, which is synthetically lethal 
with BRCA2 would result in death specifically of tumor cells. The synthetic 
lethal relationship between PARP and the BRCA proteins provides a proof of 
principle example that synthetic lethality with BRCA proteins may be utilized 
for cancer treatment. Our works demonstrates that RPA phosphorylation is 
important not only for the BRCA pathway but the RAD52 pathway. Thus, this 
interaction is a potential therapeutic target. 
MODEL FOR RAD52-DEPENDENT HR 
 Our data supports a model of RAD52-dependent HR that is promoted 
by hyperphosphorylation of RPA (Figure 16). After a DSB or fork collapse, the 
ends are resected to generate 3’ ssDNA overhangs that are bound by RPA, 
which is then hyperphosphorylated. RAD52 is recruited to the damage site by 
RPA regardless of RPA phosphorylation status. However, RPA 
phosphorylation enhances its interactions with RAD52, allowing it to recruit 
RAD51 and promote filament formation. RAD51 then catalyzes homology 
search and strand invasion. Our in vitro evidence suggests that cycling of RPA 
phosphorylation or other factors besides RPA hyperphosphorylation are 
needed, to allow RAD52 to promote RAD51 nucleoprotein filaments to form on 
RPA-ssDNA.  
           149
REFERENCES 
 
1 Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe 
to play with knives. Mol Cell 40, 179-204, 
doi:10.1016/j.molcel.2010.09.019 (2010). 
2 Hartlerode, A. J. & Scully, R. Mechanisms of double-strand break repair 
in somatic mammalian cells. The Biochemical journal 423, 157-168, 
doi:10.1042/BJ20090942 (2009). 
3 Heyer, W. D., Ehmsen, K. T. & Liu, J. Regulation of homologous 
recombination in eukaryotes. Annual review of genetics 44, 113-139, 
doi:10.1146/annurev-genet-051710-150955 (2010). 
4 Rothkamm, K., Kruger, I., Thompson, L. H. & Lobrich, M. Pathways of 
DNA double-strand break repair during the mammalian cell cycle. Mol 
Cell Biol 23, 5706-5715 (2003). 
5 Pierce, A. J., Hu, P., Han, M., Ellis, N. & Jasin, M. Ku DNA end-binding 
protein modulates homologous repair of double-strand breaks in 
mammalian cells. Genes & development 15, 3237-3242, 
doi:10.1101/gad.946401 (2001). 
6 Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is 
associated with triple-negative and BRCA-mutated breast cancers. Nat 
Struct Mol Biol 17, 688-695, doi:nsmb.1831 [pii] 
10.1038/nsmb.1831 (2010). 
7 Bunting, S. F. et al. 53BP1 inhibits homologous recombination in Brca1-
deficient cells by blocking resection of DNA breaks. Cell 141, 243-254, 
doi:S0092-8674(10)00285-0 [pii] 
10.1016/j.cell.2010.03.012 (2010). 
8 Couedel, C. et al. Collaboration of homologous recombination and 
nonhomologous end-joining factors for the survival and integrity of mice 
and cells. Genes & development 18, 1293-1304, 
doi:10.1101/gad.1209204 (2004). 
9 Mills, K. D. et al. Rad54 and DNA Ligase IV cooperate to maintain 
mammalian chromatid stability. Genes & development 18, 1283-1292, 
doi:10.1101/gad.1204304 (2004). 
10 Mimitou, E. P. & Symington, L. S. DNA end resection--unraveling the 
tail. DNA repair 10, 344-348, doi:10.1016/j.dnarep.2010.12.004 (2011). 
           150
11 Chatterjee, N. & Siede, W. Replicating damaged DNA in eukaryotes. 
Cold Spring Harbor perspectives in biology 5, a019836, 
doi:10.1101/cshperspect.a019836 (2013). 
12 Syeda, A. H., Hawkins, M. & McGlynn, P. Recombination and 
replication. Cold Spring Harbor perspectives in biology 6, a016550, 
doi:10.1101/cshperspect.a016550 (2014). 
13 Blow, J. J., Ge, X. Q. & Jackson, D. A. How dormant origins promote 
complete genome replication. Trends in biochemical sciences 36, 405-
414, doi:10.1016/j.tibs.2011.05.002 (2011). 
14 Lambert, S. & Carr, A. M. Checkpoint responses to replication fork 
barriers. Biochimie 87, 591-602, doi:10.1016/j.biochi.2004.10.020 
(2005). 
15 Lambert, S., Watson, A., Sheedy, D. M., Martin, B. & Carr, A. M. Gross 
chromosomal rearrangements and elevated recombination at an 
inducible site-specific replication fork barrier. Cell 121, 689-702, 
doi:10.1016/j.cell.2005.03.022 (2005). 
16 Pommier, Y. Drugging topoisomerases: lessons and challenges. ACS 
Chem Biol 8, 82-95, doi:10.1021/cb300648v (2013). 
17 Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome 
integrity. Nature reviews. Molecular cell biology 9, 616-627, 
doi:10.1038/nrm2450 (2008). 
18 Mazouzi, A., Velimezi, G. & Loizou, J. I. DNA replication stress: causes, 
resolution and disease. Experimental cell research 329, 85-93, 
doi:10.1016/j.yexcr.2014.09.030 (2014). 
19 Kumagai, A., Lee, J., Yoo, H. Y. & Dunphy, W. G. TopBP1 activates the 
ATR-ATRIP complex. Cell 124, 943-955, doi:10.1016/j.cell.2005.12.041 
(2006). 
20 Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP 
recognition of RPA-ssDNA complexes. Science 300, 1542-1548, 
doi:10.1126/science.1083430 (2003). 
21 Mordes, D. A., Glick, G. G., Zhao, R. & Cortez, D. TopBP1 activates 
ATR through ATRIP and a PIKK regulatory domain. Genes & 
development 22, 1478-1489, doi:10.1101/gad.1666208 (2008). 
22 Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing 
global exhaustion of RPA. Cell 155, 1088-1103, 
doi:10.1016/j.cell.2013.10.043 (2013). 
           151
23 Bachrati, C. Z. & Hickson, I. D. RecQ helicases: guardian angels of the 
DNA replication fork. Chromosoma 117, 219-233, doi:10.1007/s00412-
007-0142-4 (2008). 
24 Driscoll, R. & Cimprich, K. A. HARPing on about the DNA damage 
response during replication. Genes & development 23, 2359-2365, 
doi:10.1101/gad.1860609 (2009). 
25 Luke-Glaser, S., Luke, B., Grossi, S. & Constantinou, A. FANCM 
regulates DNA chain elongation and is stabilized by S-phase 
checkpoint signalling. The EMBO journal 29, 795-805, 
doi:10.1038/emboj.2009.371 (2010). 
26 Unk, I., Hajdu, I., Blastyak, A. & Haracska, L. Role of yeast Rad5 and 
its human orthologs, HLTF and SHPRH in DNA damage tolerance. 
DNA repair 9, 257-267, doi:10.1016/j.dnarep.2009.12.013 (2010). 
27 Heyer, W. D. Regulation of Recombination and Genomic Maintenance. 
Cold Spring Harbor perspectives in biology 7, 
doi:10.1101/cshperspect.a016501 (2015). 
28 Hoege, C., Pfander, B., Moldovan, G. L., Pyrowolakis, G. & Jentsch, S. 
RAD6-dependent DNA repair is linked to modification of PCNA by 
ubiquitin and SUMO. Nature 419, 135-141, doi:10.1038/nature00991 
(2002). 
29 Krejci, L. et al. DNA helicase Srs2 disrupts the Rad51 presynaptic 
filament. Nature 423, 305-309, doi:10.1038/nature01577 (2003). 
30 Moldovan, G. L., Pfander, B. & Jentsch, S. PCNA, the maestro of the 
replication fork. Cell 129, 665-679, doi:10.1016/j.cell.2007.05.003 
(2007). 
31 Papouli, E. et al. Crosstalk between SUMO and ubiquitin on PCNA is 
mediated by recruitment of the helicase Srs2p. Mol Cell 19, 123-133, 
doi:10.1016/j.molcel.2005.06.001 (2005). 
32 Pfander, B., Moldovan, G. L., Sacher, M., Hoege, C. & Jentsch, S. 
SUMO-modified PCNA recruits Srs2 to prevent recombination during S 
phase. Nature 436, 428-433, doi:10.1038/nature03665 (2005). 
33 Prakash, S., Johnson, R. E. & Prakash, L. Eukaryotic translesion 
synthesis DNA polymerases: specificity of structure and function. 
Annual review of biochemistry 74, 317-353, 
doi:10.1146/annurev.biochem.74.082803.133250 (2005). 
           152
34 Sale, J. E., Lehmann, A. R. & Woodgate, R. Y-family DNA polymerases 
and their role in tolerance of cellular DNA damage. Nature reviews. 
Molecular cell biology 13, 141-152, doi:10.1038/nrm3289 (2012). 
35 Schiestl, R. H., Prakash, S. & Prakash, L. The SRS2 suppressor of 
rad6 mutations of Saccharomyces cerevisiae acts by channeling DNA 
lesions into the RAD52 DNA repair pathway. Genetics 124, 817-831 
(1990). 
36 Stelter, P. & Ulrich, H. D. Control of spontaneous and damage-induced 
mutagenesis by SUMO and ubiquitin conjugation. Nature 425, 188-191, 
doi:10.1038/nature01965 (2003). 
37 Veaute, X. et al. The Srs2 helicase prevents recombination by 
disrupting Rad51 nucleoprotein filaments. Nature 423, 309-312, 
doi:10.1038/nature01585 (2003). 
38 Watts, F. Z. Sumoylation of PCNA: Wrestling with recombination at 
stalled replication forks. DNA repair 5, 399-403, 
doi:10.1016/j.dnarep.2005.11.002 (2006). 
39 Lomonosov, M., Anand, S., Sangrithi, M., Davies, R. & Venkitaraman, A. 
R. Stabilization of stalled DNA replication forks by the BRCA2 breast 
cancer susceptibility protein. Genes & development 17, 3017-3022, 
doi:10.1101/gad.279003 (2003). 
40 Sonoda, E. et al. Rad51-deficient vertebrate cells accumulate 
chromosomal breaks prior to cell death. The EMBO journal 17, 598-608, 
doi:10.1093/emboj/17.2.598 (1998). 
41 Sobeck, A. et al. Fanconi anemia proteins are required to prevent 
accumulation of replication-associated DNA double-strand breaks. Mol 
Cell Biol 26, 425-437, doi:10.1128/MCB.26.2.425-437.2006 (2006). 
42 Hashimoto, Y., Ray Chaudhuri, A., Lopes, M. & Costanzo, V. Rad51 
protects nascent DNA from Mre11-dependent degradation and 
promotes continuous DNA synthesis. Nat Struct Mol Biol 17, 1305-1311, 
doi:10.1038/nsmb.1927 (2010). 
43 Siaud, N. et al. Plasticity of BRCA2 function in homologous 
recombination: genetic interactions of the PALB2 and DNA binding 
domains. PLoS genetics 7, e1002409, 
doi:10.1371/journal.pgen.1002409 (2011). 
44 Schlacher, K. et al. Double-strand break repair-independent role for 
BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 
145, 529-542, doi:10.1016/j.cell.2011.03.041 (2011). 
           153
45 Schlacher, K., Wu, H. & Jasin, M. A distinct replication fork protection 
pathway connects Fanconi anemia tumor suppressors to RAD51-
BRCA1/2. Cancer Cell 22, 106-116, doi:10.1016/j.ccr.2012.05.015 
(2012). 
46 Sirbu, B. M. & Cortez, D. DNA damage response: three levels of DNA 
repair regulation. Cold Spring Harbor perspectives in biology 5, 
a012724, doi:10.1101/cshperspect.a012724 (2013). 
47 Meek, K., Dang, V. & Lees-Miller, S. P. DNA-PK: the means to justify 
the ends? Adv Immunol 99, 33-58, doi:10.1016/S0065-2776(08)00602-
0 (2008). 
48 Williams, R. S., Williams, J. S. & Tainer, J. A. Mre11-Rad50-Nbs1 is a 
keystone complex connecting DNA repair machinery, double-strand 
break signaling, and the chromatin template. Biochem Cell Biol 85, 509-
520, doi:10.1139/O07-069 (2007). 
49 Wang, M. et al. PARP-1 and Ku compete for repair of DNA double 
strand breaks by distinct NHEJ pathways. Nucleic acids research 34, 
6170-6182, doi:10.1093/nar/gkl840 (2006). 
50 Haince, J. F. et al. PARP1-dependent kinetics of recruitment of MRE11 
and NBS1 proteins to multiple DNA damage sites. J Biol Chem 283, 
1197-1208, doi:10.1074/jbc.M706734200 (2008). 
51 Fernandez-Capetillo, O. & Nussenzweig, A. Naked replication forks 
break apRPArt. Cell 155, 979-980, doi:10.1016/j.cell.2013.10.049 
(2013). 
52 Riley, T., Sontag, E., Chen, P. & Levine, A. Transcriptional control of 
human p53-regulated genes. Nature reviews. Molecular cell biology 9, 
402-412, doi:10.1038/nrm2395 (2008). 
53 Rogakou, E. P., Boon, C., Redon, C. & Bonner, W. M. Megabase 
chromatin domains involved in DNA double-strand breaks in vivo. The 
Journal of cell biology 146, 905-916 (1999). 
54 Rogakou, E. P., Nieves-Neira, W., Boon, C., Pommier, Y. & Bonner, W. 
M. Initiation of DNA fragmentation during apoptosis induces 
phosphorylation of H2AX histone at serine 139. J Biol Chem 275, 9390-
9395 (2000). 
55 Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S. & Bonner, W. M. 
DNA double-stranded breaks induce histone H2AX phosphorylation on 
serine 139. J Biol Chem 273, 5858-5868 (1998). 
           154
56 Huen, M. S. et al. RNF8 transduces the DNA-damage signal via histone 
ubiquitylation and checkpoint protein assembly. Cell 131, 901-914, 
doi:10.1016/j.cell.2007.09.041 (2007). 
57 Bekker-Jensen, S. & Mailand, N. Assembly and function of DNA 
double-strand break repair foci in mammalian cells. DNA repair 9, 1219-
1228, doi:10.1016/j.dnarep.2010.09.010 (2010). 
58 Wang, B. & Elledge, S. J. Ubc13/Rnf8 ubiquitin ligases control foci 
formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to 
DNA damage. Proc Natl Acad Sci U S A 104, 20759-20763, 
doi:10.1073/pnas.0710061104 (2007). 
59 Doil, C. et al. RNF168 binds and amplifies ubiquitin conjugates on 
damaged chromosomes to allow accumulation of repair proteins. Cell 
136, 435-446, doi:10.1016/j.cell.2008.12.041 (2009). 
60 Stewart, G. S. et al. The RIDDLE syndrome protein mediates a 
ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 
136, 420-434, doi:10.1016/j.cell.2008.12.042 (2009). 
61 Daley, J. M. & Sung, P. 53BP1, BRCA1, and the choice between 
recombination and end joining at DNA double-strand breaks. Mol Cell 
Biol 34, 1380-1388, doi:10.1128/MCB.01639-13 (2014). 
62 Wang, B. et al. Abraxas and RAP80 form a BRCA1 protein complex 
required for the DNA damage response. Science 316, 1194-1198, 
doi:10.1126/science.1139476 (2007). 
63 Wu, J. et al. Histone ubiquitination associates with BRCA1-dependent 
DNA damage response. Mol Cell Biol 29, 849-860, 
doi:10.1128/mcb.01302-08 (2009). 
64 Shao, G. et al. MERIT40 controls BRCA1-Rap80 complex integrity and 
recruitment to DNA double-strand breaks. Genes & development 23, 
740-754, doi:10.1101/gad.1739609 (2009). 
65 Feng, L., Huang, J. & Chen, J. MERIT40 facilitates BRCA1 localization 
and DNA damage repair. Genes & development 23, 719-728, 
doi:10.1101/gad.1770609 (2009). 
66 Sobhian, B. et al. RAP80 targets BRCA1 to specific ubiquitin structures 
at DNA damage sites. Science 316, 1198-1202, 
doi:10.1126/science.1139516 (2007). 
           155
67 Mailand, N. et al. RNF8 ubiquitylates histones at DNA double-strand 
breaks and promotes assembly of repair proteins. Cell 131, 887-900, 
doi:10.1016/j.cell.2007.09.040 (2007). 
68 Kim, H., Chen, J. & Yu, X. Ubiquitin-binding protein RAP80 mediates 
BRCA1-dependent DNA damage response. Science 316, 1202-1205, 
doi:10.1126/science.1139621 (2007). 
69 Botuyan, M. V. et al. Structural basis for the methylation state-specific 
recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 
127, 1361-1373, doi:10.1016/j.cell.2006.10.043 (2006). 
70 Galanty, Y. et al. Mammalian SUMO E3-ligases PIAS1 and PIAS4 
promote responses to DNA double-strand breaks. Nature 462, 935-939, 
doi:10.1038/nature08657 (2009). 
71 Morris, J. R. et al. The SUMO modification pathway is involved in the 
BRCA1 response to genotoxic stress. Nature 462, 886-890, 
doi:10.1038/nature08593 (2009). 
72 Shiotani, B. & Zou, L. Single-stranded DNA orchestrates an ATM-to-
ATR switch at DNA breaks. Mol Cell 33, 547-558, 
doi:10.1016/j.molcel.2009.01.024 (2009). 
73 Sorensen, C. S. et al. The cell-cycle checkpoint kinase Chk1 is required 
for mammalian homologous recombination repair. Nat Cell Biol 7, 195-
201, doi:10.1038/ncb1212 (2005). 
74 Kadyk, L. C. & Hartwell, L. H. Sister chromatids are preferred over 
homologs as substrates for recombinational repair in Saccharomyces 
cerevisiae. Genetics 132, 387-402 (1992). 
75 Fabre, F., Chan, A., Heyer, W. D. & Gangloff, S. Alternate pathways 
involving Sgs1/Top3, Mus81/ Mms4, and Srs2 prevent formation of 
toxic recombination intermediates from single-stranded gaps created by 
DNA replication. Proc Natl Acad Sci U S A 99, 16887-16892, 
doi:10.1073/pnas.252652399 (2002). 
76 Keeney, S., Giroux, C. N. & Kleckner, N. Meiosis-specific DNA double-
strand breaks are catalyzed by Spo11, a member of a widely conserved 
protein family. Cell 88, 375-384 (1997). 
77 Elliott, B. & Jasin, M. Double-strand breaks and translocations in cancer. 
Cellular and molecular life sciences : CMLS 59, 373-385 (2002). 
           156
78 Kolodner, R. D., Putnam, C. D. & Myung, K. Maintenance of genome 
stability in Saccharomyces cerevisiae. Science 297, 552-557, 
doi:10.1126/science.1075277 (2002). 
79 Lisby, M. & Rothstein, R. DNA damage checkpoint and repair centers. 
Curr Opin Cell Biol 16, 328-334, doi:10.1016/j.ceb.2004.03.011 (2004). 
80 Roy, R., Chun, J. & Powell, S. N. BRCA1 and BRCA2: different roles in 
a common pathway of genome protection. Nature reviews. Cancer 12, 
68-78, doi:10.1038/nrc3181 (2012). 
81 King, T. A. et al. Heterogenic loss of the wild-type BRCA allele in 
human breast tumorigenesis. Ann Surg Oncol 14, 2510-2518, 
doi:10.1245/s10434-007-9372-1 (2007). 
82 D'Andrea, A. D. BRCA1: a missing link in the Fanconi anemia/BRCA 
pathway. Cancer Discov 3, 376-378, doi:10.1158/2159-8290.CD-13-
0044 (2013). 
83 Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous 
recombination and human health: the roles of BRCA1, BRCA2, and 
associated proteins. Cold Spring Harbor perspectives in biology 7, 
a016600, doi:10.1101/cshperspect.a016600 (2015). 
84 Reid, S. et al. Biallelic mutations in PALB2 cause Fanconi anemia 
subtype FA-N and predispose to childhood cancer. Nature genetics 39, 
162-164, doi:10.1038/ng1947 (2007). 
85 Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. 
Science 297, 606-609, doi:10.1126/science.1073834 (2002). 
86 Meyer, S. et al. Fanconi anaemia, BRCA2 mutations and childhood 
cancer: a developmental perspective from clinical and epidemiological 
observations with implications for genetic counselling. J Med Genet 51, 
71-75, doi:10.1136/jmedgenet-2013-101642 (2014). 
87 D'Andrea, A. D. The Fanconi Anemia/BRCA signaling pathway: 
disruption in cisplatin-sensitive ovarian cancers. Cell cycle 2, 290-292 
(2003). 
88 Ellis, N. A. et al. The Bloom's syndrome gene product is homologous to 
RecQ helicases. Cell 83, 655-666 (1995). 
89 Savitsky, K. et al. A single ataxia telangiectasia gene with a product 
similar to PI-3 kinase. Science 268, 1749-1753 (1995). 
           157
90 Stracker, T. H. & Petrini, J. H. The MRE11 complex: starting from the 
ends. Nature reviews. Molecular cell biology 12, 90-103, 
doi:10.1038/nrm3047 (2011). 
91 O'Driscoll, M., Ruiz-Perez, V. L., Woods, C. G., Jeggo, P. A. & 
Goodship, J. A. A splicing mutation affecting expression of ataxia-
telangiectasia and Rad3-related protein (ATR) results in Seckel 
syndrome. Nature genetics 33, 497-501, doi:10.1038/ng1129 (2003). 
92 Qvist, P. et al. CtIP Mutations Cause Seckel and Jawad Syndromes. 
PLoS genetics 7, e1002310, doi:10.1371/journal.pgen.1002310 (2011). 
93 Stark, J. M., Pierce, A. J., Oh, J., Pastink, A. & Jasin, M. Genetic steps 
of mammalian homologous repair with distinct mutagenic 
consequences. Mol Cell Biol 24, 9305-9316, 
doi:10.1128/MCB.24.21.9305-9316.2004 (2004). 
94 Wu, L. C. et al. Identification of a RING protein that can interact in vivo 
with the BRCA1 gene product. Nature genetics 14, 430-440, 
doi:10.1038/ng1296-430 (1996). 
95 Sy, S. M., Huen, M. S. & Chen, J. PALB2 is an integral component of 
the BRCA complex required for homologous recombination repair. Proc 
Natl Acad Sci U S A 106, 7155-7160, doi:10.1073/pnas.0811159106 
(2009). 
96 Zhang, F., Fan, Q., Ren, K. & Andreassen, P. R. PALB2 functionally 
connects the breast cancer susceptibility proteins BRCA1 and BRCA2. 
Molecular cancer research : MCR 7, 1110-1118, doi:10.1158/1541-
7786.mcr-09-0123 (2009). 
97 Zhang, F. et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage 
response. Current biology : CB 19, 524-529, 
doi:10.1016/j.cub.2009.02.018 (2009). 
98 Cantor, S. B. et al. BACH1, a novel helicase-like protein, interacts 
directly with BRCA1 and contributes to its DNA repair function. Cell 105, 
149-160 (2001). 
99 Greenberg, R. A. et al. Multifactorial contributions to an acute DNA 
damage response by BRCA1/BARD1-containing complexes. Genes & 
development 20, 34-46, doi:10.1101/gad.1381306 (2006). 
100 Yu, X., Fu, S., Lai, M., Baer, R. & Chen, J. BRCA1 ubiquitinates its 
phosphorylation-dependent binding partner CtIP. Genes & development 
20, 1721-1726, doi:10.1101/gad.1431006 (2006). 
           158
101 Yu, X., Wu, L. C., Bowcock, A. M., Aronheim, A. & Baer, R. The C-
terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein 
implicated in the CtBP pathway of transcriptional repression. J Biol 
Chem 273, 25388-25392 (1998). 
102 Yun, M. H. & Hiom, K. CtIP-BRCA1 modulates the choice of DNA 
double-strand-break repair pathway throughout the cell cycle. Nature 
459, 460-463, doi:10.1038/nature07955 (2009). 
103 Coleman, K. A. & Greenberg, R. A. The BRCA1-RAP80 complex 
regulates DNA repair mechanism utilization by restricting end resection. 
J Biol Chem 286, 13669-13680, doi:10.1074/jbc.M110.213728 (2011). 
104 Huertas, P. DNA resection in eukaryotes: deciding how to fix the break. 
Nat Struct Mol Biol 17, 11-16, doi:10.1038/nsmb.1710 (2010). 
105 Moynahan, M. E. & Jasin, M. Mitotic homologous recombination 
maintains genomic stability and suppresses tumorigenesis. Nature 
reviews. Molecular cell biology 11, 196-207, doi:10.1038/nrm2851 
(2010). 
106 You, Z. & Bailis, J. M. DNA damage and decisions: CtIP coordinates 
DNA repair and cell cycle checkpoints. Trends in cell biology 20, 402-
409, doi:10.1016/j.tcb.2010.04.002 (2010). 
107 You, Z. et al. CtIP links DNA double-strand break sensing to resection. 
Mol Cell 36, 954-969, doi:10.1016/j.molcel.2009.12.002 (2009). 
108 Kass, E. M. & Jasin, M. Collaboration and competition between DNA 
double-strand break repair pathways. FEBS Lett 584, 3703-3708, 
doi:10.1016/j.febslet.2010.07.057 (2010). 
109 Symington, L. S. & Gautier, J. Double-strand break end resection and 
repair pathway choice. Annual review of genetics 45, 247-271, 
doi:10.1146/annurev-genet-110410-132435 (2011). 
110 Lee, J. H. & Paull, T. T. ATM activation by DNA double-strand breaks 
through the Mre11-Rad50-Nbs1 complex. Science 308, 551-554, 
doi:10.1126/science.1108297 (2005). 
111 Williams, R. S. et al. Mre11 dimers coordinate DNA end bridging and 
nuclease processing in double-strand-break repair. Cell 135, 97-109, 
doi:10.1016/j.cell.2008.08.017 (2008). 
112 Feng, J. et al. Protein phosphatase 2A-dependent dephosphorylation of 
replication protein A is required for the repair of DNA breaks induced by 
           159
replication stress. Mol Cell Biol 29, 5696-5709, 
doi:10.1128/MCB.00191-09 (2009). 
113 Sartori, A. A. et al. Human CtIP promotes DNA end resection. Nature 
450, 509-514, doi:10.1038/nature06337 (2007). 
114 Makharashvili, N. et al. Catalytic and noncatalytic roles of the CtIP 
endonuclease in double-strand break end resection. Mol Cell 54, 1022-
1033, doi:10.1016/j.molcel.2014.04.011 (2014). 
115 Garcia, V., Phelps, S. E., Gray, S. & Neale, M. J. Bidirectional resection 
of DNA double-strand breaks by Mre11 and Exo1. Nature 479, 241-244, 
doi:10.1038/nature10515 (2011). 
116 Symington, L. S. End resection at double-strand breaks: mechanism 
and regulation. Cold Spring Harbor perspectives in biology 6, 
doi:10.1101/cshperspect.a016436 (2014). 
117 Nimonkar, A. V. et al. BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-
MRN constitute two DNA end resection machineries for human DNA 
break repair. Genes & development 25, 350-362, 
doi:10.1101/gad.2003811 (2011). 
118 Zhu, Z., Chung, W. H., Shim, E. Y., Lee, S. E. & Ira, G. Sgs1 helicase 
and two nucleases Dna2 and Exo1 resect DNA double-strand break 
ends. Cell 134, 981-994, doi:10.1016/j.cell.2008.08.037 (2008). 
119 Mimitou, E. P. & Symington, L. S. Sae2, Exo1 and Sgs1 collaborate in 
DNA double-strand break processing. Nature 455, 770-774, 
doi:10.1038/nature07312 (2008). 
120 Tomimatsu, N. et al. Exo1 plays a major role in DNA end resection in 
humans and influences double-strand break repair and damage 
signaling decisions. DNA repair 11, 441-448, 
doi:10.1016/j.dnarep.2012.01.006 (2012). 
121 Zhong, Q. et al. Association of BRCA1 with the hRad50-hMre11-p95 
complex and the DNA damage response. Science 285, 747-750 (1999). 
122 Wong, A. K. et al. Characterization of a carboxy-terminal BRCA1 
interacting protein. Oncogene 17, 2279-2285, 
doi:10.1038/sj.onc.1202150 (1998). 
123 Moynahan, M. E., Chiu, J. W., Koller, B. H. & Jasin, M. Brca1 controls 
homology-directed DNA repair. Mol Cell 4, 511-518 (1999). 
           160
124 Bennardo, N., Cheng, A., Huang, N. & Stark, J. M. Alternative-NHEJ is 
a mechanistically distinct pathway of mammalian chromosome break 
repair. PLoS genetics 4, e1000110, doi:10.1371/journal.pgen.1000110 
(2008). 
125 Schlegel, B. P., Jodelka, F. M. & Nunez, R. BRCA1 promotes induction 
of ssDNA by ionizing radiation. Cancer research 66, 5181-5189, 
doi:10.1158/0008-5472.CAN-05-3209 (2006). 
126 Chen, L., Nievera, C. J., Lee, A. Y. & Wu, X. Cell cycle-dependent 
complex formation of BRCA1.CtIP.MRN is important for DNA double-
strand break repair. J Biol Chem 283, 7713-7720, 
doi:10.1074/jbc.M710245200 (2008). 
127 Escribano-Diaz, C. et al. A cell cycle-dependent regulatory circuit 
composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair 
pathway choice. Mol Cell 49, 872-883, 
doi:10.1016/j.molcel.2013.01.001 (2013). 
128 Zhao, G. Y. et al. A critical role for the ubiquitin-conjugating enzyme 
Ubc13 in initiating homologous recombination. Mol Cell 25, 663-675, 
doi:10.1016/j.molcel.2007.01.029 (2007). 
129 Nakamura, K. et al. Collaborative action of Brca1 and CtIP in 
elimination of covalent modifications from double-strand breaks to 
facilitate subsequent break repair. PLoS genetics 6, e1000828, 
doi:10.1371/journal.pgen.1000828 (2010). 
130 Parameswaran, B. et al. Damage-induced BRCA1 phosphorylation by 
Chk2 contributes to the timing of end resection. Cell cycle 14, 437-448, 
doi:10.4161/15384101.2014.972901 (2015). 
131 Reczek, C. R., Szabolcs, M., Stark, J. M., Ludwig, T. & Baer, R. The 
interaction between CtIP and BRCA1 is not essential for resection-
mediated DNA repair or tumor suppression. The Journal of cell biology 
201, 693-707, doi:10.1083/jcb.201302145 (2013). 
132 Zhou, Y., Caron, P., Legube, G. & Paull, T. T. Quantitation of DNA 
double-strand break resection intermediates in human cells. Nucleic 
acids research 42, e19, doi:10.1093/nar/gkt1309 (2014). 
133 Zhou, Y. & Paull, T. T. DNA-dependent protein kinase regulates DNA 
end resection in concert with Mre11-Rad50-Nbs1 (MRN) and ataxia 
telangiectasia-mutated (ATM). J Biol Chem 288, 37112-37125, 
doi:10.1074/jbc.M113.514398 (2013). 
           161
134 Wang, H. et al. The interaction of CtIP and Nbs1 connects CDK and 
ATM to regulate HR-mediated double-strand break repair. PLoS 
genetics 9, e1003277, doi:10.1371/journal.pgen.1003277 (2013). 
135 Germani, A. et al. SIAH-1 interacts with CtIP and promotes its 
degradation by the proteasome pathway. Oncogene 22, 8845-8851, 
doi:10.1038/sj.onc.1206994 (2003). 
136 Simsek, D. et al. DNA ligase III promotes alternative nonhomologous 
end-joining during chromosomal translocation formation. PLoS genetics 
7, e1002080, doi:10.1371/journal.pgen.1002080 (2011). 
137 Zhang, Y. & Jasin, M. An essential role for CtIP in chromosomal 
translocation formation through an alternative end-joining pathway. Nat 
Struct Mol Biol 18, 80-84, doi:10.1038/nsmb.1940 (2011). 
138 Tomimatsu, N. et al. Phosphorylation of EXO1 by CDKs 1 and 2 
regulates DNA end resection and repair pathway choice. Nature 
communications 5, 3561, doi:10.1038/ncomms4561 (2014). 
139 Nakamura, K. et al. Genetic dissection of vertebrate 53BP1: a major 
role in non-homologous end joining of DNA double strand breaks. DNA 
repair 5, 741-749, doi:10.1016/j.dnarep.2006.03.008 (2006). 
140 Xie, A. et al. Distinct roles of chromatin-associated proteins MDC1 and 
53BP1 in mammalian double-strand break repair. Mol Cell 28, 1045-
1057, doi:10.1016/j.molcel.2007.12.005 (2007). 
141 Bothmer, A. et al. 53BP1 regulates DNA resection and the choice 
between classical and alternative end joining during class switch 
recombination. J Exp Med 207, 855-865, doi:10.1084/jem.20100244 
(2010). 
142 Chapman, J. R., Sossick, A. J., Boulton, S. J. & Jackson, S. P. BRCA1-
associated exclusion of 53BP1 from DNA damage sites underlies 
temporal control of DNA repair. Journal of cell science 125, 3529-3534, 
doi:10.1242/jcs.105353 (2012). 
143 Chapman, J. R. et al. RIF1 is essential for 53BP1-dependent 
nonhomologous end joining and suppression of DNA double-strand 
break resection. Mol Cell 49, 858-871, 
doi:10.1016/j.molcel.2013.01.002 (2013). 
144 Di Virgilio, M. et al. Rif1 prevents resection of DNA breaks and 
promotes immunoglobulin class switching. Science 339, 711-715, 
doi:10.1126/science.1230624 (2013). 
           162
145 Zimmermann, M., Lottersberger, F., Buonomo, S. B., Sfeir, A. & de 
Lange, T. 53BP1 regulates DSB repair using Rif1 to control 5' end 
resection. Science 339, 700-704, doi:10.1126/science.1231573 (2013). 
146 Daley, J. M. & Sung, P. RIF1 in DNA break repair pathway choice. Mol 
Cell 49, 840-841, doi:10.1016/j.molcel.2013.02.019 (2013). 
147 Feng, L., Fong, K. W., Wang, J., Wang, W. & Chen, J. RIF1 counteracts 
BRCA1-mediated end resection during DNA repair. J Biol Chem 288, 
11135-11143, doi:10.1074/jbc.M113.457440 (2013). 
148 Callen, E. et al. 53BP1 mediates productive and mutagenic DNA repair 
through distinct phosphoprotein interactions. Cell 153, 1266-1280, 
doi:10.1016/j.cell.2013.05.023 (2013). 
149 Stavnezer, J., Guikema, J. E. & Schrader, C. E. Mechanism and 
regulation of class switch recombination. Annu Rev Immunol 26, 261-
292, doi:10.1146/annurev.immunol.26.021607.090248 (2008). 
150 Difilippantonio, S. et al. 53BP1 facilitates long-range DNA end-joining 
during V(D)J recombination. Nature 456, 529-533, 
doi:10.1038/nature07476 (2008). 
151 Dimitrova, N., Chen, Y. C., Spector, D. L. & de Lange, T. 53BP1 
promotes non-homologous end joining of telomeres by increasing 
chromatin mobility. Nature 456, 524-528, doi:10.1038/nature07433 
(2008). 
152 Cao, L. et al. A selective requirement for 53BP1 in the biological 
response to genomic instability induced by Brca1 deficiency. Mol Cell 
35, 534-541, doi:S1097-2765(09)00548-6 [pii] 
10.1016/j.molcel.2009.06.037 (2009). 
153 Bowman-Colin, C. et al. Palb2 synergizes with Trp53 to suppress 
mammary tumor formation in a model of inherited breast cancer. Proc 
Natl Acad Sci U S A 110, 8632-8637, doi:10.1073/pnas.1305362110 
(2013). 
154 Bunting, S. F. et al. BRCA1 functions independently of homologous 
recombination in DNA interstrand crosslink repair. Mol Cell 46, 125-135, 
doi:10.1016/j.molcel.2012.02.015 (2012). 
155 Sung, P. Function of yeast Rad52 protein as a mediator between 
replication protein A and the Rad51 recombinase. J Biol Chem 272, 
28194-28197 (1997). 
           163
156 New, J. H., Sugiyama, T., Zaitseva, E. & Kowalczykowski, S. C. Rad52 
protein stimulates DNA strand exchange by Rad51 and replication 
protein A. Nature 391, 407-410, doi:10.1038/34950 (1998). 
157 Jensen, R. B., Carreira, A. & Kowalczykowski, S. C. Purified human 
BRCA2 stimulates RAD51-mediated recombination. Nature 467, 678-
683, doi:10.1038/nature09399 (2010). 
158 Liu, J., Doty, T., Gibson, B. & Heyer, W. D. Human BRCA2 protein 
promotes RAD51 filament formation on RPA-covered single-stranded 
DNA. Nat Struct Mol Biol 17, 1260-1262, doi:10.1038/nsmb.1904 
(2010). 
159 Rijkers, T. et al. Targeted inactivation of mouse RAD52 reduces 
homologous recombination but not resistance to ionizing radiation. Mol 
Cell Biol 18, 6423-6429 (1998). 
160 Yamaguchi-Iwai, Y. et al. Homologous recombination, but not DNA 
repair, is reduced in vertebrate cells deficient in RAD52. Mol Cell Biol 
18, 6430-6435 (1998). 
161 Liu, J. & Heyer, W. D. Who's who in human recombination: BRCA2 and 
RAD52. Proc Natl Acad Sci U S A 108, 441-442, doi:1016614108 [pii] 
10.1073/pnas.1016614108 (2011). 
162 Feng, Z. et al. Rad52 inactivation is synthetically lethal with BRCA2 
deficiency. Proc Natl Acad Sci U S A 108, 686-691, 
doi:10.1073/pnas.1010959107 (2011). 
163 Cole, F., Keeney, S. & Jasin, M. Evolutionary conservation of meiotic 
DSB proteins: more than just Spo11. Genes & development 24, 1201-
1207, doi:10.1101/gad.1944710 (2010). 
164 LaRocque, J. R. et al. Interhomolog recombination and loss of 
heterozygosity in wild-type and Bloom syndrome helicase (BLM)-
deficient mammalian cells. Proc Natl Acad Sci U S A 108, 11971-11976, 
doi:10.1073/pnas.1104421108 (2011). 
165 Amunugama, R. & Fishel, R. Homologous recombination in eukaryotes. 
Prog Mol Biol Transl Sci 110, 155-206, doi:10.1016/B978-0-12-387665-
2.00007-9 (2012). 
166 Nassif, N., Penney, J., Pal, S., Engels, W. R. & Gloor, G. B. Efficient 
copying of nonhomologous sequences from ectopic sites via P-
element-induced gap repair. Mol Cell Biol 14, 1613-1625 (1994). 
           164
167 Ferguson, D. O. & Holloman, W. K. Recombinational repair of gaps in 
DNA is asymmetric in Ustilago maydis and can be explained by a 
migrating D-loop model. Proc Natl Acad Sci U S A 93, 5419-5424 
(1996). 
168 Paliwal, S., Kanagaraj, R., Sturzenegger, A., Burdova, K. & Janscak, P. 
Human RECQ5 helicase promotes repair of DNA double-strand breaks 
by synthesis-dependent strand annealing. Nucleic acids research 42, 
2380-2390, doi:10.1093/nar/gkt1263 (2014). 
169 Barber, L. J. et al. RTEL1 maintains genomic stability by suppressing 
homologous recombination. Cell 135, 261-271, 
doi:10.1016/j.cell.2008.08.016 (2008). 
170 Wu, L. & Hickson, I. D. The Bloom's syndrome helicase suppresses 
crossing over during homologous recombination. Nature 426, 870-874, 
doi:10.1038/nature02253 (2003). 
171 Ho, C. K., Mazon, G., Lam, A. F. & Symington, L. S. Mus81 and Yen1 
promote reciprocal exchange during mitotic recombination to maintain 
genome integrity in budding yeast. Mol Cell 40, 988-1000, 
doi:10.1016/j.molcel.2010.11.016 (2010). 
172 Wechsler, T., Newman, S. & West, S. C. Aberrant chromosome 
morphology in human cells defective for Holliday junction resolution. 
Nature 471, 642-646, doi:10.1038/nature09790 (2011). 
173 De Muyt, A. et al. BLM helicase ortholog Sgs1 is a central regulator of 
meiotic recombination intermediate metabolism. Mol Cell 46, 43-53, 
doi:10.1016/j.molcel.2012.02.020 (2012). 
174 Zakharyevich, K., Tang, S., Ma, Y. & Hunter, N. Delineation of joint 
molecule resolution pathways in meiosis identifies a crossover-specific 
resolvase. Cell 149, 334-347, doi:10.1016/j.cell.2012.03.023 (2012). 
175 Allers, T. & Lichten, M. Differential timing and control of noncrossover 
and crossover recombination during meiosis. Cell 106, 47-57 (2001). 
176 McIlwraith, M. J. & West, S. C. DNA repair synthesis facilitates RAD52-
mediated second-end capture during DSB repair. Mol Cell 29, 510-516, 
doi:10.1016/j.molcel.2007.11.037 (2008). 
177 Nimonkar, A. V., Sica, R. A. & Kowalczykowski, S. C. Rad52 promotes 
second-end DNA capture in double-stranded break repair to form 
complement-stabilized joint molecules. Proc Natl Acad Sci U S A 106, 
3077-3082, doi:10.1073/pnas.0813247106 (2009). 
           165
178 Shi, I. et al. Role of the Rad52 amino-terminal DNA binding activity in 
DNA strand capture in homologous recombination. J Biol Chem 284, 
33275-33284, doi:10.1074/jbc.M109.057752 (2009). 
179 Sugiyama, T. & Kantake, N. Dynamic regulatory interactions of rad51, 
rad52, and replication protein-a in recombination intermediates. Journal 
of molecular biology 390, 45-55, doi:10.1016/j.jmb.2009.05.009 (2009). 
180 Wu, Y., Kantake, N., Sugiyama, T. & Kowalczykowski, S. C. Rad51 
protein controls Rad52-mediated DNA annealing. J Biol Chem 283, 
14883-14892, doi:10.1074/jbc.M801097200 (2008). 
181 Mazloum, N. & Holloman, W. K. Second-end capture in DNA double-
strand break repair promoted by Brh2 protein of Ustilago maydis. Mol 
Cell 33, 160-170, doi:10.1016/j.molcel.2008.12.023 (2009). 
182 Hu, Y. et al. RECQL5/Recql5 helicase regulates homologous 
recombination and suppresses tumor formation via disruption of Rad51 
presynaptic filaments. Genes & development 21, 3073-3084, 
doi:10.1101/gad.1609107 (2007). 
183 George, C. M. & Alani, E. Multiple cellular mechanisms prevent 
chromosomal rearrangements involving repetitive DNA. Crit Rev 
Biochem Mol Biol 47, 297-313, doi:10.3109/10409238.2012.675644 
(2012). 
184 Harfe, B. D. & Jinks-Robertson, S. DNA mismatch repair and genetic 
instability. Annual review of genetics 34, 359-399, 
doi:10.1146/annurev.genet.34.1.359 (2000). 
185 Saydam, N. et al. Physical and functional interactions between Werner 
syndrome helicase and mismatch-repair initiation factors. Nucleic acids 
research 35, 5706-5716, doi:10.1093/nar/gkm500 (2007). 
186 Larocque, J. R. & Jasin, M. Mechanisms of recombination between 
diverged sequences in wild-type and BLM-deficient mouse and human 
cells. Mol Cell Biol 30, 1887-1897, doi:10.1128/MCB.01553-09 (2010). 
187 Broderick, S., Rehmet, K., Concannon, C. & Nasheuer, H. P. Eukaryotic 
single-stranded DNA binding proteins: central factors in genome 
stability. Sub-cellular biochemistry 50, 143-163, doi:10.1007/978-90-
481-3471-7_8 (2010). 
188 Fanning, E., Klimovich, V. & Nager, A. R. A dynamic model for 
replication protein A (RPA) function in DNA processing pathways. 
Nucleic acids research 34, 4126-4137, doi:10.1093/nar/gkl550 (2006). 
           166
189 Oakley, G. G. & Patrick, S. M. Replication protein A: directing traffic at 
the intersection of replication and repair. Frontiers in bioscience 15, 
883-900 (2010). 
190 Wold, M. S. Replication protein A: a heterotrimeric, single-stranded 
DNA-binding protein required for eukaryotic DNA metabolism. Annual 
review of biochemistry 66, 61-92, doi:10.1146/annurev.biochem.66.1.61 
(1997). 
191 Zou, Y., Liu, Y., Wu, X. & Shell, S. M. Functions of Human Replication 
Protein A (RPA): From DNA Replication to DNA Damage and Stress 
Responses. Journal of cellular physiology 208, 267-273, 
doi:10.1002/jcp.20622 (2006). 
192 Wold, M. S. & Kelly, T. Purification and characterization of replication 
protein A, a cellular protein required for in vitro replication of simian 
virus 40 DNA. Proc Natl Acad Sci U S A 85, 2523-2527 (1988). 
193 Kenny, M. K., Schlegel, U., Furneaux, H. & Hurwitz, J. The role of 
human single-stranded DNA binding protein and its individual subunits 
in simian virus 40 DNA replication. J Biol Chem 265, 7693-7700 (1990). 
194 Seroussi, E. & Lavi, S. Replication protein A is the major single-
stranded DNA binding protein detected in mammalian cell extracts by 
gel retardation assays and UV cross-linking of long and short single-
stranded DNA molecules. J Biol Chem 268, 7147-7154 (1993). 
195 Din, S., Brill, S. J., Fairman, M. P. & Stillman, B. Cell-cycle-regulated 
phosphorylation of DNA replication factor A from human and yeast cells. 
Genes & development 4, 968-977 (1990). 
196 Bochkarev, A. & Bochkareva, E. From RPA to BRCA2: lessons from 
single-stranded DNA binding by the OB-fold. Current opinion in 
structural biology 14, 36-42, doi:10.1016/j.sbi.2004.01.001 (2004). 
197 Gomes, X. V., Henricksen, L. A. & Wold, M. S. Proteolytic mapping of 
human replication protein A: evidence for multiple structural domains 
and a conformational change upon interaction with single-stranded 
DNA. Biochemistry 35, 5586-5595, doi:10.1021/bi9526995 (1996). 
198 Brosey, C. A. et al. NMR analysis of the architecture and functional 
remodeling of a modular multidomain protein, RPA. Journal of the 
American Chemical Society 131, 6346-6347, doi:10.1021/ja9013634 
(2009). 
           167
199 Henricksen, L. A., Umbricht, C. B. & Wold, M. S. Recombinant 
replication protein A: expression, complex formation, and functional 
characterization. J Biol Chem 269, 11121-11132 (1994). 
200 Bochkarev, A., Bochkareva, E., Frappier, L. & Edwards, A. M. The 
crystal structure of the complex of replication protein A subunits RPA32 
and RPA14 reveals a mechanism for single-stranded DNA binding. The 
EMBO journal 18, 4498-4504, doi:10.1093/emboj/18.16.4498 (1999). 
201 Bochkareva, E., Korolev, S. & Bochkarev, A. The role for zinc in 
replication protein A. J Biol Chem 275, 27332-27338, 
doi:10.1074/jbc.M000620200 (2000). 
202 Daughdrill, G. W. et al. The weak interdomain coupling observed in the 
70 kDa subunit of human replication protein A is unaffected by ssDNA 
binding. Nucleic acids research 29, 3270-3276 (2001). 
203 Anantha, R. W. & Borowiec, J. A. Mitotic crisis: the unmasking of a 
novel role for RPA. Cell cycle 8, 357-361 (2009). 
204 Anantha, R. W., Vassin, V. M. & Borowiec, J. A. Sequential and 
synergistic modification of human RPA stimulates chromosomal DNA 
repair. J Biol Chem 282, 35910-35923, doi:10.1074/jbc.M704645200 
(2007). 
205 Ashley, A. K. et al. DNA-PK phosphorylation of RPA32 Ser4/Ser8 
regulates replication stress checkpoint activation, fork restart, 
homologous recombination and mitotic catastrophe. DNA repair 21, 
131-139, doi:10.1016/j.dnarep.2014.04.008 (2014). 
206 Binz, S. K., Lao, Y., Lowry, D. F. & Wold, M. S. The phosphorylation 
domain of the 32-kDa subunit of replication protein A (RPA) modulates 
RPA-DNA interactions. Evidence for an intersubunit interaction. J Biol 
Chem 278, 35584-35591, doi:10.1074/jbc.M305388200 (2003). 
207 Binz, S. K., Sheehan, A. M. & Wold, M. S. Replication protein A 
phosphorylation and the cellular response to DNA damage. DNA repair 
3, 1015-1024, doi:10.1016/j.dnarep.2004.03.028 (2004). 
208 Blackwell, L. J., Borowiec, J. A. & Mastrangelo, I. A. Single-stranded-
DNA binding alters human replication protein A structure and facilitates 
interaction with DNA-dependent protein kinase. Mol Cell Biol 16, 4798-
4807 (1996). 
209 Block, W. D., Yu, Y. & Lees-Miller, S. P. Phosphatidyl inositol 3-kinase-
like serine/threonine protein kinases (PIKKs) are required for DNA 
damage-induced phosphorylation of the 32 kDa subunit of replication 
           168
protein A at threonine 21. Nucleic acids research 32, 997-1005, 
doi:10.1093/nar/gkh265 (2004). 
210 Bochkareva, E. et al. Single-stranded DNA mimicry in the p53 
transactivation domain interaction with replication protein A. Proc Natl 
Acad Sci U S A 102, 15412-15417, doi:10.1073/pnas.0504614102 
(2005). 
211 Borgstahl, G. E. et al. Interplay of DNA damage and cell cycle signaling 
at the level of human replication protein A. DNA repair 21, 12-23, 
doi:10.1016/j.dnarep.2014.05.005 (2014). 
212 Brush, G. S. & Kelly, T. J. Phosphorylation of the replication protein A 
large subunit in the Saccharomyces cerevisiae checkpoint response. 
Nucleic acids research 28, 3725-3732 (2000). 
213 Carty, M. P., Zernik-Kobak, M., McGrath, S. & Dixon, K. UV light-
induced DNA synthesis arrest in HeLa cells is associated with changes 
in phosphorylation of human single-stranded DNA-binding protein. The 
EMBO journal 13, 2114-2123 (1994). 
214 Chen, S. H., Albuquerque, C. P., Liang, J., Suhandynata, R. T. & Zhou, 
H. A proteome-wide analysis of kinase-substrate network in the DNA 
damage response. J Biol Chem 285, 12803-12812, 
doi:10.1074/jbc.M110.106989 (2010). 
215 Cheng, X., Cheong, N., Wang, Y. & Iliakis, G. Ionizing radiation-induced 
phosphorylation of RPA p34 is deficient in ataxia telangiectasia and 
reduced in aged normal fibroblasts. Radiotherapy and oncology : 
journal of the European Society for Therapeutic Radiology and 
Oncology 39, 43-52 (1996). 
216 Deng, X. et al. Human replication protein A-Rad52-single-stranded DNA 
complex: stoichiometry and evidence for strand transfer regulation by 
phosphorylation. Biochemistry 48, 6633-6643, doi:10.1021/bi900564k 
(2009). 
217 Dephoure, N. et al. A quantitative atlas of mitotic phosphorylation. Proc 
Natl Acad Sci U S A 105, 10762-10767, doi:10.1073/pnas.0805139105 
(2008). 
218 Dutta, A., Din, S., Brill, S. J. & Stillman, B. Phosphorylation of 
replication protein A: a role for cdc2 kinase in G1/S regulation. Cold 
Spring Harbor symposia on quantitative biology 56, 315-324 (1991). 
           169
219 Dutta, A. & Stillman, B. cdc2 family kinases phosphorylate a human cell 
DNA replication factor, RPA, and activate DNA replication. The EMBO 
journal 11, 2189-2199 (1992). 
220 Fang, F. & Newport, J. W. Distinct roles of cdk2 and cdc2 in RP-A 
phosphorylation during the cell cycle. Journal of cell science 106 ( Pt 3), 
983-994 (1993). 
221 Fotedar, R. & Roberts, J. M. Cell cycle regulated phosphorylation of 
RPA-32 occurs within the replication initiation complex. The EMBO 
journal 11, 2177-2187 (1992). 
222 Francon, P. et al. A hypophosphorylated form of RPA34 is a specific 
component of pre-replication centers. Journal of cell science 117, 4909-
4920, doi:10.1242/jcs.01361 (2004). 
223 Fried, L. M. et al. The DNA damage response in DNA-dependent 
protein kinase-deficient SCID mouse cells: replication protein A 
hyperphosphorylation and p53 induction. Proc Natl Acad Sci U S A 93, 
13825-13830 (1996). 
224 Ghospurkar, P. L. et al. Phosphorylation and cellular function of the 
human Rpa2 N-terminus in the budding yeast Saccharomyces 
cerevisiae. Experimental cell research 331, 183-199, 
doi:10.1016/j.yexcr.2014.12.002 (2015). 
225 Gnad, F., Gunawardena, J. & Mann, M. PHOSIDA 2011: the 
posttranslational modification database. Nucleic acids research 39, 
D253-260, doi:10.1093/nar/gkq1159 (2011). 
226 Guo, S. et al. Regulation of replication protein A functions in DNA 
mismatch repair by phosphorylation. J Biol Chem 281, 21607-21616, 
doi:10.1074/jbc.M603504200 (2006). 
227 Hass, C. S., Chen, R. & Wold, M. S. Detection of posttranslational 
modifications of replication protein A. Methods in molecular biology 922, 
193-204, doi:10.1007/978-1-62703-032-8_15 (2012). 
228 Hornbeck, P. V. et al. PhosphoSitePlus: a comprehensive resource for 
investigating the structure and function of experimentally determined 
post-translational modifications in man and mouse. Nucleic acids 
research 40, D261-270, doi:10.1093/nar/gkr1122 (2012). 
229 Jacobs, D. M. et al. Human replication protein A: global fold of the N-
terminal RPA-70 domain reveals a basic cleft and flexible C-terminal 
linker. J Biomol NMR 14, 321-331 (1999). 
           170
230 Lee, D. H. et al. A PP4 phosphatase complex dephosphorylates RPA2 
to facilitate DNA repair via homologous recombination. Nat Struct Mol 
Biol 17, 365-372, doi:10.1038/nsmb.1769 (2010). 
231 Liaw, H., Lee, D. & Myung, K. DNA-PK-dependent RPA2 
hyperphosphorylation facilitates DNA repair and suppresses sister 
chromatid exchange. PloS one 6, e21424, 
doi:10.1371/journal.pone.0021424 (2011). 
232 Liu, J. et al. Protein phosphatase PP4 is involved in NHEJ-mediated 
repair of DNA double-strand breaks. Cell cycle 11, 2643-2649, 
doi:10.4161/cc.20957 (2012). 
233 Liu, S. et al. Distinct roles for DNA-PK, ATM and ATR in RPA 
phosphorylation and checkpoint activation in response to replication 
stress. Nucleic acids research 40, 10780-10794, 
doi:10.1093/nar/gks849 (2012). 
234 Liu, V. F. & Weaver, D. T. The ionizing radiation-induced replication 
protein A phosphorylation response differs between ataxia 
telangiectasia and normal human cells. Mol Cell Biol 13, 7222-7231 
(1993). 
235 Liu, Y., Kvaratskhelia, M., Hess, S., Qu, Y. & Zou, Y. Modulation of 
replication protein A function by its hyperphosphorylation-induced 
conformational change involving DNA binding domain B. J Biol Chem 
280, 32775-32783, doi:10.1074/jbc.M505705200 (2005). 
236 Murphy, A. K. et al. Phosphorylated RPA recruits PALB2 to stalled DNA 
replication forks to facilitate fork recovery. The Journal of cell biology 
206, 493-507, doi:10.1083/jcb.201404111 (2014). 
237 Niu, H. et al. Mapping of amino acid residues in the p34 subunit of 
human single-stranded DNA-binding protein phosphorylated by DNA-
dependent protein kinase and Cdc2 kinase in vitro. J Biol Chem 272, 
12634-12641 (1997). 
238 Nuss, J. E. et al. DNA damage induced hyperphosphorylation of 
replication protein A. 1. Identification of novel sites of phosphorylation in 
response to DNA damage. Biochemistry 44, 8428-8437, 
doi:10.1021/bi0480584 (2005). 
239 Oakley, G. G. et al. UV-induced hyperphosphorylation of replication 
protein a depends on DNA replication and expression of ATM protein. 
Molecular biology of the cell 12, 1199-1213 (2001). 
           171
240 Oakley, G. G. et al. RPA phosphorylation in mitosis alters DNA binding 
and protein-protein interactions. Biochemistry 42, 3255-3264, 
doi:10.1021/bi026377u (2003). 
241 Olson, E., Nievera, C. J., Klimovich, V., Fanning, E. & Wu, X. RPA2 is a 
direct downstream target for ATR to regulate the S-phase checkpoint. J 
Biol Chem 281, 39517-39533, doi:10.1074/jbc.M605121200 (2006). 
242 Pan, Z. Q., Amin, A. A., Gibbs, E., Niu, H. & Hurwitz, J. Phosphorylation 
of the p34 subunit of human single-stranded-DNA-binding protein in 
cyclin A-activated G1 extracts is catalyzed by cdk-cyclin A complex and 
DNA-dependent protein kinase. Proc Natl Acad Sci U S A 91, 8343-
8347 (1994). 
243 Pan, Z. Q., Park, C. H., Amin, A. A., Hurwitz, J. & Sancar, A. 
Phosphorylated and unphosphorylated forms of human single-stranded 
DNA-binding protein are equally active in simian virus 40 DNA 
replication and in nucleotide excision repair. Proc Natl Acad Sci U S A 
92, 4636-4640 (1995). 
244 Patrick, S. M., Oakley, G. G., Dixon, K. & Turchi, J. J. DNA damage 
induced hyperphosphorylation of replication protein A. 2. 
Characterization of DNA binding activity, protein interactions, and 
activity in DNA replication and repair. Biochemistry 44, 8438-8448, 
doi:10.1021/bi048057b (2005). 
245 Robison, J. G., Elliott, J., Dixon, K. & Oakley, G. G. Replication protein 
A and the Mre11.Rad50.Nbs1 complex co-localize and interact at sites 
of stalled replication forks. J Biol Chem 279, 34802-34810, 
doi:10.1074/jbc.M404750200 (2004). 
246 Rodrigo, G., Roumagnac, S., Wold, M. S., Salles, B. & Calsou, P. DNA 
replication but not nucleotide excision repair is required for UVC-
induced replication protein A phosphorylation in mammalian cells. Mol 
Cell Biol 20, 2696-2705 (2000). 
247 Sakasai, R. et al. Differential involvement of phosphatidylinositol 3-
kinase-related protein kinases in hyperphosphorylation of replication 
protein A2 in response to replication-mediated DNA double-strand 
breaks. Genes to cells : devoted to molecular & cellular mechanisms 11, 
237-246, doi:10.1111/j.1365-2443.2006.00942.x (2006). 
248 Shao, R. G. et al. Replication-mediated DNA damage by camptothecin 
induces phosphorylation of RPA by DNA-dependent protein kinase and 
dissociates RPA:DNA-PK complexes. The EMBO journal 18, 1397-
1406, doi:10.1093/emboj/18.5.1397 (1999). 
           172
249 Shi, W. et al. The role of RPA2 phosphorylation in homologous 
recombination in response to replication arrest. Carcinogenesis 31, 
994-1002, doi:10.1093/carcin/bgq035 (2010). 
250 Stephan, H., Concannon, C., Kremmer, E., Carty, M. P. & Nasheuer, H. 
P. Ionizing radiation-dependent and independent phosphorylation of the 
32-kDa subunit of replication protein A during mitosis. Nucleic acids 
research 37, 6028-6041, doi:10.1093/nar/gkp605 (2009). 
251 Unsal-Kacmaz, K. & Sancar, A. Quaternary structure of ATR and 
effects of ATRIP and replication protein A on its DNA binding and 
kinase activities. Mol Cell Biol 24, 1292-1300 (2004). 
252 Vassin, V. M., Anantha, R. W., Sokolova, E., Kanner, S. & Borowiec, J. 
A. Human RPA phosphorylation by ATR stimulates DNA synthesis and 
prevents ssDNA accumulation during DNA-replication stress. Journal of 
cell science 122, 4070-4080, doi:10.1242/jcs.053702 (2009). 
253 Vassin, V. M., Wold, M. S. & Borowiec, J. A. Replication protein A 
(RPA) phosphorylation prevents RPA association with replication 
centers. Mol Cell Biol 24, 1930-1943 (2004). 
254 Wang, H. et al. Replication protein A2 phosphorylation after DNA 
damage by the coordinated action of ataxia telangiectasia-mutated and 
DNA-dependent protein kinase. Cancer research 61, 8554-8563 (2001). 
255 Wu, X., Yang, Z., Liu, Y. & Zou, Y. Preferential localization of 
hyperphosphorylated replication protein A to double-strand break repair 
and checkpoint complexes upon DNA damage. The Biochemical journal 
391, 473-480, doi:10.1042/BJ20050379 (2005). 
256 Zernik-Kobak, M., Vasunia, K., Connelly, M., Anderson, C. W. & Dixon, 
K. Sites of UV-induced phosphorylation of the p34 subunit of replication 
protein A from HeLa cells. J Biol Chem 272, 23896-23904 (1997). 
257 Anantha, R. W., Sokolova, E. & Borowiec, J. A. RPA phosphorylation 
facilitates mitotic exit in response to mitotic DNA damage. Proc Natl 
Acad Sci U S A 105, 12903-12908, doi:10.1073/pnas.0803001105 
(2008). 
258 Brush, G. S., Anderson, C. W. & Kelly, T. J. The DNA-activated protein 
kinase is required for the phosphorylation of replication protein A during 
simian virus 40 DNA replication. Proc Natl Acad Sci U S A 91, 12520-
12524 (1994). 
           173
259 Henricksen, L. A. & Wold, M. S. Replication protein A mutants lacking 
phosphorylation sites for p34cdc2 kinase support DNA replication. J 
Biol Chem 269, 24203-24208 (1994). 
260 Brush, G. S., Morrow, D. M., Hieter, P. & Kelly, T. J. The ATM 
homologue MEC1 is required for phosphorylation of replication protein 
A in yeast. Proc Natl Acad Sci U S A 93, 15075-15080 (1996). 
261 Morgan, S. E. & Kastan, M. B. Dissociation of radiation-induced 
phosphorylation of replication protein A from the S-phase checkpoint. 
Cancer research 57, 3386-3389 (1997). 
262 Barr, S. M., Leung, C. G., Chang, E. E. & Cimprich, K. A. ATR kinase 
activity regulates the intranuclear translocation of ATR and RPA 
following ionizing radiation. Current biology : CB 13, 1047-1051 (2003). 
263 Kim, H. S. & Brill, S. J. MEC1-dependent phosphorylation of yeast 
RPA1 in vitro. DNA repair 2, 1321-1335 (2003). 
264 Manthey, K. C. et al. NBS1 mediates ATR-dependent RPA 
hyperphosphorylation following replication-fork stall and collapse. 
Journal of cell science 120, 4221-4229, doi:10.1242/jcs.004580 (2007). 
265 Binz, S. K. & Wold, M. S. Regulatory functions of the N-terminal domain 
of the 70-kDa subunit of replication protein A (RPA). J Biol Chem 283, 
21559-21570, doi:10.1074/jbc.M802450200 (2008). 
266 Cruet-Hennequart, S., Glynn, M. T., Murillo, L. S., Coyne, S. & Carty, M. 
P. Enhanced DNA-PK-mediated RPA2 hyperphosphorylation in DNA 
polymerase eta-deficient human cells treated with cisplatin and 
oxaliplatin. DNA repair 7, 582-596, doi:10.1016/j.dnarep.2007.12.012 
(2008). 
267 Oakley, G. G. et al. Physical interaction between replication protein A 
(RPA) and MRN: involvement of RPA2 phosphorylation and the N-
terminus of RPA1. Biochemistry 48, 7473-7481, doi:10.1021/bi900694p 
(2009). 
268 Serrano, M. A. et al. DNA-PK, ATM and ATR collaboratively regulate 
p53-RPA interaction to facilitate homologous recombination DNA repair. 
Oncogene 32, 2452-2462, doi:10.1038/onc.2012.257 (2013). 
269 Bochkareva, E., Korolev, S., Lees-Miller, S. P. & Bochkarev, A. 
Structure of the RPA trimerization core and its role in the multistep 
DNA-binding mechanism of RPA. The EMBO journal 21, 1855-1863, 
doi:10.1093/emboj/21.7.1855 (2002). 
           174
270 Philipova, D. et al. A hierarchy of SSB protomers in replication protein A. 
Genes & development 10, 2222-2233 (1996). 
271 Chen, R. & Wold, M. S. Replication protein A: single-stranded DNA's 
first responder: dynamic DNA-interactions allow replication protein A to 
direct single-strand DNA intermediates into different pathways for 
synthesis or repair. BioEssays : news and reviews in molecular, cellular 
and developmental biology 36, 1156-1161, 
doi:10.1002/bies.201400107 (2014). 
272 de Laat, W. L. et al. DNA-binding polarity of human replication protein A 
positions nucleases in nucleotide excision repair. Genes & development 
12, 2598-2609 (1998). 
273 Iftode, C. & Borowiec, J. A. 5' --> 3' molecular polarity of human 
replication protein A (hRPA) binding to pseudo-origin DNA substrates. 
Biochemistry 39, 11970-11981 (2000). 
274 Kolpashchikov, D. M. et al. Polarity of human replication protein A 
binding to DNA. Nucleic acids research 29, 373-379 (2001). 
275 Kim, C., Paulus, B. F. & Wold, M. S. Interactions of human replication 
protein A with oligonucleotides. Biochemistry 33, 14197-14206 (1994). 
276 Kim, C., Snyder, R. O. & Wold, M. S. Binding properties of replication 
protein A from human and yeast cells. Mol Cell Biol 12, 3050-3059 
(1992). 
277 Patrick, S. M. & Turchi, J. J. Stopped-flow kinetic analysis of replication 
protein A-binding DNA: damage recognition and affinity for single-
stranded DNA reveal differential contributions of k(on) and k(off) rate 
constants. J Biol Chem 276, 22630-22637, 
doi:10.1074/jbc.M010314200 (2001). 
278 Bochkarev, A., Pfuetzner, R. A., Edwards, A. M. & Frappier, L. 
Structure of the single-stranded-DNA-binding domain of replication 
protein A bound to DNA. Nature 385, 176-181, doi:10.1038/385176a0 
(1997). 
279 Kumaran, S., Kozlov, A. G. & Lohman, T. M. Saccharomyces cerevisiae 
replication protein A binds to single-stranded DNA in multiple salt-
dependent modes. Biochemistry 45, 11958-11973, 
doi:10.1021/bi060994r (2006). 
280 Nguyen, B. et al. Diffusion of human replication protein A along single-
stranded DNA. Journal of molecular biology 426, 3246-3261, 
doi:10.1016/j.jmb.2014.07.014 (2014). 
           175
281 Gibb, B. et al. Concentration-dependent exchange of replication protein 
A on single-stranded DNA revealed by single-molecule imaging. PloS 
one 9, e87922, doi:10.1371/journal.pone.0087922 (2014). 
282 Lao, Y., Lee, C. G. & Wold, M. S. Replication protein A interactions with 
DNA. 2. Characterization of double-stranded DNA-binding/helix-
destabilization activities and the role of the zinc-finger domain in DNA 
interactions. Biochemistry 38, 3974-3984, doi:10.1021/bi982371m 
(1999). 
283 Patrick, S. M. & Turchi, J. J. Replication protein A (RPA) binding to 
duplex cisplatin-damaged DNA is mediated through the generation of 
single-stranded DNA. J Biol Chem 274, 14972-14978 (1999). 
284 Treuner, K., Ramsperger, U. & Knippers, R. Replication protein A 
induces the unwinding of long double-stranded DNA regions. Journal of 
molecular biology 259, 104-112, doi:10.1006/jmbi.1996.0305 (1996). 
285 Burns, J. L., Guzder, S. N., Sung, P., Prakash, S. & Prakash, L. An 
affinity of human replication protein A for ultraviolet-damaged DNA. J 
Biol Chem 271, 11607-11610 (1996). 
286 Buschta-Hedayat, N., Buterin, T., Hess, M. T., Missura, M. & Naegeli, H. 
Recognition of nonhybridizing base pairs during nucleotide excision 
repair of DNA. Proc Natl Acad Sci U S A 96, 6090-6095 (1999). 
287 Clugston, C. K., McLaughlin, K., Kenny, M. K. & Brown, R. Binding of 
human single-stranded DNA binding protein to DNA damaged by the 
anticancer drug cis-diamminedichloroplatinum (II). Cancer research 52, 
6375-6379 (1992). 
288 Missura, M. et al. Double-check probing of DNA bending and unwinding 
by XPA-RPA: an architectural function in DNA repair. The EMBO 
journal 20, 3554-3564, doi:10.1093/emboj/20.13.3554 (2001). 
289 Patrick, S. M. & Turchi, J. J. Human replication protein A preferentially 
binds cisplatin-damaged duplex DNA in vitro. Biochemistry 37, 8808-
8815, doi:10.1021/bi9730590 (1998). 
290 Liu, Y. et al. Interactions of human replication protein A with single-
stranded DNA adducts. The Biochemical journal 385, 519-526, 
doi:10.1042/bj20041151 (2005). 
291 Allen, C., Ashley, A. K., Hromas, R. & Nickoloff, J. A. More forks on the 
road to replication stress recovery. J Mol Cell Biol 3, 4-12, 
doi:10.1093/jmcb/mjq049 (2011). 
           176
292 Jackson, D., Dhar, K., Wahl, J. K., Wold, M. S. & Borgstahl, G. E. 
Analysis of the human replication protein A:Rad52 complex: evidence 
for crosstalk between RPA32, RPA70, Rad52 and DNA. Journal of 
molecular biology 321, 133-148 (2002). 
293 Davis, A. P. & Symington, L. S. The Rad52-Rad59 complex interacts 
with Rad51 and replication protein A. DNA repair 2, 1127-1134 (2003). 
294 Mer, G. et al. Structural basis for the recognition of DNA repair proteins 
UNG2, XPA, and RAD52 by replication factor RPA. Cell 103, 449-456 
(2000). 
295 Grimme, J. M. et al. Human Rad52 binds and wraps single-stranded 
DNA and mediates annealing via two hRad52-ssDNA complexes. 
Nucleic acids research 38, 2917-2930, doi:10.1093/nar/gkp1249 (2010). 
296 Ciccia, A. et al. The SIOD disorder protein SMARCAL1 is an RPA-
interacting protein involved in replication fork restart. Genes & 
development 23, 2415-2425, doi:10.1101/gad.1832309 (2009). 
297 Plate, I. et al. Interaction with RPA is necessary for Rad52 repair center 
formation and for its mediator activity. J Biol Chem 283, 29077-29085, 
doi:10.1074/jbc.M804881200 (2008). 
298 Park, M. S., Ludwig, D. L., Stigger, E. & Lee, S. H. Physical interaction 
between human RAD52 and RPA is required for homologous 
recombination in mammalian cells. J Biol Chem 271, 18996-19000 
(1996). 
299 Keshav, K. F., Chen, C. & Dutta, A. Rpa4, a homolog of the 34-
kilodalton subunit of the replication protein A complex. Mol Cell Biol 15, 
3119-3128 (1995). 
300 Mason, A. C., Roy, R., Simmons, D. T. & Wold, M. S. Functions of 
alternative replication protein A in initiation and elongation. 
Biochemistry 49, 5919-5928, doi:10.1021/bi100380n (2010). 
301 Haring, S. J., Humphreys, T. D. & Wold, M. S. A naturally occurring 
human RPA subunit homolog does not support DNA replication or cell-
cycle progression. Nucleic acids research 38, 846-858, 
doi:10.1093/nar/gkp1062 (2010). 
302 Kemp, M. G. et al. An alternative form of replication protein a expressed 
in normal human tissues supports DNA repair. J Biol Chem 285, 4788-
4797, doi:10.1074/jbc.M109.079418 (2010). 
           177
303 Mason, A. C. et al. An alternative form of replication protein a prevents 
viral replication in vitro. J Biol Chem 284, 5324-5331, 
doi:10.1074/jbc.M808963200 (2009). 
304 Haring, S. J., Mason, A. C., Binz, S. K. & Wold, M. S. Cellular functions 
of human RPA1. Multiple roles of domains in replication, repair, and 
checkpoints. J Biol Chem 283, 19095-19111, 
doi:10.1074/jbc.M800881200 (2008). 
305 Bolderson, E. et al. Human single-stranded DNA binding protein 1 
(hSSB1/NABP2) is required for the stability and repair of stalled 
replication forks. Nucleic acids research 42, 6326-6336, 
doi:10.1093/nar/gku276 (2014). 
306 Huang, J., Gong, Z., Ghosal, G. & Chen, J. SOSS complexes 
participate in the maintenance of genomic stability. Mol Cell 35, 384-
393, doi:10.1016/j.molcel.2009.06.011 (2009). 
307 Kar, A. et al. RPA70 depletion induces hSSB1/2-INTS3 complex to 
initiate ATR signaling. Nucleic acids research 43, 4962-4974, 
doi:10.1093/nar/gkv369 (2015). 
308 Li, Y. et al. HSSB1 and hSSB2 form similar multiprotein complexes that 
participate in DNA damage response. J Biol Chem 284, 23525-23531, 
doi:10.1074/jbc.C109.039586 (2009). 
309 Richard, D. J. et al. hSSB1 interacts directly with the MRN complex 
stimulating its recruitment to DNA double-strand breaks and its endo-
nuclease activity. Nucleic acids research 39, 3643-3651, 
doi:10.1093/nar/gkq1340 (2011). 
310 Richard, D. J. et al. hSSB1 rapidly binds at the sites of DNA double-
strand breaks and is required for the efficient recruitment of the MRN 
complex. Nucleic acids research 39, 1692-1702, 
doi:10.1093/nar/gkq1098 (2011). 
311 Skaar, J. R. et al. INTS3 controls the hSSB1-mediated DNA damage 
response. The Journal of cell biology 187, 25-32, 
doi:10.1083/jcb.200907026 (2009). 
312 Zhang, F., Wu, J. & Yu, X. Integrator3, a partner of single-stranded 
DNA-binding protein 1, participates in the DNA damage response. J 
Biol Chem 284, 30408-30415, doi:10.1074/jbc.M109.039404 (2009). 
313 Richard, D. J. et al. Single-stranded DNA-binding protein hSSB1 is 
critical for genomic stability. Nature 453, 677-681, 
doi:10.1038/nature06883 (2008). 
           178
314 Xu, S. et al. hSSB1 binds and protects p21 from ubiquitin-mediated 
degradation and positively correlates with p21 in human hepatocellular 
carcinomas. Oncogene 30, 2219-2229, doi:10.1038/onc.2010.596 
(2011). 
315 Feldhahn, N. et al. The hSSB1 orthologue Obfc2b is essential for 
skeletogenesis but dispensable for the DNA damage response in vivo. 
The EMBO journal 31, 4045-4056, doi:10.1038/emboj.2012.247 (2012). 
316 Gu, P., Deng, W., Lei, M. & Chang, S. Single strand DNA binding 
proteins 1 and 2 protect newly replicated telomeres. Cell research 23, 
705-719, doi:10.1038/cr.2013.31 (2013). 
317 Xu, S. et al. hSSB1 regulates both the stability and the transcriptional 
activity of p53. Cell research 23, 423-435, doi:10.1038/cr.2012.162 
(2013). 
318 Yang, S. H. et al. The SOSS1 single-stranded DNA binding complex 
promotes DNA end resection in concert with Exo1. The EMBO journal 
32, 126-139, doi:10.1038/emboj.2012.314 (2013). 
319 Zhang, F., Ma, T. & Yu, X. A core hSSB1-INTS complex participates in 
the DNA damage response. Journal of cell science 126, 4850-4855, 
doi:10.1242/jcs.132514 (2013). 
320 Chen, Z. W. et al. FBXL5-mediated degradation of single-stranded 
DNA-binding protein hSSB1 controls DNA damage response. Nucleic 
acids research 42, 11560-11569, doi:10.1093/nar/gku876 (2014). 
321 Wu, Y. et al. Acetylation-dependent function of human single-stranded 
DNA binding protein 1. Nucleic acids research 43, 7878-7887, 
doi:10.1093/nar/gkv707 (2015). 
322 Wu, X., Shell, S. M. & Zou, Y. Interaction and colocalization of 
Rad9/Rad1/Hus1 checkpoint complex with replication protein A in 
human cells. Oncogene 24, 4728-4735, doi:10.1038/sj.onc.1208674 
(2005). 
323 Janssens, V., Goris, J. & Van Hoof, C. PP2A: the expected tumor 
suppressor. Current opinion in genetics & development 15, 34-41, 
doi:10.1016/j.gde.2004.12.004 (2005). 
324 Janssens, V., Longin, S. & Goris, J. PP2A holoenzyme assembly: in 
cauda venenum (the sting is in the tail). Trends in biochemical sciences 
33, 113-121, doi:10.1016/j.tibs.2007.12.004 (2008). 
           179
325 Virshup, D. M. & Shenolikar, S. From promiscuity to precision: protein 
phosphatases get a makeover. Mol Cell 33, 537-545, 
doi:10.1016/j.molcel.2009.02.015 (2009). 
326 Chowdhury, D. et al. A PP4-phosphatase complex dephosphorylates 
gamma-H2AX generated during DNA replication. Mol Cell 31, 33-46, 
doi:10.1016/j.molcel.2008.05.016 (2008). 
327 Lee, D. H. et al. Phosphoproteomic analysis reveals that PP4 
dephosphorylates KAP-1 impacting the DNA damage response. The 
EMBO journal 31, 2403-2415, doi:10.1038/emboj.2012.86 (2012). 
328 Nakada, S., Chen, G. I., Gingras, A. C. & Durocher, D. PP4 is a gamma 
H2AX phosphatase required for recovery from the DNA damage 
checkpoint. EMBO Rep 9, 1019-1026, doi:10.1038/embor.2008.162 
(2008). 
329 Lee, D. H. et al. Dephosphorylation enables the recruitment of 53BP1 to 
double-strand DNA breaks. Mol Cell 54, 512-525, 
doi:10.1016/j.molcel.2014.03.020 (2014). 
330 Lim, D. S. & Hasty, P. A mutation in mouse rad51 results in an early 
embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 
16, 7133-7143 (1996). 
331 Tsuzuki, T. et al. Targeted disruption of the Rad51 gene leads to 
lethality in embryonic mice. Proc Natl Acad Sci U S A 93, 6236-6240 
(1996). 
332 Raderschall, E., Golub, E. I. & Haaf, T. Nuclear foci of mammalian 
recombination proteins are located at single-stranded DNA regions 
formed after DNA damage. Proc Natl Acad Sci U S A 96, 1921-1926 
(1999). 
333 Moynahan, M. E., Pierce, A. J. & Jasin, M. BRCA2 is required for 
homology-directed repair of chromosomal breaks. Mol Cell 7, 263-272 
(2001). 
334 Barlow, J. H., Lisby, M. & Rothstein, R. Differential regulation of the 
cellular response to DNA double-strand breaks in G1. Mol Cell 30, 73-
85, doi:10.1016/j.molcel.2008.01.016 (2008). 
335 Chen, Z., Yang, H. & Pavletich, N. P. Mechanism of homologous 
recombination from the RecA-ssDNA/dsDNA structures. Nature 453, 
489-484, doi:10.1038/nature06971 (2008). 
           180
336 Kowalczykowski, S. C. Biochemistry of genetic recombination: 
energetics and mechanism of DNA strand exchange. Annu Rev 
Biophys Biophys Chem 20, 539-575, 
doi:10.1146/annurev.bb.20.060191.002543 (1991). 
337 Chi, P., Van Komen, S., Sehorn, M. G., Sigurdsson, S. & Sung, P. 
Roles of ATP binding and ATP hydrolysis in human Rad51 
recombinase function. DNA repair 5, 381-391, 
doi:10.1016/j.dnarep.2005.11.005 (2006). 
338 Bugreev, D. V. & Mazin, A. V. Ca2+ activates human homologous 
recombination protein Rad51 by modulating its ATPase activity. Proc 
Natl Acad Sci U S A 101, 9988-9993, doi:10.1073/pnas.0402105101 
(2004). 
339 San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic 
homologous recombination. Annual review of biochemistry 77, 229-257, 
doi:10.1146/annurev.biochem.77.061306.125255 (2008). 
340 Stark, J. M. et al. ATP hydrolysis by mammalian RAD51 has a key role 
during homology-directed DNA repair. J Biol Chem 277, 20185-20194, 
doi:10.1074/jbc.M112132200 (2002). 
341 Sigurdsson, S., Trujillo, K., Song, B., Stratton, S. & Sung, P. Basis for 
avid homologous DNA strand exchange by human Rad51 and RPA. J 
Biol Chem 276, 8798-8806, doi:10.1074/jbc.M010011200 (2001). 
342 Liu, Y. et al. Conformational changes modulate the activity of human 
RAD51 protein. Journal of molecular biology 337, 817-827, 
doi:10.1016/j.jmb.2004.02.022 (2004). 
343 Connor, F. et al. Tumorigenesis and a DNA repair defect in mice with a 
truncating Brca2 mutation. Nature genetics 17, 423-430, 
doi:10.1038/ng1297-423 (1997). 
344 Sharan, S. K. et al. Embryonic lethality and radiation hypersensitivity 
mediated by Rad51 in mice lacking Brca2. Nature 386, 804-810, 
doi:10.1038/386804a0 (1997). 
345 Yu, V. P. et al. Gross chromosomal rearrangements and genetic 
exchange between nonhomologous chromosomes following BRCA2 
inactivation. Genes & development 14, 1400-1406 (2000). 
346 Chen, C. F., Chen, P. L., Zhong, Q., Sharp, Z. D. & Lee, W. H. 
Expression of BRC repeats in breast cancer cells disrupts the BRCA2-
Rad51 complex and leads to radiation hypersensitivity and loss of 
G(2)/M checkpoint control. J Biol Chem 274, 32931-32935 (1999). 
           181
347 Katagiri, T. et al. Multiple possible sites of BRCA2 interacting with DNA 
repair protein RAD51. Genes, chromosomes & cancer 21, 217-222 
(1998). 
348 Davies, A. A. et al. Role of BRCA2 in control of the RAD51 
recombination and DNA repair protein. Mol Cell 7, 273-282 (2001). 
349 Yuan, S. S. et al. BRCA2 is required for ionizing radiation-induced 
assembly of Rad51 complex in vivo. Cancer research 59, 3547-3551 
(1999). 
350 Godthelp, B. C., Artwert, F., Joenje, H. & Zdzienicka, M. Z. Impaired 
DNA damage-induced nuclear Rad51 foci formation uniquely 
characterizes Fanconi anemia group D1. Oncogene 21, 5002-5005, 
doi:10.1038/sj.onc.1205656 (2002). 
351 Buisson, R. et al. Cooperation of breast cancer proteins PALB2 and 
piccolo BRCA2 in stimulating homologous recombination. Nat Struct 
Mol Biol 17, 1247-1254, doi:10.1038/nsmb.1915 (2010). 
352 Dray, E. et al. Enhancement of RAD51 recombinase activity by the 
tumor suppressor PALB2. Nat Struct Mol Biol 17, 1255-1259, 
doi:10.1038/nsmb.1916 (2010). 
353 Li, J. et al. DSS1 is required for the stability of BRCA2. Oncogene 25, 
1186-1194, doi:10.1038/sj.onc.1209153 (2006). 
354 Carreira, A. & Kowalczykowski, S. C. Two classes of BRC repeats in 
BRCA2 promote RAD51 nucleoprotein filament function by distinct 
mechanisms. Proc Natl Acad Sci U S A 108, 10448-10453, 
doi:10.1073/pnas.1106971108 (2011). 
355 Saeki, H. et al. Suppression of the DNA repair defects of BRCA2-
deficient cells with heterologous protein fusions. Proc Natl Acad Sci U S 
A 103, 8768-8773, doi:10.1073/pnas.0600298103 (2006). 
356 Esashi, F. et al. CDK-dependent phosphorylation of BRCA2 as a 
regulatory mechanism for recombinational repair. Nature 434, 598-604, 
doi:10.1038/nature03404 (2005). 
357 Hucl, T. et al. A syngeneic variance library for functional annotation of 
human variation: application to BRCA2. Cancer research 68, 5023-
5030, doi:10.1158/0008-5472.CAN-07-6189 (2008). 
358 Ayoub, N. et al. The carboxyl terminus of Brca2 links the disassembly of 
Rad51 complexes to mitotic entry. Current biology : CB 19, 1075-1085, 
doi:10.1016/j.cub.2009.05.057 (2009). 
           182
359 Thorslund, T. et al. The breast cancer tumor suppressor BRCA2 
promotes the specific targeting of RAD51 to single-stranded DNA. Nat 
Struct Mol Biol 17, 1263-1265, doi:10.1038/nsmb.1905 (2010). 
360 Zou, L. DNA repair: A protein giant in its entirety. Nature 467, 667-668, 
doi:10.1038/467667a (2010). 
361 Carreira, A. et al. The BRC repeats of BRCA2 modulate the DNA-
binding selectivity of RAD51. Cell 136, 1032-1043, 
doi:10.1016/j.cell.2009.02.019 (2009). 
362 Carreira, A. & Kowalczykowski, S. C. BRCA2: Shining light on the 
regulation of DNA-binding selectivity by RAD51. Cell cycle 8, 3445-
3447 (2009). 
363 Esashi, F., Galkin, V. E., Yu, X., Egelman, E. H. & West, S. C. 
Stabilization of RAD51 nucleoprotein filaments by the C-terminal region 
of BRCA2. Nat Struct Mol Biol 14, 468-474, doi:10.1038/nsmb1245 
(2007). 
364 Marmorstein, L. Y., Ouchi, T. & Aaronson, S. A. The BRCA2 gene 
product functionally interacts with p53 and RAD51. Proc Natl Acad Sci 
U S A 95, 13869-13874 (1998). 
365 Petalcorin, M. I., Sandall, J., Wigley, D. B. & Boulton, S. J. CeBRC-2 
stimulates D-loop formation by RAD-51 and promotes DNA single-
strand annealing. Journal of molecular biology 361, 231-242, 
doi:10.1016/j.jmb.2006.06.020 (2006). 
366 San Filippo, J. et al. Recombination mediator and Rad51 targeting 
activities of a human BRCA2 polypeptide. J Biol Chem 281, 11649-
11657, doi:10.1074/jbc.M601249200 (2006). 
367 Yang, H. et al. BRCA2 function in DNA binding and recombination from 
a BRCA2-DSS1-ssDNA structure. Science 297, 1837-1848, 
doi:10.1126/science.297.5588.1837 (2002). 
368 Yang, H., Li, Q., Fan, J., Holloman, W. K. & Pavletich, N. P. The 
BRCA2 homologue Brh2 nucleates RAD51 filament formation at a 
dsDNA-ssDNA junction. Nature 433, 653-657, doi:10.1038/nature03234 
(2005). 
369 Morimatsu, K., Wu, Y. & Kowalczykowski, S. C. RecFOR proteins target 
RecA protein to a DNA gap with either DNA or RNA at the 5' terminus: 
implication for repair of stalled replication forks. J Biol Chem 287, 
35621-35630, doi:10.1074/jbc.M112.397034 (2012). 
           183
370 Holloman, W. K. Unraveling the mechanism of BRCA2 in homologous 
recombination. Nat Struct Mol Biol 18, 748-754, doi:10.1038/nsmb.2096 
(2011). 
371 Morimatsu, K. & Kowalczykowski, S. C. RecFOR proteins load RecA 
protein onto gapped DNA to accelerate DNA strand exchange: a 
universal step of recombinational repair. Mol Cell 11, 1337-1347 (2003). 
372 Jensen, R. B. BRCA2: one small step for DNA repair, one giant protein 
purified. Yale J Biol Med 86, 479-489 (2013). 
373 Mazloum, N., Zhou, Q. & Holloman, W. K. DNA binding, annealing, and 
strand exchange activities of Brh2 protein from Ustilago maydis. 
Biochemistry 46, 7163-7173, doi:10.1021/bi700399m (2007). 
374 Muris, D. F. et al. Cloning of human and mouse genes homologous to 
RAD52, a yeast gene involved in DNA repair and recombination. Mutat 
Res 315, 295-305 (1994). 
375 Mortensen, U. H., Bendixen, C., Sunjevaric, I. & Rothstein, R. DNA 
strand annealing is promoted by the yeast Rad52 protein. Proc Natl 
Acad Sci U S A 93, 10729-10734 (1996). 
376 Shen, Z., Cloud, K. G., Chen, D. J. & Park, M. S. Specific interactions 
between the human RAD51 and RAD52 proteins. J Biol Chem 271, 
148-152 (1996). 
377 Shinohara, A., Shinohara, M., Ohta, T., Matsuda, S. & Ogawa, T. 
Rad52 forms ring structures and co-operates with RPA in single-strand 
DNA annealing. Genes to cells : devoted to molecular & cellular 
mechanisms 3, 145-156 (1998). 
378 Hays, S. L., Firmenich, A. A., Massey, P., Banerjee, R. & Berg, P. 
Studies of the interaction between Rad52 protein and the yeast single-
stranded DNA binding protein RPA. Mol Cell Biol 18, 4400-4406 (1998). 
379 Song, B. & Sung, P. Functional interactions among yeast Rad51 
recombinase, Rad52 mediator, and replication protein A in DNA strand 
exchange. J Biol Chem 275, 15895-15904, 
doi:10.1074/jbc.M910244199 (2000). 
380 Sugiyama, T. & Kowalczykowski, S. C. Rad52 protein associates with 
replication protein A (RPA)-single-stranded DNA to accelerate Rad51-
mediated displacement of RPA and presynaptic complex formation. J 
Biol Chem 277, 31663-31672, doi:10.1074/jbc.M203494200 (2002). 
           184
381 Essers, J. et al. Nuclear dynamics of RAD52 group homologous 
recombination proteins in response to DNA damage. The EMBO journal 
21, 2030-2037, doi:10.1093/emboj/21.8.2030 (2002). 
382 Kojic, M., Mao, N., Zhou, Q., Lisby, M. & Holloman, W. K. 
Compensatory role for Rad52 during recombinational repair in Ustilago 
maydis. Molecular microbiology 67, 1156-1168, doi:10.1111/j.1365-
2958.2008.06116.x (2008). 
383 Muris, D. F. et al. Homologous recombination in the fission yeast 
Schizosaccharomyces pombe: different requirements for the rhp51+, 
rhp54+ and rad22+ genes. Curr Genet 31, 248-254 (1997). 
384 Liu, Y. & Maizels, N. Coordinated response of mammalian Rad51 and 
Rad52 to DNA damage. EMBO Rep 1, 85-90, 
doi:10.1038/sj.embor.embor634 (2000). 
385 Kurumizaka, H., Aihara, H., Kagawa, W., Shibata, T. & Yokoyama, S. 
Human Rad51 amino acid residues required for Rad52 binding. Journal 
of molecular biology 291, 537-548, doi:10.1006/jmbi.1999.2950 (1999). 
386 Wray, J., Liu, J., Nickoloff, J. A. & Shen, Z. Distinct RAD51 associations 
with RAD52 and BCCIP in response to DNA damage and replication 
stress. Cancer research 68, 2699-2707, doi:10.1158/0008-5472.CAN-
07-6505 (2008). 
387 Park, M. S. Expression of human RAD52 confers resistance to ionizing 
radiation in mammalian cells. J Biol Chem 270, 15467-15470 (1995). 
388 Yanez, R. J. & Porter, A. C. Differential effects of Rad52p 
overexpression on gene targeting and extrachromosomal homologous 
recombination in a human cell line. Nucleic acids research 30, 740-748 
(2002). 
389 Fujimori, A. et al. Rad52 partially substitutes for the Rad51 paralog 
XRCC3 in maintaining chromosomal integrity in vertebrate cells. The 
EMBO journal 20, 5513-5520, doi:10.1093/emboj/20.19.5513 (2001). 
390 de Vries, F. A. et al. Inactivation of RAD52 aggravates RAD54 defects 
in mice but not in Schizosaccharomyces pombe. DNA repair 4, 1121-
1128, doi:10.1016/j.dnarep.2005.06.002 (2005). 
391 van Veelen, L. R. et al. Ionizing radiation-induced foci formation of 
mammalian Rad51 and Rad54 depends on the Rad51 paralogs, but not 
on Rad52. Mutat Res 574, 34-49, doi:10.1016/j.mrfmmm.2005.01.020 
(2005). 
           185
392 Lok, B. H., Carley, A. C., Tchang, B. & Powell, S. N. RAD52 inactivation 
is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition 
to BRCA2 through RAD51-mediated homologous recombination. 
Oncogene 32, 3552-3558, doi:10.1038/onc.2012.391 (2013). 
393 Altmannova, V. et al. Rad52 SUMOylation affects the efficiency of the 
DNA repair. Nucleic acids research 38, 4708-4721, 
doi:10.1093/nar/gkq195 (2010). 
394 Esta, A. et al. Rad52 sumoylation prevents the toxicity of unproductive 
Rad51 filaments independently of the anti-recombinase Srs2. PLoS 
genetics 9, e1003833, doi:10.1371/journal.pgen.1003833 (2013). 
395 Ho, J. C., Warr, N. J., Shimizu, H. & Watts, F. Z. SUMO modification of 
Rad22, the Schizosaccharomyces pombe homologue of the 
recombination protein Rad52. Nucleic acids research 29, 4179-4186 
(2001). 
396 Sacher, M., Pfander, B., Hoege, C. & Jentsch, S. Control of Rad52 
recombination activity by double-strand break-induced SUMO 
modification. Nat Cell Biol 8, 1284-1290, doi:10.1038/ncb1488 (2006). 
397 Shen, Z., Pardington-Purtymun, P. E., Comeaux, J. C., Moyzis, R. K. & 
Chen, D. J. Associations of UBE2I with RAD52, UBL1, p53, and RAD51 
proteins in a yeast two-hybrid system. Genomics 37, 183-186, 
doi:10.1006/geno.1996.0540 (1996). 
398 Shen, Z., Pardington-Purtymun, P. E., Comeaux, J. C., Moyzis, R. K. & 
Chen, D. J. UBL1, a human ubiquitin-like protein associating with 
human RAD51/RAD52 proteins. Genomics 36, 271-279, 
doi:10.1006/geno.1996.0462 (1996). 
399 Choi, B. H., Chen, Y. & Dai, W. Chromatin PTEN is involved in DNA 
damage response partly through regulating Rad52 sumoylation. Cell 
cycle 12, 3442-3447, doi:10.4161/cc.26465 (2013). 
400 Honda, M., Okuno, Y., Yoo, J., Ha, T. & Spies, M. Tyrosine 
phosphorylation enhances RAD52-mediated annealing by modulating 
its DNA binding. The EMBO journal 30, 3368-3382, 
doi:10.1038/emboj.2011.238 (2011). 
401 Kitao, H. & Yuan, Z. M. Regulation of ionizing radiation-induced Rad52 
nuclear foci formation by c-Abl-mediated phosphorylation. J Biol Chem 
277, 48944-48948, doi:10.1074/jbc.M208151200 (2002). 
           186
402 Murfuni, I. et al. Survival of the replication checkpoint deficient cells 
requires MUS81-RAD52 function. PLoS genetics 9, e1003910, 
doi:10.1371/journal.pgen.1003910 (2013). 
403 Baynton, K. et al. WRN interacts physically and functionally with the 
recombination mediator protein RAD52. J Biol Chem 278, 36476-36486, 
doi:10.1074/jbc.M303885200 (2003). 
404 Kito, K., Wada, H., Yeh, E. T. & Kamitani, T. Identification of novel 
isoforms of human RAD52. Biochimica et biophysica acta 1489, 303-
314 (1999). 
405 Milne, G. T. & Weaver, D. T. Dominant negative alleles of RAD52 
reveal a DNA repair/recombination complex including Rad51 and 
Rad52. Genes & development 7, 1755-1765 (1993). 
406 Thorpe, P. H. et al. Cells expressing murine RAD52 splice variants 
favor sister chromatid repair. Mol Cell Biol 26, 3752-3763, 
doi:10.1128/mcb.26.10.3752-3763.2006 (2006). 
407 Ranatunga, W. et al. Human RAD52 exhibits two modes of self-
association. J Biol Chem 276, 15876-15880, 
doi:10.1074/jbc.M011747200 (2001). 
408 Lloyd, J. A., Forget, A. L. & Knight, K. L. Correlation of biochemical 
properties with the oligomeric state of human rad52 protein. J Biol 
Chem 277, 46172-46178, doi:10.1074/jbc.M207262200 (2002). 
409 Kagawa, W., Kurumizaka, H., Ikawa, S., Yokoyama, S. & Shibata, T. 
Homologous pairing promoted by the human Rad52 protein. J Biol 
Chem 276, 35201-35208, doi:10.1074/jbc.M104938200 (2001). 
410 Van Dyck, E., Hajibagheri, N. M., Stasiak, A. & West, S. C. 
Visualisation of human rad52 protein and its complexes with hRad51 
and DNA. Journal of molecular biology 284, 1027-1038, 
doi:10.1006/jmbi.1998.2203 (1998). 
411 Stasiak, A. Z. et al. The human Rad52 protein exists as a heptameric 
ring. Current biology : CB 10, 337-340 (2000). 
412 Kagawa, W. et al. Crystal structure of the homologous-pairing domain 
from the human Rad52 recombinase in the undecameric form. Mol Cell 
10, 359-371 (2002). 
413 Singleton, M. R., Wentzell, L. M., Liu, Y., West, S. C. & Wigley, D. B. 
Structure of the single-strand annealing domain of human RAD52 
           187
protein. Proc Natl Acad Sci U S A 99, 13492-13497, 
doi:10.1073/pnas.212449899 (2002). 
414 Parsons, C. A., Baumann, P., Van Dyck, E. & West, S. C. Precise 
binding of single-stranded DNA termini by human RAD52 protein. The 
EMBO journal 19, 4175-4181, doi:10.1093/emboj/19.15.4175 (2000). 
415 Kagawa, W. et al. Identification of a second DNA binding site in the 
human Rad52 protein. J Biol Chem 283, 24264-24273, 
doi:10.1074/jbc.M802204200 (2008). 
416 Van Dyck, E., Stasiak, A. Z., Stasiak, A. & West, S. C. Visualization of 
recombination intermediates produced by RAD52-mediated single-
strand annealing. EMBO Rep 2, 905-909, doi:10.1093/embo-
reports/kve201 (2001). 
417 Benson, F. E., Baumann, P. & West, S. C. Synergistic actions of Rad51 
and Rad52 in recombination and DNA repair. Nature 391, 401-404, 
doi:10.1038/34937 (1998). 
418 Reddy, G., Golub, E. I. & Radding, C. M. Human Rad52 protein 
promotes single-strand DNA annealing followed by branch migration. 
Mutat Res 377, 53-59 (1997). 
419 Van Dyck, E., Stasiak, A. Z., Stasiak, A. & West, S. C. Binding of 
double-strand breaks in DNA by human Rad52 protein. Nature 398, 
728-731, doi:10.1038/19560 (1999). 
420 Lloyd, J. A., McGrew, D. A. & Knight, K. L. Identification of residues 
important for DNA binding in the full-length human Rad52 protein. 
Journal of molecular biology 345, 239-249, 
doi:10.1016/j.jmb.2004.10.065 (2005). 
421 Nimonkar, A. V. & Kowalczykowski, S. C. Second-end DNA capture in 
double-strand break repair: how to catch a DNA by its tail. Cell cycle 8, 
1816-1817 (2009). 
422 Rothenberg, E., Grimme, J. M., Spies, M. & Ha, T. Human Rad52-
mediated homology search and annealing occurs by continuous 
interactions between overlapping nucleoprotein complexes. Proc Natl 
Acad Sci U S A 105, 20274-20279, doi:10.1073/pnas.0810317106 
(2008). 
423 Bugreev, D. V., Hanaoka, F. & Mazin, A. V. Rad54 dissociates 
homologous recombination intermediates by branch migration. Nat 
Struct Mol Biol 14, 746-753, doi:10.1038/nsmb1268 (2007). 
           188
424 Baumann, P., Benson, F. E. & West, S. C. Human Rad51 protein 
promotes ATP-dependent homologous pairing and strand transfer 
reactions in vitro. Cell 87, 757-766 (1996). 
425 Baumann, P. & West, S. C. The human Rad51 protein: polarity of 
strand transfer and stimulation by hRP-A. The EMBO journal 16, 5198-
5206, doi:10.1093/emboj/16.17.5198 (1997). 
426 Gupta, R. C., Bazemore, L. R., Golub, E. I. & Radding, C. M. Activities 
of human recombination protein Rad51. Proc Natl Acad Sci U S A 94, 
463-468 (1997). 
427 Baumann, P. & West, S. C. Heteroduplex formation by human Rad51 
protein: effects of DNA end-structure, hRP-A and hRad52. Journal of 
molecular biology 291, 363-374, doi:10.1006/jmbi.1999.2954 (1999). 
428 McIlwraith, M. J. et al. Reconstitution of the strand invasion step of 
double-strand break repair using human Rad51 Rad52 and RPA 
proteins. Journal of molecular biology 304, 151-164, 
doi:10.1006/jmbi.2000.4180 (2000). 
429 Bi, B., Rybalchenko, N., Golub, E. I. & Radding, C. M. Human and 
yeast Rad52 proteins promote DNA strand exchange. Proc Natl Acad 
Sci U S A 101, 9568-9572, doi:10.1073/pnas.0403205101 (2004). 
430 Navadgi, V. M., Shukla, A. & Rao, B. J. Effect of DNA sequence and 
nucleotide cofactors on hRad51 binding to ssDNA: role of hRad52 in 
recruitment. Biochem Biophys Res Commun 334, 696-701, 
doi:10.1016/j.bbrc.2005.06.145 (2005). 
431 Navadgi, V. M., Shukla, A., Vempati, R. K. & Rao, B. J. DNA mediated 
disassembly of hRad51 and hRad52 proteins and recruitment of 
hRad51 to ssDNA by hRad52. The FEBS journal 273, 199-207, 
doi:10.1111/j.1742-4658.2005.05058.x (2006). 
432 Jensen, R. B., Ozes, A., Kim, T., Estep, A. & Kowalczykowski, S. C. 
BRCA2 is epistatic to the RAD51 paralogs in response to DNA damage. 
DNA repair 12, 306-311, doi:10.1016/j.dnarep.2012.12.007 (2013). 
433 Chun, J., Buechelmaier, E. S. & Powell, S. N. Rad51 paralog 
complexes BCDX2 and CX3 act at different stages in the BRCA1-
BRCA2-dependent homologous recombination pathway. Mol Cell Biol 
33, 387-395, doi:10.1128/MCB.00465-12 (2013). 
434 Qing, Y. et al. The epistatic relationship between BRCA2 and the other 
RAD51 mediators in homologous recombination. PLoS genetics 7, 
e1002148, doi:10.1371/journal.pgen.1002148 (2011). 
           189
435 Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with 
inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917, 
doi:nature03443 [pii] 
10.1038/nature03443 (2005). 
436 Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells 
as a therapeutic strategy. Nature 434, 917-921, doi:nature03445 [pii] 
10.1038/nature03445 (2005). 
437 Yap, T. A., Sandhu, S. K., Carden, C. P. & de Bono, J. S. Poly(ADP-
ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal 
strategy in the clinic. CA Cancer J Clin 61, 31-49, doi:caac.20095 [pii] 
10.3322/caac.20095 (2011). 
438 Annunziata, C. M. & O'Shaughnessy, J. Poly (ADP-ribose) polymerase 
as a novel therapeutic target in cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research 16, 
4517-4526, doi:1078-0432.CCR-10-0526 [pii] 
10.1158/1078-0432.CCR-10-0526 (2010). 
439 Anders, C. K. et al. Poly(ADP-Ribose) polymerase inhibition: "targeted" 
therapy for triple-negative breast cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research 16, 
4702-4710, doi:1078-0432.CCR-10-0939 [pii] 
10.1158/1078-0432.CCR-10-0939 (2010). 
440 Aly, A. & Ganesan, S. BRCA1, PARP, and 53BP1: conditional synthetic 
lethality and synthetic viability. J Mol Cell Biol 3, 66-74, doi:mjq055 [pii] 
10.1093/jmcb/mjq055 (2011). 
441 Krishnakumar, R. & Kraus, W. L. The PARP side of the nucleus: 
molecular actions, physiological outcomes, and clinical targets. Mol Cell 
39, 8-24, doi:S1097-2765(10)00458-2 [pii] 
10.1016/j.molcel.2010.06.017 (2010). 
442 Woodhouse, B. C. & Dianov, G. L. Poly ADP-ribose polymerase-1: an 
international molecule of mystery. DNA repair 7, 1077-1086, doi:S1568-
7864(08)00118-3 [pii] 
10.1016/j.dnarep.2008.03.009 (2008). 
443 Masson, M. et al. XRCC1 is specifically associated with poly(ADP-
ribose) polymerase and negatively regulates its activity following DNA 
damage. Mol Cell Biol 18, 3563-3571 (1998). 
444 El-Khamisy, S. F., Masutani, M., Suzuki, H. & Caldecott, K. W. A 
requirement for PARP-1 for the assembly or stability of XRCC1 nuclear 
           190
foci at sites of oxidative DNA damage. Nucleic acids research 31, 5526-
5533 (2003). 
445 Schreiber, V. et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is 
required for efficient base excision DNA repair in association with 
PARP-1 and XRCC1. J Biol Chem 277, 23028-23036, 
doi:10.1074/jbc.M202390200 
M202390200 [pii] (2002). 
446 Yelamos, J., Schreiber, V. & Dantzer, F. Toward specific functions of 
poly(ADP-ribose) polymerase-2. Trends Mol Med 14, 169-178, 
doi:S1471-4914(08)00062-2 [pii] 
10.1016/j.molmed.2008.02.003 (2008). 
447 Bryant, H. E. et al. PARP is activated at stalled forks to mediate Mre11-
dependent replication restart and recombination. The EMBO journal 28, 
2601-2615, doi:emboj2009206 [pii] 
10.1038/emboj.2009.206 (2009). 
448 Wang, Z. Q. et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation 
develop normally but are susceptible to skin disease. Genes & 
development 9, 509-520 (1995). 
449 D'Amours, D., Desnoyers, S., D'Silva, I. & Poirier, G. G. Poly(ADP-
ribosyl)ation reactions in the regulation of nuclear functions. The 
Biochemical journal 342 ( Pt 2), 249-268 (1999). 
450 Lindahl, T., Satoh, M. S., Poirier, G. G. & Klungland, A. Post-
translational modification of poly(ADP-ribose) polymerase induced by 
DNA strand breaks. Trends in biochemical sciences 20, 405-411, 
doi:S0968-0004(00)89089-1 [pii] (1995). 
451 de Murcia, J. M. et al. Requirement of poly(ADP-ribose) polymerase in 
recovery from DNA damage in mice and in cells. Proc Natl Acad Sci U 
S A 94, 7303-7307 (1997). 
452 Wang, Z. Q. et al. PARP is important for genomic stability but 
dispensable in apoptosis. Genes & development 11, 2347-2358 (1997). 
453 Molinete, M. et al. Overproduction of the poly(ADP-ribose) polymerase 
DNA-binding domain blocks alkylation-induced DNA repair synthesis in 
mammalian cells. The EMBO journal 12, 2109-2117 (1993). 
454 Helleday, T., Bryant, H. E. & Schultz, N. Poly(ADP-ribose) polymerase 
(PARP-1) in homologous recombination and as a target for cancer 
therapy. Cell cycle 4, 1176-1178, doi:2031 [pii] (2005). 
           191
455 Ashworth, A. A synthetic lethal therapeutic approach: poly(ADP) ribose 
polymerase inhibitors for the treatment of cancers deficient in DNA 
double-strand break repair. J Clin Oncol 26, 3785-3790, 
doi:10.1200/JCO.2008.16.0812 
JCO.2008.16.0812 [pii] (2008). 
456 Saleh-Gohari, N. et al. Spontaneous homologous recombination is 
induced by collapsed replication forks that are caused by endogenous 
DNA single-strand breaks. Mol Cell Biol 25, 7158-7169, doi:25/16/7158 
[pii] 
10.1128/MCB.25.16.7158-7169.2005 (2005). 
457 Wang, M. et al. PARP-1 and Ku compete for repair of DNA double 
strand breaks by distinct NHEJ pathways. Nucleic acids research 34, 
6170-6182, doi:gkl840 [pii] 
10.1093/nar/gkl840 (2006). 
458 Helleday, T. The underlying mechanism for the PARP and BRCA 
synthetic lethality: Clearing up the misunderstandings. Mol Oncol, 
doi:S1574-7891(11)00074-3 [pii] 
10.1016/j.molonc.2011.07.001 (2011). 
459 Strom, C. E. et al. Poly (ADP-ribose) polymerase (PARP) is not 
involved in base excision repair but PARP inhibition traps a single-
strand intermediate. Nucleic acids research 39, 3166-3175, 
doi:gkq1241 [pii] 
10.1093/nar/gkq1241 (2011). 
460 McCabe, N. et al. Deficiency in the repair of DNA damage by 
homologous recombination and sensitivity to poly(ADP-ribose) 
polymerase inhibition. Cancer research 66, 8109-8115, doi:66/16/8109 
[pii] 
10.1158/0008-5472.CAN-06-0140 (2006). 
461 Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors 
from BRCA mutation carriers. The New England journal of medicine 
361, 123-134, doi:NEJMoa0900212 [pii] 
10.1056/NEJMoa0900212 (2009). 
462 Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent 
durable responses in BRCA carrier ovarian cancer correlating with 
platinum-free interval. J Clin Oncol 28, 2512-2519, 
doi:JCO.2009.26.9589 [pii] 
10.1200/JCO.2009.26.9589 (2010). 
           192
463 Kowalczykowski, S. C. An Overview of the Molecular Mechanisms of 
Recombinational DNA Repair. Cold Spring Harbor perspectives in 
biology 7, doi:10.1101/cshperspect.a016410 (2015). 
464 Masson, J. Y. et al. Identification and purification of two distinct 
complexes containing the five RAD51 paralogs. Genes & development 
15, 3296-3307, doi:10.1101/gad.947001 (2001). 
465 Wiese, C. et al. Interactions involving the Rad51 paralogs Rad51C and 
XRCC3 in human cells. Nucleic acids research 30, 1001-1008 (2002). 
466 Liu, N., Schild, D., Thelen, M. P. & Thompson, L. H. Involvement of 
Rad51C in two distinct protein complexes of Rad51 paralogs in human 
cells. Nucleic acids research 30, 1009-1015 (2002). 
467 Park, J. Y. et al. Breast cancer-associated missense mutants of the 
PALB2 WD40 domain, which directly binds RAD51C, RAD51 and 
BRCA2, disrupt DNA repair. Oncogene 33, 4803-4812, 
doi:10.1038/onc.2013.421 (2014). 
468 Lio, Y. C., Mazin, A. V., Kowalczykowski, S. C. & Chen, D. J. Complex 
formation by the human Rad51B and Rad51C DNA repair proteins and 
their activities in vitro. J Biol Chem 278, 2469-2478, 
doi:10.1074/jbc.M211038200 (2003). 
469 Bishop, D. K. et al. Xrcc3 is required for assembly of Rad51 complexes 
in vivo. J Biol Chem 273, 21482-21488 (1998). 
470 Takata, M. et al. The Rad51 paralog Rad51B promotes homologous 
recombinational repair. Mol Cell Biol 20, 6476-6482 (2000). 
471 Rodrigue, A. et al. Interplay between human DNA repair proteins at a 
unique double-strand break in vivo. The EMBO journal 25, 222-231, 
doi:10.1038/sj.emboj.7600914 (2006). 
472 Sung, P., Krejci, L., Van Komen, S. & Sehorn, M. G. Rad51 
recombinase and recombination mediators. J Biol Chem 278, 42729-
42732, doi:10.1074/jbc.R300027200 (2003). 
473 Fuller, L. F. & Painter, R. B. A Chinese hamster ovary cell line 
hypersensitive to ionizing radiation and deficient in repair replication. 
Mutat Res 193, 109-121 (1988). 
474 Jones, N. J., Cox, R. & Thacker, J. Isolation and cross-sensitivity of X-
ray-sensitive mutants of V79-4 hamster cells. Mutat Res 183, 279-286 
(1987). 
           193
475 Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 
promotes homology-directed repair of DNA damage in mammalian cells. 
Genes & development 13, 2633-2638 (1999). 
476 Takata, M. et al. Chromosome instability and defective recombinational 
repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol 21, 
2858-2866, doi:10.1128/mcb.21.8.2858-2866.2001 (2001). 
477 Deans, B., Griffin, C. S., Maconochie, M. & Thacker, J. Xrcc2 is 
required for genetic stability, embryonic neurogenesis and viability in 
mice. The EMBO journal 19, 6675-6685, doi:10.1093/emboj/19.24.6675 
(2000). 
478 Pittman, D. L. & Schimenti, J. C. Midgestation lethality in mice deficient 
for the RecA-related gene, Rad51d/Rad51l3. Genesis (New York, N.Y. : 
2000) 26, 167-173 (2000). 
479 Shu, Z., Smith, S., Wang, L., Rice, M. C. & Kmiec, E. B. Disruption of 
muREC2/RAD51L1 in mice results in early embryonic lethality which 
can Be partially rescued in a p53(-/-) background. Mol Cell Biol 19, 
8686-8693 (1999). 
480 Zelensky, A., Kanaar, R. & Wyman, C. Mediators of homologous DNA 
pairing. Cold Spring Harbor perspectives in biology 6, a016451, 
doi:10.1101/cshperspect.a016451 (2014). 
481 Kurumizaka, H. et al. Homologous-pairing activity of the human DNA-
repair proteins Xrcc3.Rad51C. Proc Natl Acad Sci U S A 98, 5538-5543, 
doi:10.1073/pnas.091603098 (2001). 
482 Sigurdsson, S. et al. Mediator function of the human Rad51B-Rad51C 
complex in Rad51/RPA-catalyzed DNA strand exchange. Genes & 
development 15, 3308-3318, doi:10.1101/gad.935501 (2001). 
483 Kurumizaka, H. et al. Homologous pairing and ring and filament 
structure formation activities of the human Xrcc2*Rad51D complex. J 
Biol Chem 277, 14315-14320, doi:10.1074/jbc.M105719200 (2002). 
484 Brenneman, M. A., Wagener, B. M., Miller, C. A., Allen, C. & Nickoloff, J. 
A. XRCC3 controls the fidelity of homologous recombination: roles for 
XRCC3 in late stages of recombination. Mol Cell 10, 387-395 (2002). 
485 Nagaraju, G., Hartlerode, A., Kwok, A., Chandramouly, G. & Scully, R. 
XRCC2 and XRCC3 regulate the balance between short- and long-tract 
gene conversions between sister chromatids. Mol Cell Biol 29, 4283-
4294, doi:10.1128/mcb.01406-08 (2009). 
           194
486 Liu, Y., Masson, J. Y., Shah, R., O'Regan, P. & West, S. C. RAD51C is 
required for Holliday junction processing in mammalian cells. Science 
303, 243-246, doi:10.1126/science.1093037 (2004). 
487 Liu, Y., Tarsounas, M., O'Regan, P. & West, S. C. Role of RAD51C and 
XRCC3 in genetic recombination and DNA repair. J Biol Chem 282, 
1973-1979, doi:10.1074/jbc.M609066200 (2007). 
488 Martin, V. et al. Sws1 is a conserved regulator of homologous 
recombination in eukaryotic cells. The EMBO journal 25, 2564-2574, 
doi:10.1038/sj.emboj.7601141 (2006). 
489 Liu, T., Wan, L., Wu, Y., Chen, J. & Huang, J. hSWS1.SWSAP1 is an 
evolutionarily conserved complex required for efficient homologous 
recombination repair. J Biol Chem 286, 41758-41766, 
doi:10.1074/jbc.M111.271080 (2011). 
490 Agarwal, S. et al. ATP-dependent and independent functions of Rad54 
in genome maintenance. The Journal of cell biology 192, 735-750, 
doi:10.1083/jcb.201011025 (2011). 
491 Tanaka, K., Kagawa, W., Kinebuchi, T., Kurumizaka, H. & Miyagawa, K. 
Human Rad54B is a double-stranded DNA-dependent ATPase and has 
biochemical properties different from its structural homolog in yeast, 
Tid1/Rdh54. Nucleic acids research 30, 1346-1353 (2002). 
492 Mazina, O. M. & Mazin, A. V. Human Rad54 protein stimulates DNA 
strand exchange activity of hRad51 protein in the presence of Ca2+. J 
Biol Chem 279, 52042-52051, doi:10.1074/jbc.M410244200 (2004). 
493 Akamatsu, Y. & Jasin, M. Role for the mammalian Swi5-Sfr1 complex in 
DNA strand break repair through homologous recombination. PLoS 
genetics 6, e1001160, doi:10.1371/journal.pgen.1001160 (2010). 
494 Galkin, V. E. et al. BRCA2 BRC motifs bind RAD51-DNA filaments. 
Proc Natl Acad Sci U S A 102, 8537-8542, 
doi:10.1073/pnas.0407266102 (2005). 
495 Yuan, J. & Chen, J. The role of the human SWI5-MEI5 complex in 
homologous recombination repair. J Biol Chem 286, 9888-9893, 
doi:10.1074/jbc.M110.207290 (2011). 
496 Tsai, S. P. et al. Rad51 presynaptic filament stabilization function of the 
mouse Swi5-Sfr1 heterodimeric complex. Nucleic acids research 40, 
6558-6569, doi:10.1093/nar/gks305 (2012). 
           195
497 Su, G. C. et al. Enhancement of ADP release from the RAD51 
presynaptic filament by the SWI5-SFR1 complex. Nucleic acids 
research 42, 349-358, doi:10.1093/nar/gkt879 (2014). 
498 Kurokawa, Y., Murayama, Y., Haruta-Takahashi, N., Urabe, I. & Iwasaki, 
H. Reconstitution of DNA strand exchange mediated by Rhp51 
recombinase and two mediators. PLoS biology 6, e88, 
doi:10.1371/journal.pbio.0060088 (2008). 
499 Kuwabara, N. et al. Mechanistic insights into the activation of Rad51-
mediated strand exchange from the structure of a recombination 
activator, the Swi5-Sfr1 complex. Structure 20, 440-449, 
doi:10.1016/j.str.2012.01.005 (2012). 
 
           196
